<SEC-DOCUMENT>0001193125-20-317038.txt : 20201214
<SEC-HEADER>0001193125-20-317038.hdr.sgml : 20201214
<ACCEPTANCE-DATETIME>20201214164819
ACCESSION NUMBER:		0001193125-20-317038
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20201214
DATE AS OF CHANGE:		20201214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARVINAS, INC.
		CENTRAL INDEX KEY:			0001655759
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472566120
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-251326
		FILM NUMBER:		201386716

	BUSINESS ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
		BUSINESS PHONE:		203-535-1456

	MAIL ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS INC.
		DATE OF NAME CHANGE:	20181001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS HOLDING COMPANY, LLC
		DATE OF NAME CHANGE:	20151015
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d20220d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) <BR> Registration No. 333-251326 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e">The information in this preliminary prospectus supplement is not
complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer
to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#de1a1e"><B>Subject To Completion, Dated December 14, 2020 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Preliminary Prospectus Supplement </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>(To Prospectus Dated December 14, 2020)
</I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>$250,000,000 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g20220g01m85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are offering
$250.0&nbsp;million of shares of our common stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;ARVN&#148;.
On December 14, 2020, the last reported sale price of our common stock on The Nasdaq Global Select Market was $58.38 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>We are an
&#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company requirements. </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock involves significant risks. See &#147;<A HREF="#suptx20220_4">Risk Factors</A>&#148; beginning on <FONT
STYLE="white-space:nowrap">page&nbsp;S-9</FONT> to read about factors you should consider before buying shares of our common stock. </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a
criminal offense. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Per&nbsp;Share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to Arvinas, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See the section titled &#147;Underwriting&#148; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-20</FONT> for a
description of the compensation payable to the underwriters. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that the underwriters sell more than
$250.0&nbsp;million of shares of our common stock, the underwriters have the option to purchase up to an additional $37.5&nbsp;million of shares of our common stock from us at the price to the public less underwriting discounts and commissions,
within 30 days from the date of this prospectus supplement. See &#147;Underwriting&#148; for more information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver
the shares against payment in New York, New York on December&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Piper&nbsp;Sandler</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus dated December &nbsp;&nbsp;&nbsp;&nbsp;, 2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suptx20220_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suptx20220_2">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-iv</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suptx20220_3">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suptx20220_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suptx20220_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suptx20220_6">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-12</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suptx20220_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suptx20220_8">MATERIAL U.S. TAX CONSIDERATIONS FOR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS
 OF COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-16</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suptx20220_9">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suptx20220_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suptx20220_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suptx20220_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suptx20220_13">INCORPORATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_3">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_4">INCORPORATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_5">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_6">ARVINAS, INC.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_8">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_9">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_10">DESCRIPTION OF DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_11">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_12">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_13">FORMS OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_14">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_15">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc211246_16">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptx20220_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and adds to and updates
information contained in the accompanying prospectus and the documents incorporated by reference herein. The second part, the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus, we are referring
to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus or any document incorporated by reference therein
filed prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document having a later
date&#151;for example, a document incorporated by reference in the accompanying prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is
incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the
current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide any information other than that contained or
incorporated by reference in this prospectus supplement, in the accompanying prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor the underwriters take any responsibility for,
and can provide no assurance as to the reliability of, any other information that others may give you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus supplement, the accompanying
prospectus and any such free writing prospectus do not constitute an offer to sell, or a solicitation of an offer to purchase, the securities offered by this prospectus supplement, the accompanying prospectus and any such free writing prospectus in
any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. You should assume that the information appearing in this prospectus supplement, the accompanying
prospectus and the documents incorporated by reference herein and in any free writing prospectus that we have authorized for use in connection with this offering is accurate only as of the date of those respective documents. It is important for you
to read and consider all information contained in this prospectus supplement and in the accompanying prospectus, including the documents incorporated by reference herein and therein, in making your investment decision. You should also read and
consider the information in the documents to which we have referred you in the sections entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation by Reference&#148; in this prospectus supplement and in the accompanying
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other than in the United States, no action has been taken by us that would permit a public offering of the securities offered by this
prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in
connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose
possession this prospectus supplement and accompanying prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement and accompanying prospectus.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated or the context otherwise requires, references in this prospectus supplement
and the accompanying prospectus to &#147;Arvinas,&#148; &#147;we,&#148; &#147;our,&#148; &#147;us,&#148; and &#147;the Company&#148; refer, collectively, to Arvinas, Inc., a Delaware corporation, and its consolidated subsidiaries, or any one or more
of them as the context may require. When we refer to &#147;you&#148; in this prospectus supplement, we mean all purchasers of the securities being offered by this prospectus supplement and the accompanying prospectus, whether they are the holders or
only indirect owners of those securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Arvinas name and logo are our trademarks. We also own the service mark for, and have a pending
registered U.S. trademark application for, PROTAC<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. The trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. We have omitted the <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> designations, as applicable, for the trademarks named in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptx20220_2"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus supplement and the information incorporated by reference in this prospectus supplement and the accompanying prospectus include
&#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities and Exchange Act of 1934, as amended, or the Exchange Act. All
statements, other than statements of historical facts, contained in this prospectus supplement and the accompanying prospectus, and the information incorporated by reference herein and therein, including statements regarding our strategy, future
operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148;
&#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;target,&#148; &#147;potential,&#148; &#147;goals,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148;
&#147;should,&#148; &#147;continue&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The forward-looking statements included or incorporated by reference in this prospectus supplement and the accompanying prospectus include, among other
things, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the initiation, timing, progress and results of our current and future clinical trials of
<FONT STYLE="white-space:nowrap">ARV-110,</FONT> <FONT STYLE="white-space:nowrap">ARV-471</FONT> and <FONT STYLE="white-space:nowrap">ARV-766,</FONT> including statements regarding the period during which the results of the clinical trials will
become available; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of, and our ability to obtain, marketing approval <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">of&nbsp;ARV-110&nbsp;and&nbsp;ARV-471,&nbsp;and</FONT></FONT> the ability of <FONT STYLE="white-space:nowrap">ARV-110</FONT> and <FONT STYLE="white-space:nowrap">ARV-471</FONT> and our other product candidates to meet
existing or future regulatory standards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our plans to pursue research and development of other product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential advantages of our platform technology and our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which our scientific approach and platform technology may potentially address a broad range of diseases;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential benefits of our arrangements with Yale University and Professor Craig Crews; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential receipt of revenue from future sales of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rate and degree of market acceptance and clinical utility of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our estimates regarding the potential market opportunity for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our sales, marketing and distribution capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to establish and maintain arrangements for manufacture of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential achievement of milestones and receipt of payments under our collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to enter into additional collaborations with third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our intellectual property position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our business and operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the impact of government laws and regulations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitive position. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking
statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. See the
&#147;Risk Factors&#148; section of this prospectus supplement and the accompanying prospectus, the risk factors included in our periodic reports filed with the Securities and Exchange Commission, or the SEC, and in the other documents incorporated
by reference in this prospectus supplement and the accompanying prospectus for more information. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we
may make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You should read this prospectus supplement and the accompanying prospectus, and the documents incorporated by reference herein and
therein, completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements except as required by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus supplement and the accompanying prospectus include statistical and other industry and market data that we obtained from industry
publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although
they do not guarantee the accuracy or completeness of such information. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptx20220_3"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>This summary highlights selected information contained elsewhere in this prospectus supplement and the accompanying prospectus and in the documents
incorporated by reference herein and therein. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus supplement and the accompanying prospectus carefully,
especially the risks of investing in our common stock discussed under &#147;Risk Factors&#148; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-9</FONT> of this prospectus supplement and in our Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the period ended September&nbsp;30, 2020, along with our consolidated financial statements and notes to those consolidated financial statements and the other information incorporated by reference in this
prospectus supplement and the accompanying prospectus, before making an investment decision. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ARVINAS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our Business </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a clinical-stage
biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. We use our
PROTAC Discovery Engine, our proprietary technology platform, to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body&#146;s own natural protein disposal system to selectively remove
disease-causing proteins. We believe that our targeted protein degradation approach is a therapeutic modality that may provide distinct advantages over existing modalities, including traditional small molecule therapies and gene-based medicines. Our
small molecule PROTAC technology has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to
as &#147;undruggable&#148; targets. We are using our PROTAC platform to build an extensive pipeline of protein degradation product candidates to target diseases in oncology (including immune-oncology), neuroscience, and other therapeutic areas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our two lead product candidates are <FONT STYLE="white-space:nowrap">ARV-110</FONT> and <FONT STYLE="white-space:nowrap">ARV-471.</FONT> We are
developing <FONT STYLE="white-space:nowrap">ARV-110,</FONT> a PROTAC protein degrader targeting the androgen receptor protein, or AR, for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC. We initiated a Phase 1
clinical trial of <FONT STYLE="white-space:nowrap">ARV-110</FONT> in March 2019. We are also developing <FONT STYLE="white-space:nowrap">ARV-471,</FONT> a PROTAC protein degrader targeting the estrogen receptor protein, or ER, for the treatment of
patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. We initiated a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">ARV-471</FONT> in August 2019. In the fourth quarter of 2019 and the first quarter of
2020, we amended the protocols for each of our Phase 1 clinical trials for <FONT STYLE="white-space:nowrap">ARV-110</FONT> and <FONT STYLE="white-space:nowrap">ARV-471,</FONT> respectively, to include the Phase 2 expansion cohorts. In October 2020,
we initiated the Phase 2 expansion for <FONT STYLE="white-space:nowrap">ARV-110.</FONT> We recently announced clinical program updates, including updated interim data, for ARV-110 and ARV-471. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our platform has generated several promising degradation product candidates that may be capable of
targeting diseases in a wide range of organ systems and tissues. We and our collaborators have initiated programs across multiple therapeutic areas with the goal of developing and delivering life-changing therapies to patients in need. Our lead
therapeutic programs, for which we retain full worldwide development and commercialization rights, are summarized in the table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g20220g75k20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">IND dates referenced in the table above are anticipated; ER+/HER2-, estrogen receptor+/human epidermal growth factor receptor <FONT
STYLE="white-space:nowrap">2-;</FONT> NSCLC, <FONT STYLE="white-space:nowrap">non-small-cell</FONT> lung carcinoma; CRC, colorectal cancer; <FONT STYLE="white-space:nowrap">FTLD-tau,</FONT> frontotemporal lobar
<FONT STYLE="white-space:nowrap">degeneration-tau;</FONT> PSP, progressive supranuclear palsy; MSA, multiple systems atrophy </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recent Developments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>ARV-471 Clinical Update </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On December 14, 2020, we
announced updated interim data from the dose escalation portion of our ongoing Phase 1/2 clinical trial of ARV-471 in patients with locally advanced or metastatic ER+/HER2- breast cancer. The dose escalation portion of our Phase 1/2 clinical trial
of ARV-471 is designed to assess the safety, tolerability and pharmacokinetics, or PK, of ARV-471 and also includes measures of anti-tumor activity as secondary endpoints. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of the data cut-off date of November 11, 2020, 21 adult patients with locally advanced or metastatic ER+/HER2- breast cancer were dosed with ARV-471
(orally, once-daily) in the Phase 1 clinical trial. 100% of these patients were previously treated with a cyclin-dependent kinase (CDK) 4/6 inhibitor, 71% of patients also received prior fulvestrant, and 23% of patients were also pretreated with
investigational selective estrogen receptor degraders, or SERDs. Overall, patients had a median of five prior therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">One patient in the ARV-471
trial had a confirmed partial response, with a 51% reduction in target lesion size as assessed by Response Evaluation Criteria in Solid Tumors (RECIST), a standardized set of rules for response assessment based on tumor shrinkage. In addition to the
confirmed partial response, two additional patients had unconfirmed partial responses and one additional patient demonstrated stable disease with greater than 50% target lesion shrinkage. For a clinical benefit rate, or CBR, evaluation, 12 patients
had sufficient follow-up to be included. Five of 12 patients (42%) achieved CBR. CBR is defined to include partial responses, complete responses and stable disease at 6 months. Three of these five patients had previously received fulvestrant, and
another was treated with two investigational SERDs. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">ARV-471 has also been well tolerated at all dose levels, as of the data cut-off date. The most common
treatment-related Grade 1-2 adverse events were nausea (24%), arthralgia (19%), fatigue (19%), and decreased appetite (14%). None of these led to discontinuation or dose reduction of ARV-471. No patients reported treatment-related Grade 3 of 4
adverse events, and no dose-limiting toxicities have been reported. A maximum tolerated dose has not been reached and dose escalation continues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The plasma exposures of ARV-471 have been dose proportional up to and including 360 mg orally once daily and have substantially exceeded our predicted
thresholds of efficacy based on preclinical studies. The estimated half-life of ARV-471 is 28 hours, supporting a once-daily schedule of administration. Analysis of five paired tumor biopsies at doses up to 120 mg provide compelling proof of
mechanism for ARV-471. At those doses, we have observed ER degradation up to 90% (average of 62%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that the interim data from our
ongoing clinical trial compares favorably to previously reported Phase 1 clinical trial results of other SERDs with respect to tolerability, ER degradation and efficacy signals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to complete the dose escalation portion of the trial and initiate the dose expansion portion of the Phase 1/2 clinical trial of ARV-471 in the
first half of 2021 and anticipate sharing interim data from the dose expansion portion in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also expect to initiate a Phase 1b cohort
expansion of ARV-471 in combination with Ibrance<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (palbociclib) in December 2020. This trial will evaluate the safety and tolerability of ARV-471 in combination with palbociclib and seek to
identify a recommended combination dose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to begin two additional studies of ARV-471 in the second half of 2021: a combination trial of
ARV-471 and another targeted therapy in second line and/or third line metastatic breast cancer, and a window of opportunity study in adjuvant breast cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The combined data from these studies will inform our global development strategy and path forward toward the goal for ARV-471 to become the leading
endocrine therapy in ER+/HER2- breast cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>ARV-110 Clinical Update </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On December 14, 2020, we also announced updated interim data from the dose escalation portion of our ongoing Phase 1/2 clinical trial of ARV-110 in men
with mCRPC. The dose escalation portion of our Phase 1/2 clinical trial of ARV-110 is designed to assess safety, tolerability and PK of ARV-110 in men with mCRPC who have progressed on standard of care therapies, as well as to identify a recommended
Phase 2 dose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that ARV-110 continues to show promising activity in a very late-line population, with prostate specific antigen, or PSA,
reductions equal to or greater than 50%, or a PSA50 response, observed at doses greater than 280 mg, the last cohort for which we had previously disclosed data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">ARV-110 exposures have risen dose proportionally, and at 420 mg oral daily dosing, exposures in nearly all patients have surpassed a threshold we
associated with tumor responses with ARV-110 in enzalutamide-resistant preclinical models of prostate cancer. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the dose escalation portion of the trial, 76% of patients had been treated with prior chemotherapy,
and 82% previously received both abiraterone and enzalutamide. Patients had a median of five prior lines of therapy. Multiple lines of therapy in nonmetastatic and metastatic castrate resistant prostate cancer are associated with a decreased
responsiveness to AR-directed therapies and an increase in tumor heterogeneity, including in genetic mutations, which reduce the tumor&#146;s dependence on the AR signaling axis. Genetic profiling of trial patient tumors showed genetic variability,
with 84% of patients in the trial having non-AR gene mutations. As such, these patients would not be expected to respond to AR-directed agents such as ARV-110. In addition, we found that rates of specific AR mutations have been found to be higher
than we anticipated based on previously published studies of men with mCRPC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have identified a molecularly defined, late-line population with a
particularly strong response to ARV-110. Two of five patients (40%) with T878 or H875 mutations in AR had a PSA50 response, including one patient with a tumor size reduction of 80%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, two of 15 patients (13%) with wild-type AR also had a PSA50 response, representing activity in a broader patient population. In the full
group of patients with exposures above the minimum threshold we predicted to be efficacious by preclinical studies, four of 28 (14%) had PSA reductions greater than 50%. We believe that this PSA50 response rate is substantially higher than would be
expected from approved AR-directed therapies in such late line patients. Specifically, PSA50 response rates from standard-of-care AR-directed therapies generally decrease to 8%-15% in mCRPC patients with fewer prior therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The dual signals of ARV-110 activity in a molecularly defined population (T878/H875) and in wild-type patients support our two-pronged strategy for
ARV-110 development and suggest a robust opportunity to address unmet need in patients with mCRPC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2020, we initiated the ARDENT Phase 2
expansion portion of the trial comprising patient subgroups. T878/H875 patients will be enriched in a subgroup to ensure sufficient patient numbers in an effort to confirm the potential for accelerated regulatory approval for ARV-110 in this
population. A separate subgroup will enrich for less-pretreated patients (i.e., no prior chemotherapy and with only one previous second-generation AR-directed therapy, such as enzalutamide or abiraterone), to ensure sufficient numbers of patients
whose tumors are expected to be more AR-dependent, less genetically complex, and potentially more responsive to ARV-110. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to provide
complete data from the dose escalation portion of the Phase 1/2 trial in 2021 and provide interim data from the ARDENT Phase 2 expansion portion of the Phase 1/2 trial in the second half of 2021, with full data following in 2022. In 2021, we also
expect to begin at least one Phase 1b combination trial with a standard-of-care prostate cancer therapy and provide data in 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Anticipated
Milestones </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we expect to file an investigational new drug, or IND, application for ARV-766, an AR degrader with a different
profile from ARV-110, and initiate a Phase 1 trial in the first half of 2021, and if ARV-766 progresses as planned, we expect to provide data from the Phase 1 trial and transition to Phase 2 in 2022. We anticipate filing IND applications for our
B-cell lymphoma 6 protein (BCL6) and tau programs as well as a further undisclosed oncology program in 2022. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Company Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We were formed under the laws of the State of Delaware in February 2013 as a limited liability company under the name Arvinas, LLC. In July 2013,
Arvinas, LLC converted into a Delaware corporation and changed its name to Arvinas, Inc. In December 2014, we completed a series of transactions pursuant to which Arvinas, Inc. became a direct, wholly owned subsidiary of Arvinas Holding Company,
LLC, a Delaware limited liability company. Immediately prior to our initial public offering, we converted from a Delaware limited liability company to a Delaware corporation and changed our name to Arvinas, Inc. Our office is located at 5 Science
Park, 395 Winchester Ave., New Haven, CT 06511 and our telephone number is (203) <FONT STYLE="white-space:nowrap">535-1456.</FONT> Our website address is www.arvinas.com. The information contained on, or that can be accessed through, our website is
not a part of this prospectus supplement. We have included our website address in this prospectus supplement solely as an inactive textual reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we currently qualify as an &#147;emerging growth company,&#148; as
defined in the Jumpstart Our Business Startups Act of 2012. However, based on the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> as of June&nbsp;30, 2020, we will cease to be an emerging growth
company on December&nbsp;31, 2020. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to public companies that are not emerging growth
companies. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> as of June&nbsp;30, 2020, we have
determined that we are no longer a &#147;smaller reporting company.&#148; However, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller
reporting companies until our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
public float, as of December&nbsp;9, 2020, was $1.03&nbsp;billion, based on 36,270,176 shares of our common stock issued and outstanding and held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> and a per share price of $28.48, based on
the last reported sale price of our common stock on December&nbsp;9, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Risks Associated with Our Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in
the &#147;Risk Factors&#148; section of this prospectus supplement immediately following this prospectus summary and in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended September&nbsp;30, 2020, which are
incorporated by reference herein. These risks include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have incurred significant losses since our inception. To date, we have not generated any revenue from product sales and
may never be profitable. We expect to incur losses over at least the next several years and may never achieve or maintain profitability. Our net loss was $77.8&nbsp;million for the nine months ended September&nbsp;30, 2020, $70.3&nbsp;million for
the year ended December&nbsp;31, 2019 and $41.5&nbsp;million for the year ended December&nbsp;31, 2018. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We will need substantial additional funding. If we are unable to raise capital when needed, we may be required to delay,
limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which has spread worldwide, may affect our ability to
initiate and complete preclinical studies, delay the initiation of our planned clinical trials or future clinical trials, disrupt regulatory activities, disrupt our manufacturing and supply chain or have other adverse effects on our business and
operations. We cannot be certain what the overall impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will be on our business, and it has the potential to materially and adversely affect our business, financial condition, results
of operations and prospects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our approach to the discovery and development of product candidates based on our PROTAC technology platform is unproven,
which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have a limited operating history that may make it difficult to evaluate the success of our business to date and to
assess our future viability and are very early in our development efforts. We initiated our first Phase 1 clinical trial for a product candidate, <FONT STYLE="white-space:nowrap">ARV-110,</FONT> in March 2019, and we initiated a Phase 1 clinical
trial of <FONT STYLE="white-space:nowrap">ARV-471</FONT> in August 2019. Both of these trials remain ongoing. In October 2020, we initiated the Phase 2 expansion for <FONT STYLE="white-space:nowrap">ARV-110.</FONT> All of our other product
candidates are still in preclinical development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We cannot be certain of the timely completion or outcome of our preclinical testing and clinical trials. The results of
preclinical studies may not be predictive of the results of clinical trials, and the results of early-stage clinical trials may not be predictive of the results of later-stage clinical trials. In addition, interim and preliminary data from our
clinical trials that we announce from time to time, such as the recently announced interim data from our ongoing Phase 1/2 clinical trials of <FONT STYLE="white-space:nowrap">ARV-110</FONT> and <FONT STYLE="white-space:nowrap">ARV-471,</FONT> may
change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data. If we are unable to obtain, or there are delays in obtaining, required regulatory approvals,
we will not be able to commercialize our product candidates, our business will be materially harmed and our ability to generate revenue from product sales will be materially impaired. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or
more successfully than we do. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We rely and expect to continue to rely on agreements with Yale University to supplement our internal research and
development program. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We rely, and expect to continue to rely, on third party manufacturing organizations for the manufacture of both drug
substance and finished drug product for our product candidates for preclinical testing and clinical trials, and we expect to continue to do so for commercialization. This reliance on third parties may increase the risk that we will not have
sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent
protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired, and we
may not be able to compete effectively in our market. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock offered by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$250.0&nbsp;million of shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock to be outstanding after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Option to purchase additional shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We have granted the underwriters an option for a period of 30&nbsp;days to purchase up to an additional $37.5&nbsp;million of shares of our common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We estimate that the net proceeds to us from this offering, after deducting estimated underwriting discounts and commissions and estimated offering
expenses payable by us, will be approximately $234.4 million (or approximately $269.6 million if the underwriters exercise in full their option to purchase additional shares).</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">We intend to use the net proceeds from this offering, together with our existing cash, cash
equivalents and marketable securities, to fund advancement of our <FONT STYLE="white-space:nowrap">ARV-110</FONT> clinical program, to fund advancement of our <FONT STYLE="white-space:nowrap">ARV-471</FONT> clinical program, to fund the anticipated
clinical development of <FONT STYLE="white-space:nowrap">ARV-766,</FONT> for preclinical studies for research stage programs in oncology and neuroscience and for research and development of our PROTAC platform, and for working capital and other
general corporate purposes. See the &#147;Use of Proceeds&#148; section of this prospectus supplement for a more complete description of the intended use of proceeds from this offering.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk Factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You should read the &#147;Risk Factors&#148; section of this prospectus supplement beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-9</FONT> and in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT>
for the period ended September&nbsp;30, 2020, as well as those risk factors in the other documents incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of factors to consider carefully before
deciding to purchase shares of our common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nasdaq Global Select Market symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;ARVN&#148;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock that will be outstanding immediately after this offering as shown above is
based on 41,844,381 shares of our common stock issued and outstanding, including 257,890 shares of unvested restricted common stock subject to repurchase by us, as of December&nbsp;9, 2020. The number of shares outstanding as of December&nbsp;9,
2020 as used throughout this prospectus supplement, unless otherwise indicated, excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">4,600,526 shares of our common stock issuable upon the exercise of stock options outstanding as of December&nbsp;9, 2020,
at a weighted average exercise price of $25.84 per share; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">133,049 shares of our common stock issuable upon the vesting of restricted stock units outstanding as of December&nbsp;9,
2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,875,303 additional shares of our common stock available for future issuance under our 2018 stock incentive plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,014,552 additional shares of our common stock available for future issuance under our 2018 employee stock purchase plan.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated or the context otherwise requires, all information in this prospectus supplement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">assumes no exercise of the outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">assumes no exercise by the underwriters of their option to purchase up to $37.5&nbsp;million of additional shares of common
stock from us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">does not reflect the potential issuance of shares of our common stock that remain available for sale as of the date of this
prospectus supplement under our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offering program, pursuant to which we may sell common stock for remaining gross proceeds of up to
$34.4&nbsp;million from time to time under our equity distribution agreement with Piper Sandler&nbsp;&amp; Co. (formerly Piper Jaffray&nbsp;&amp; Co.). </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptx20220_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with
all of the other information contained in this prospectus supplement, the accompanying prospectus and in the documents incorporated by reference herein and therein, including the risks described in the &#147;Risk Factors&#148; section of our
Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended September&nbsp;30, 2020, before deciding to invest in our common stock. If any of these risks actually occur, our business, prospects, operating results and
financial condition could suffer materially. In such event, the trading price of our common stock could decline and you might lose all or part of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Risks Related to This Offering </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If you purchase shares
of common stock in this offering, you will suffer immediate dilution of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The price of our common stock in this offering is
substantially higher than the net tangible book value per share of our outstanding common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book
value per share after this offering. To the extent shares subsequently are issued under outstanding options, you will incur further dilution. Based on a public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, you will experience immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share, representing the difference between our as adjusted net tangible book value per share, after giving effect to this offering, and the public offering price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the
section of this prospectus supplement titled &#147;Use of Proceeds,&#148; and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds
effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net
proceeds from this offering in a manner that does not produce income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If a significant portion of our total outstanding shares are sold
into the market, the market price of our common stock could drop significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sales of a substantial
number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.&nbsp;Holders of a significant portion
of our common stock have rights, subject to specified conditions, to require us to file&nbsp;registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, in July 2019, we issued 1,346,313 shares of our common stock to Bayer AG. On October&nbsp;1, 2019, we filed a registration statement
on Form <FONT STYLE="white-space:nowrap">S-3</FONT> covering the resale of these shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have registered all shares of common stock that we may
currently issue under our equity compensation plans. These shares can be freely sold in the public market upon&nbsp;issuance, subject to volume, notice and manner of sale limitations applicable to affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently have on&nbsp;file with the SEC universal shelf registration statements on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> which allow us to offer and sell registered common stock, preferred stock, debt securities, depositary shares, units and/or warrants from time to time pursuant to one or more offerings at prices and terms to be
determined at the time of sale. In October 2019, we entered into an Equity Distribution Agreement, or Distribution Agreement, with Piper Sandler&nbsp;&amp; Co. (formerly Piper Jaffray&nbsp;&amp; Co.), or Piper Sandler, pursuant to which, from time
to time, we may offer and sell through Piper Sandler up to $100.0&nbsp;million of the common stock registered under a universal shelf registration statement pursuant to one or more
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offerings. In November 2019, we completed a <FONT STYLE="white-space:nowrap">follow-on</FONT> offering of common stock, which resulted in
5,227,273 shares of common stock being sold under our universal shelf registration statement. From September through December 2020, we sold 2,593,637 shares of common stock in an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> offering for aggregate net proceeds of $64.1&nbsp;million. As of the date of this prospectus supplement, we have common stock that we may issue and sell
for gross proceeds of up to $34.4&nbsp;million that remain available under our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offering program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sales of substantial amounts of shares of our common stock or other securities by our stockholders, by Piper Sandler pursuant to the Distribution
Agreement, under our universal shelf registration statements or otherwise could also dilute our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptx20220_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that the net proceeds from our issuance and sale of $250.0&nbsp;million of shares of our common stock in this offering will be approximately
$234.4 million, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise in full their option to purchase additional shares, we estimate that the net proceeds from
this offering will be approximately $269.6 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently estimate that we will use the net proceeds from this offering to fund advancement
of our <FONT STYLE="white-space:nowrap">ARV-110</FONT> clinical program, to fund advancement of our <FONT STYLE="white-space:nowrap">ARV-471</FONT> clinical program, to fund the anticipated clinical development of
<FONT STYLE="white-space:nowrap">ARV-766,</FONT> for preclinical studies for research stage programs in oncology and neuroscience and for research and development of our PROTAC platform, and for working capital and other general corporate purposes.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. The
amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development efforts, the status of and results from clinical trials, as well as any collaborations that we may enter
into with third parties for our product candidates, and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of September 30, 2020, we had cash, cash equivalents and marketable securities of approximately $248.6&nbsp;million. From October through December
2020, we sold 1,430,563 shares of our common stock in an at-the-market offering for aggregate net proceeds of $34.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based upon our current
operating plan, we estimate that the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, will enable us to fund our operating expenses and capital expenditure requirements into the second
half of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. See the &#147;Risk Factors&#148; section of this prospectus supplement and the
documents incorporated by reference for a discussion of the risks affecting our business that could have an adverse effect on our available capital resources. We do not expect that our existing cash, cash equivalents and marketable securities and
net proceeds from this offering alone will be sufficient to enable us to fund the completion of the development of any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may also use a portion of the net proceeds from this offering for the acquisition or <FONT STYLE="white-space:nowrap">in-license</FONT> of other
products, product candidates, businesses or technologies, although we have no current agreements or commitments for any material acquisitions or licenses of any products, businesses or technologies. Pending application of the net proceeds as
described above, we may temporarily invest the net proceeds in a variety of capital preservation instruments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptx20220_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth our cash, cash equivalents and marketable securities and capitalization as of September&nbsp;30, 2020, as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an actual basis; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an as adjusted basis to give effect to our issuance and sale of $250.0&nbsp;million of shares of our common stock in
this offering at a public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, after deducting underwriting discounts and commissions and estimated offering expenses payable
by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You should read the following table together with our consolidated financial statements and related notes to those
statements and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2019 and
our Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the nine months ended September&nbsp;30, 2020, which are incorporated by reference into this prospectus supplement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;September 30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(unaudited)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Long term debt, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preferred stock, par value $0.001 per share; 5,000,000 shares authorized, no shares issued or outstanding,
actual and as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock, $0.001 par value: 200,000,000 shares authorized, actual and as adjusted; 40,410,812 shares
issued and outstanding, actual; shares issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">654,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(450,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">207,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table above is based on 40,410,812 shares of our common stock issued and outstanding, including 314,811 shares of
unvested restricted common stock subject to repurchase by us, as of September&nbsp;30, 2020, and does not include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">4,528,607 shares of our common stock issuable upon the exercise of stock options outstanding as of September&nbsp;30, 2020,
at a weighted average exercise price of $25.88 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">133,049 shares of our common stock issuable upon the vesting of restricted stock units outstanding as of September&nbsp;30,
2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,950,228 additional shares of our common stock available for future issuance under our 2018 stock incentive plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,014,552 additional shares of our common stock available for future issuance under our 2018 employee stock purchase plan;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,430,563 shares of common stock issued and sold after September&nbsp;30, 2020 pursuant to our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offering program for aggregate gross sale proceeds of $34.8&nbsp;million, before </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
deducting sales commissions and offering expenses, and the potential issuance of shares of common stock that remain available for sale as of the date of this prospectus supplement under our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offering program, pursuant to which we may sell common stock for remaining gross proceeds of up to $34.4&nbsp;million from time to time under our
equity distribution agreement with Piper Sandler. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The as adjusted information discussed above will be based on the number of
shares, the offering price and other terms determined at pricing of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptx20220_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the
public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our net tangible book value as of September&nbsp;30, 2020 was $205.1&nbsp;million, or $5.08 per share of our common stock, based on approximately
40,410,812 shares of our common stock then outstanding, including 314,811 shares of unvested restricted stock subject to repurchase by us. Our net tangible book value is the amount of our total tangible assets less our total liabilities. Net
tangible book value per share represents our net tangible book value divided by the 40,410,812 shares of our common stock outstanding, including 314,811 shares of unvested restricted common stock subject to repurchase by us as of September&nbsp;30,
2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After giving effect to our issuance and sale of $250.0&nbsp;million of shares of our common stock in this offering at a public offering price
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible
book value as of September&nbsp;30, 2020 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This represents an immediate increase in as adjusted net tangible book value per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to existing stockholders and immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in
as adjusted net tangible book value per share to new investors purchasing common stock in this offering. Dilution per share to new investors is determined by subtracting as adjusted net tangible book value per share after this offering from the
public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net tangible book value per share as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in net tangible book value per share attributable to new investors purchasing shares in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">$</P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to new investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the underwriters exercise their option to purchase $37.5&nbsp;million of additional shares of our common stock in
full at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us, the as adjusted net tangible book value per share of our common stock immediately after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing an
increase to existing stockholders of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and an immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to new investors in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table and
calculations above are based on 40,410,812 shares of our common stock issued and outstanding, including 314,811 shares of unvested restricted common stock subject to repurchase by us, as of September&nbsp;30, 2020, and exclude the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">4,528,607 shares of our common stock issuable upon the exercise of stock options outstanding as of September&nbsp;30, 2020,
at a weighted average exercise price of $25.88 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">133,049 shares of our common stock issuable upon the vesting of restricted stock units outstanding as of September&nbsp;30,
2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,950,228 additional shares of our common stock available for future issuance under our 2018 stock incentive plan;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,014,552 additional shares of our common stock available for future issuance under our 2018 employee stock purchase plan;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,430,563 shares of common stock issued and sold after September&nbsp;30, 2020 pursuant to our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offering program for aggregate gross sale proceeds of $34.8&nbsp;million, before deducting sales commissions and offering expenses, and the potential
issuance of shares of common stock that remain available for sale as of the date of this prospectus supplement under our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offering program,
pursuant to which we may sell common stock for remaining gross proceeds of up to $34.4&nbsp;million from time to time under our equity distribution agreement with Piper Sandler. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If any additional shares are issued in connection with the exercise of options or pursuant to our equity distribution agreement with Piper Sandler, you
will experience further dilution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The as adjusted information discussed above will be based on the number of shares, the offering price and other
terms determined at pricing of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptx20220_8"></A>MATERIAL U.S. TAX CONSIDERATIONS FOR
<FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following is a discussion of material U.S. federal income and
estate tax considerations relating to ownership and disposition of our common stock by <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;holder.</FONT> For purposes of this discussion, the
<FONT STYLE="white-space:nowrap">term&nbsp;&#147;non-U.S.&nbsp;holder&#148;</FONT> means a beneficial owner (other than a partnership or other pass-through&nbsp;entity) of our common stock that is not, for U.S. federal income tax purposes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized in or
under the laws of the United States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a trust if (1)&nbsp;a U.S. court is able to exercise primary supervision over the administration of the trust and one or
more U.S. persons have authority to control all substantial decisions of the trust or (2)&nbsp;the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion does not address the tax treatment of partnerships or other entities that are&nbsp;pass-through&nbsp;entities for U.S. federal income
tax purposes or persons who hold their shares of our common stock through partnerships or such other&nbsp;pass-through&nbsp;entities. A partner in a partnership or other pass-through&nbsp;entity that will hold our common stock should consult his,
her or its own tax advisor regarding the tax consequences of the ownership and disposition of our common stock through a partnership or other&nbsp;pass-through&nbsp;entity, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion is based on current provisions of the Internal Revenue Code of 1986, or the Code, existing and proposed U.S. Treasury Regulations
promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any change or
differing interpretation could alter the tax consequences <FONT STYLE="white-space:nowrap">to&nbsp;non-U.S.&nbsp;holders</FONT> described in this prospectus. There can be no assurance that the Internal Revenue Service, or the IRS, will not challenge
one or more of the tax consequences described in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We assume in this discussion that
<FONT STYLE="white-space:nowrap">each&nbsp;non-U.S.&nbsp;holder</FONT> holds shares of our common stock as a capital asset (generally, property held for investment). This discussion does not address all aspects of U.S. federal income and estate
taxation that may be relevant to a <FONT STYLE="white-space:nowrap">particular&nbsp;non-U.S.&nbsp;holder</FONT> in light of <FONT STYLE="white-space:nowrap">that&nbsp;non-U.S.</FONT> holder&#146;s individual circumstances nor does it address any
aspects of U.S. state, local <FONT STYLE="white-space:nowrap">or&nbsp;non-U.S.&nbsp;taxes,</FONT> the alternative minimum tax, or the Medicare tax on net investment income. This discussion also does not consider any specific facts or circumstances
that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special tax rules applicable to <FONT STYLE="white-space:nowrap">particular&nbsp;non-U.S.&nbsp;holders,</FONT> such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">financial institutions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt&nbsp;organizations;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">pension plans, including &#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and
entities all of the interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">owners that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other
integrated investment or who have elected to mark securities to market; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">controlled foreign corporations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">passive foreign investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">non-U.S.&nbsp;governments;</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">certain U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT, AND IS NOT INTENDED TO BE, LEGAL OR TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT
THEIR OWN TAX ADVISORS REGARDING THE U.S. FEDERAL, STATE, LOCAL, <FONT STYLE="white-space:nowrap">AND&nbsp;NON-U.S.</FONT> INCOME, ESTATE AND OTHER TAX CONSIDERATIONS OF ACQUIRING, HOLDING AND DISPOSING OF OUR COMMON STOCK. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Distributions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we make distributions in
respect of our common stock, those distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax
principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as <FONT STYLE="white-space:nowrap">a&nbsp;tax-free&nbsp;return</FONT> of
<FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder&#146;s</FONT> investment, up to the holder&#146;s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below under
the heading &#147;Gain on Sale, Exchange or Other Taxable Disposition of Our Common Stock.&#148; Any distributions will also be subject to the discussions below under the headings &#147;Information Reporting and Backup Withholding&#148; and
&#147;FATCA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Dividends paid to <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;holder</FONT> generally will be subject to withholding
of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Dividends that are treated as effectively connected with a trade or business conducted by
<FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;holder</FONT> within the United States, and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by <FONT
STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder</FONT> within the United States, are generally exempt from the 30% withholding tax if <FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder</FONT> satisfies applicable certification
and disclosure requirements (generally including provision of a valid IRS&nbsp;Form <FONT STYLE="white-space:nowrap">W-8ECI&nbsp;(or</FONT> applicable successor form) certifying that the dividends are effectively connected with <FONT
STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder&#146;s</FONT> conduct of a trade or business within the United States). However, such U.S. effectively connected income is taxed on a net income basis at the same U.S. federal income tax rates
applicable to U.S. persons (as defined in the Code). Any U.S. effectively connected income received by <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;holder</FONT> that is classified as a corporation for U.S. federal income tax purposes may
also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of
residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">A&nbsp;non-U.S.&nbsp;holder</FONT> of our common stock who claims the benefit of an applicable income
tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a properly executed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8BEN&nbsp;or&nbsp;W-8BEN-E&nbsp;(or</FONT></FONT></FONT> successor form) and satisfy applicable certification and other
requirements.&nbsp;A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an
appropriate claim with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.&nbsp;holders</FONT> are urged to consult their own tax advisors regarding their entitlement to benefits under a relevant income tax treaty and the specific methods available
to them to satisfy these requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Gain on Sale, Exchange or Other Taxable Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">A&nbsp;non-U.S.&nbsp;holder</FONT> generally will not be subject to U.S. federal income tax on any gain realized upon <FONT
STYLE="white-space:nowrap">such&nbsp;non-U.S.&nbsp;holder&#146;s</FONT> sale, exchange or other disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the gain is effectively connected with <FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder&#146;s</FONT> conduct
of a trade or business in the United States, and, if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by <FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder</FONT>
in the United States; in these cases, <FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder</FONT> generally will be taxed on a net income basis at the same U.S. federal income tax rates applicable to U.S. persons (as defined in the Code),
and, if <FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder</FONT> is a foreign corporation, the branch profits tax described above under the heading &#147;Distributions&#148; may also apply; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder</FONT> is
<FONT STYLE="white-space:nowrap">a&nbsp;non-resident&nbsp;alien</FONT> present in the United States for 183&nbsp;days or more in the taxable year of the disposition and certain other requirements are met, in which case the <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain
derived from the disposition, which may be offset by certain&nbsp;U.S.-source&nbsp;capital losses of <FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder,</FONT> if any; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we are or have been, at any time during the&nbsp;five-year&nbsp;period preceding such disposition (or <FONT
STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder&#146;s</FONT> holding period, if shorter) a &#147;U.S. real property holding corporation&#148; unless our common stock is regularly traded on an established securities market and the <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;holder</FONT> held no more than 5% of our outstanding common stock, directly or indirectly, during the shorter of the&nbsp;five-year&nbsp;period ending on the date of the disposition or the period that <FONT
STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder</FONT> held our common stock. If we are determined to be a U.S. real property holding corporation and the foregoing exception does not apply, then the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on its net gain derived from the disposition at the U.S. federal income tax rates applicable to U.S. persons (as defined in the Code). Generally, a corporation is a
&#147;U.S. real property holding corporation&#148; if the fair market value of its &#147;U.S. real property interests&#148; equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used
or held for use in a trade or business. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming, a &#147;U.S. real property holding corporation&#148; for U.S. federal income tax purposes. No
assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rule described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>U.S. Federal Estate Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares of our common stock
that are owned or treated as owned by an individual who is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (as specially defined for U.S. federal estate tax purposes) at the time of death are considered U.S. situs assets and will be
included in the individual&#146;s gross estate for U.S. federal estate tax purposes. Such shares, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax or other treaty provides otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We must report annually to the IRS and to <FONT STYLE="white-space:nowrap">each&nbsp;non-U.S.&nbsp;holder</FONT> the gross amount of the distributions
on our common stock paid to such holder and the tax withheld, if any, with respect to such <FONT STYLE="white-space:nowrap">distributions.&nbsp;Non-U.S.&nbsp;holders</FONT> may have to comply with specific certification procedures to establish that
the holder is not a U.S. person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Generally, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will comply with
such procedures if it provides a properly executed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8BEN&nbsp;or&nbsp;W-8BEN-E&nbsp;(or</FONT></FONT></FONT> other <FONT
STYLE="white-space:nowrap">applicable&nbsp;Form&nbsp;W-8),&nbsp;or</FONT> otherwise meets documentary evidence requirements for establishing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
that it is <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;holder,</FONT> or otherwise establishes an exemption. Dividends paid
<FONT STYLE="white-space:nowrap">to&nbsp;non-U.S.&nbsp;holders</FONT> subject to withholding of U.S. federal income tax, as described above under the heading &#147;Distributions,&#148; will generally be exempt from U.S. backup withholding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Information reporting and backup withholding generally will apply to the proceeds of a disposition of our common stock by
<FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;holder</FONT> effected by or through the U.S. office of any broker, U.S. <FONT STYLE="white-space:nowrap">or&nbsp;non-U.S.,&nbsp;unless</FONT> the holder certifies its status as <FONT
STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;holder</FONT> and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition
proceeds to <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;holder</FONT> where the transaction is effected outside the United States through <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;office</FONT> of a broker. However, for
information reporting purposes, dispositions effected through <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;office</FONT> of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions
effected through a U.S. office of a <FONT STYLE="white-space:nowrap">broker.&nbsp;Non-U.S.&nbsp;holders</FONT> should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Copies of information returns may be made available to the tax authorities of the country in which
<FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder</FONT> resides or is incorporated under the provisions of a specific treaty or agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Backup withholding is not an additional tax. Rather, any amounts withheld under the backup withholding rules from a payment to <FONT
STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;holder</FONT> can be refunded or credited against the <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;holder&#146;s</FONT> U.S. federal income tax liability, if any, provided that an appropriate claim
is timely filed with the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FATCA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Provisions of the Code commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, generally impose a 30% withholding tax on dividends on,
and gross proceeds from the sale or other disposition of, our common stock if paid to a foreign entity unless (1)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; the foreign entity undertakes certain due diligence,
reporting, withholding, and certification obligations, (2)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; the foreign entity identifies certain of its U.S. investors, or (3)&nbsp;the foreign entity is otherwise
excepted under FATCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Withholding under FATCA generally applies to payments of dividends on our common stock. While withholding under FATCA may
apply to payments of gross proceeds from a sale or other disposition of our common stock under proposed U.S. Treasury Regulations, withholding on payments of gross proceeds is not required. Although such regulations are not final, applicable
withholding agents may rely on the proposed regulations until final regulations are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If withholding under FATCA is required on any payment
related to our common stock, investors not otherwise subject to withholding (or that otherwise would be entitled to a reduced rate of withholding) on such payment may be required to seek a refund or credit from the IRS. An intergovernmental
agreement between the United States and an applicable foreign country may modify the requirements described in this section. <FONT STYLE="white-space:nowrap">Non-U.S.&nbsp;holders</FONT> should consult their own tax advisors regarding the possible
implications of FATCA on their investment in our common stock and the entities through which they hold our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>The preceding
discussion of material U.S. federal tax considerations is for informational purposes only. It is not legal or tax advice. Prospective investors should consult their own tax advisors regarding the particular U.S. federal, state, local, <FONT
STYLE="white-space:nowrap">and&nbsp;non-U.S.&nbsp;tax</FONT> consequences of purchasing, holding and disposing of our common stock, including the consequences of any proposed changes in applicable laws. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptx20220_9"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are offering the shares of common stock described in this prospectus supplement through the underwriters named below. We have entered into an
underwriting agreement with the underwriters named below. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering
price less the underwriting discounts and commissions set forth on the cover page of this prospectus supplement, the number of shares of common stock listed next to its name in the following table: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares. The
underwriting agreement also provides that if an underwriter defaults, the purchase <FONT STYLE="white-space:nowrap">commitments&nbsp;of&nbsp;non-defaulting&nbsp;underwriters&nbsp;may</FONT> also be increased or the offering may be terminated. The
offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#146; right to reject any order in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters have a 30 day option to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock from us. If any shares are purchased with this option, the underwriters will purchase shares in approximately the
same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common
stock. The underwriting fee is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. The underwriters have advised us that they propose to offer the shares of common stock to the public at the
public offering price set forth on the cover page of this prospectus supplement and to certain dealers, which may include the underwriters, at that price less a concession not in excess of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock. After the public offering of the shares, the offering price and other selling terms may be changed by the underwriters. The
following table shows the per share and total underwriting discounts we will pay to the underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total to be paid by Arvinas, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and
legal and accounting expenses, but excluding the underwriting discounts, will be approximately $400,000. We have agreed to reimburse the underwriters up to an aggregate of $20,000 for fees incurred by them in connection with any required filings
with the Financial Industry Regulatory Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and our executive officers, directors and certain stockholders have agreed or will agree with
the underwriters, subject to certain exceptions, not to dispose of or hedge any of our or their common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus continuing
through the date 60 days after the date of this prospectus, except with the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC and Piper Sandler&nbsp;&amp; Co. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have agreed to indemnify the several underwriters against certain liabilities, including
liabilities under the Securities Act of 1933, as amended, the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our common stock is listed on the Nasdaq Global Select Market under
the symbol &#147;ARVN&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids
for, purchasing and selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making
short sales of the common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover
positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option referred to above, or may be &#147;naked&#148; shorts, which are short positions
in excess of that amount. The underwriters may close out any covered short position either by exercising their option, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider,
among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option. A naked short position is more likely to be created if the underwriters are
concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will
purchase shares in the open market to cover the position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities
Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in
the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market
price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The
underwriters may carry out these transactions on the Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter&nbsp;market&nbsp;or</FONT></FONT> otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, in connection with this offering certain of the underwriters (and selling group members) may engage in passive market making transactions
in our common stock on the Nasdaq Global Select Market prior to the pricing and completion of this offering. Passive market making consists of displaying bids on the Nasdaq Global Select Market no higher than the bid prices of independent market
makers and making purchases at prices no higher than these independent bids and effected in response to order flow. Net purchases by a passive market maker on each day are generally limited to a specified percentage of the passive market
maker&#146;s average daily trading volume in the common stock during a specified period and must be discontinued when such limit is reached. Passive market making may cause the price of our common stock to be higher than the price that otherwise
would exist in the open market in the absence of these transactions. If passive market making is commenced, it may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A
prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters
and selling group members for sale to their online </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as
other allocations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Other Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and
trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other
<FONT STYLE="white-space:nowrap">financial&nbsp;and&nbsp;non-financial&nbsp;activities&nbsp;and</FONT> services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to
the Company and to persons and entities with relationships with the Company, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors and employees may
purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers, and
such investment and trading activities may involve or relate to assets, securities and/or instruments of the Company (directly, as collateral securing other obligations or otherwise) and/or persons and entities with relationships with the Company.
The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such assets, securities or instruments and
may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Selling Restrictions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>European Economic Area
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a &#147;Relevant Member
State&#148;) an offer to the public of our common shares may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of our common shares may be made at any time under the following exemptions
under the Prospectus Directive: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive),
subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">provided that no such offer of shares of our common stock shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article
3 of the Prospectus Directive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to our common
shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and our common shares to be offered so as to enable an investor to decide to purchase our common shares, as
the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended), including by Directive 2010/73/EU, and
includes any relevant implementing measure in the Relevant Member State. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This European Economic Area selling restriction is in addition to any other selling restrictions set
out below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each underwriter has
represented and agreed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation
or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000 (&#147;FSMA&#148;) received by it in connection with the issue or sale of the shares of our common stock in
circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in
relation to the shares of our common stock in, from or otherwise involving the United Kingdom. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in <FONT
STYLE="white-space:nowrap">National&nbsp;Instrument&nbsp;45-106&nbsp;Prospectus&nbsp;Exemptions</FONT> or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration&nbsp;Requirements,</FONT> Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not
subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may
provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a <FONT
STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not
required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares may not be offered or sold by
means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap.&nbsp;32, Laws of Hong&nbsp;Kong), or (ii)&nbsp;to &#147;professional investors&#148; within
the meaning of the Securities and Futures Ordinance (Cap.&nbsp;571, Laws of Hong Kong) and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the
Companies Ordinance (Cap.&nbsp;32, Laws of Hong Kong), and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or
elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to shares which are or are intended to be
disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.&nbsp;571, Laws of Hong Kong) and any rules made thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or
purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter&nbsp;289 of Singapore (the &#147;SFA&#148;), (ii)&nbsp;to a relevant
person, or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions, specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of
the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 by a relevant person which is: (a)&nbsp;a corporation (which is not an
accredited investor) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (b)&nbsp;a trust (where the trustee is not an accredited
investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, shares, debentures and units of shares and debentures of that corporation or the beneficiaries&#146; rights and interest in that trust shall not be
transferable for 6&nbsp;months after that corporation or that trust has acquired the shares under Section&nbsp;275 except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person, or any person pursuant to
Section&nbsp;275(1A), and in accordance with the conditions, specified in Section&nbsp;275 of the SFA; (2)&nbsp;where no consideration is given for the transfer; or (3)&nbsp;by operation of law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities have not been and will not be
registered under the Financial Instruments and Exchange Law of Japan (the Financial Instruments and Exchange Law) and each underwriter has agreed that it will not offer or sell any securities, directly or indirectly, in Japan or to, or for the
benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to
<FONT STYLE="white-space:nowrap">others&nbsp;for&nbsp;re-offering&nbsp;or&nbsp;resale,</FONT> directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in
compliance with, the Financial Instruments and Exchange Law and any other applicable laws, regulations and ministerial guidelines of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Israel
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli
Securities Law, 5728&#151;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728&#151;1968, including, inter
alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the &#147;Addressed Investors&#148;); or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors
defined in the First Addendum of the Israeli Securities Law, 5728&#151;1968, subject to certain conditions (the &#147;Qualified Investors&#148;). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may
be offered to purchase securities in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&#151;1968.
We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. Qualified
Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&#151;1968. In particular, we may request, as a condition to be offered common stock, that Qualified
Investors will each represent, warrant and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law,
5728&#151;1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli
Securities Law, 5728&#151;1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv)&nbsp;that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli
Securities Law, 5728&#151;1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law,
5728&#151;1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration
containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptx20220_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The validity of the shares of common stock offered hereby is being passed upon for us by Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP. Goodwin
Procter&nbsp;LLP is acting as counsel for the underwriters in connection with this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptx20220_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The consolidated financial statements incorporated in this prospectus supplement by reference from the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019 have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report, which is incorporated herein by
reference. Such consolidated financial statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptx20220_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the
Internet at the SEC&#146;s website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at www.arvinas.com. Our website is not a part of this prospectus supplement and is not incorporated by
reference in this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus supplement is part of a registration statement we filed with the SEC. This prospectus
supplement omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the accompanying prospectus and the registration statement for further
information about us and our consolidated subsidiaries and the securities we are offering. Statements in this prospectus supplement concerning any document we filed as an exhibit to the accompany prospectus, the registration statement or that we
otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements. You can obtain a copy of the accompanying prospectus and the
registration statement from the SEC&#146;s website. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suptx20220_13"></A>INCORPORATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The SEC allows us to incorporate by reference in this prospectus supplement much of the information we file with the SEC, which means that we can
disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus supplement and the accompanying prospectus is considered to be part of this prospectus
supplement. Because we are incorporating by reference future filings with the SEC, this prospectus supplement is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus
supplement. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus supplement or the accompanying prospectus or in any document previously incorporated by
reference have been modified or superseded. This prospectus supplement incorporates by reference the documents listed below <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;001-38672)&nbsp;and</FONT> any future filings we make with the SEC under
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
than those documents or the portions of those documents not deemed to be filed) until the offering of the securities under the registration statement is terminated or completed: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000156459020011004/arvn-10k_20191231.htm">Form 10-K
</A> for the fiscal year ended December 31, 2019, filed on March 16, 2020, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000156459020017721/arvn-def14a_20200603.htm">definitive
 proxy statement</A> for the 2020 Annual Meeting of Stockholders, filed on April 21, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarters ended March&nbsp;31, 2020,
June&nbsp;30, 2020 and September&nbsp;30, 2020, filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000156459020019266/arvn-10q_20200331.htm">April<U></U>&nbsp;
28, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1655759/000156459020036168/arvn-10q_20200630.htm">August&nbsp;
4, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1655759/000156459020051413/arvn-10q_20200930.htm">November&nbsp;5, 2020</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520026873/d879012d8k.htm">February
<U></U>&nbsp;6, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520141786/d905925d8k.htm">May<U></U>&nbsp;
14, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520154927/d845849d8k.htm">May<U></U>&nbsp;
29, 2020</A> (other than Item 7.01), <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520160809/d912019d8k.htm">June<U></U>&nbsp;
4, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520162331/d938314d8k.htm">June<U></U>&nbsp;5, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520166729/d941240d8k.htm">June<U></U>&nbsp;11,
2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520184135/d945997d8k.htm">June<U></U>&nbsp;
30, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1655759/000119312520268956/d98837d8k.htm">October&nbsp;
14, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1655759/000119312520316409/d96003d8k.htm">December 14, 2020</A> (other than Item 7.01); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The description of our common stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312518280053/d589006d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed on September&nbsp;21, 2018, including any amendments or reports filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Arvinas, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 Science Park </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">395 Winchester Ave. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">New Haven, Connecticut 06511 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="white-space:nowrap">(203)&nbsp;535-1456</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Arvinas, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt
Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Depositary Shares </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell
securities from time to time in one or more offerings. This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide the specific terms of these securities in
supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information contained in this document. You should read this
prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as the documents incorporated by reference herein or therein, carefully before you invest. This prospectus may not be used to offer and sell our
securities unless accompanied by a prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer these securities in amounts, at prices and on terms determined at the time of
offering. The securities may be sold directly to you, through agents, or through underwriters and dealers. If agents, underwriters or dealers are used to sell the securities, we will name them and describe their compensation in a prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;ARVN&#148;. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in these securities involves significant risks. See &#147;<A HREF="#toc211246_2">Risk Factors</A>&#148; on page&nbsp;2 of this prospectus and the
risk factors set forth in any accompanying prospectus supplement and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. We urge you to read the entire prospectus,
any amendments or supplements, any free writing prospectuses, and any documents incorporated by reference carefully before you make your investment decision. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is December&nbsp;14, 2020 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_3">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_4">INCORPORATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_5">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_6">ARVINAS, INC.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_8">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_9">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_10">DESCRIPTION OF DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_11">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_12">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_13">FORMS OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_14">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_15">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc211246_16">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, which we refer to as the SEC, as a
&#147;well-known seasoned issuer&#148; as defined in Rule 405 under the Securities Act of 1933, as amended, which we refer to as the Securities Act, utilizing an automatic &#147;shelf&#148; registration process. Under this shelf registration
process, we may from time to time sell any combination of the securities described in this prospectus in one or more offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus provides
you with a general description of the securities we may offer. Each time we sell securities, we will provide one or more prospectus supplements that will contain specific information about the terms of the offering. The prospectus supplement may
also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read both this prospectus and the accompanying prospectus supplement together with the
additional information described under the heading &#147;Where You Can Find More Information&#148; beginning on page 4 of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should
rely only on the information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with
different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus or such accompanying
prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any
prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially
since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise indicates, references in this prospectus to &#147;Arvinas,&#148; &#147;we,&#148; &#147;our,&#148;
&#147;us,&#148; and &#147;the Company&#148; refer, collectively, to Arvinas, Inc., a Delaware corporation, and its consolidated subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our securities involves significant risks. You should carefully consider the risks and uncertainties described in this prospectus, including
those set forth below, and any accompanying prospectus supplement, including the risk factors set forth in our filings with the SEC that are incorporated by reference herein, before making an investment decision pursuant to this prospectus and any
accompanying prospectus supplement relating to a specific offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business, financial condition and results of operations could be materially and
adversely affected by any or all of these risks or by additional risks and uncertainties not presently known to us or that we currently deem immaterial that may adversely affect us in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These risks include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant losses since our inception. To date, we have not generated any revenue from product
sales and may never be profitable. We expect to incur losses over at least the next several years and may never achieve or maintain profitability. Our net loss was $77.8 million for the nine months ended September 30, 2020, $70.3&nbsp;million for
the year ended December&nbsp;31, 2019 and $41.5&nbsp;million for the year ended December&nbsp;31, 2018. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need substantial additional funding. If we are unable to raise capital when needed, we may be required to
delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The COVID-19 pandemic, which has spread worldwide, may affect our ability to initiate and complete preclinical
studies, delay the initiation of our planned clinical trials or future clinical trials, disrupt regulatory activities, disrupt our manufacturing and supply chain or have other adverse effects on our business and operations. We cannot be certain what
the overall impact of the COVID-19 pandemic will be on our business, and it has the potential to materially and adversely affect our business, financial condition, results of operations and prospects. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our approach to the discovery and development of product candidates based on our PROTAC technology platform is
unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history that may make it difficult to evaluate the success of our business to date
and to assess our future viability and are very early in our development efforts. We initiated our first Phase 1 clinical trial for a product candidate, ARV-110, in March 2019, and we initiated a Phase 1 clinical trial of ARV-471 in August 2019.
Both of these trials remain ongoing. In October 2020, we initiated the Phase 2 expansion for ARV-110. All of our other product candidates are still in preclinical development. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We cannot be certain of the timely completion or outcome of our preclinical testing and clinical trials. The
results of preclinical studies may not be predictive of the results of clinical trials, and the results of early-stage clinical trials may not be predictive of the results of later-stage clinical trials. In addition, interim and preliminary data
from our clinical trials that we announce from time to time, such as the recently announced interim data from our ongoing Phase 1/2 clinical trials of ARV-110 and ARV-471, may change as more patient data becomes available and are subject to audit
and verification procedures that could result in material changes in the final data. If we are unable to obtain, or there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, our
business will be materially harmed and our ability to generate revenue from product sales will be materially impaired. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face substantial competition, which may result in others discovering, developing or commercializing products
before or more successfully than we do. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely and expect to continue to rely on agreements with Yale University to supplement our internal research and
development program. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely, and expect to continue to rely, on third party manufacturing organizations for the manufacture of both
drug substance and finished drug product for our product candidates for preclinical testing and clinical trials, and we expect to continue to do so for commercialization. This reliance on third parties may increase the risk that we will not have
sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the
patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired,
and we may not be able to compete effectively in our market. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_3"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the
Internet at the SEC&#146;s website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at www.arvinas.com. Our website is not a part of this prospectus and is not incorporated by reference
in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. This prospectus omits some information contained in the
registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiaries and the securities we are offering.
Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should
review the complete document to evaluate these statements. You can obtain a copy of the registration statement from the SEC&#146;s website. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_4"></A>INCORPORATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference in this prospectus much of the information we file with the SEC, which means that we can disclose important
information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with
the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by
reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-38672)</FONT> and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in each case, other than those
documents or the portions of those documents not deemed to be filed) until the offering of the securities under the registration statement is terminated or completed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000156459020011004/arvn-10k_20191231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2019, filed on March&nbsp;16, 2020, including the information specifically incorporated by reference into the Annual Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> from our <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000156459020017721/arvn-def14a_20200603.htm">definitive proxy statement</A> for the 2020 Annual Meeting of Stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarters ended
March&nbsp;31, 2020, June&nbsp;30, 2020 and September&nbsp;30, 2020, filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000156459020019266/arvn-10q_20200331.htm">April&nbsp;
28, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1655759/000156459020036168/arvn-10q_20200630.htm">August&nbsp;
4, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1655759/000156459020051413/arvn-10q_20200930.htm">November&nbsp;5, 2020</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520026873/d879012d8k.htm">February&nbsp;6,
 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520141786/d905925d8k.htm">May&nbsp;14, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520154927/d845849d8k.htm">May&nbsp;29, 2020</A> (other than
Item&nbsp;7.01), <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520160809/d912019d8k.htm">June&nbsp;4, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520162331/d938314d8k.htm">June&nbsp;
5, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520166729/d941240d8k.htm">June&nbsp;11, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312520184135/d945997d8k.htm">June&nbsp;
30, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1655759/000119312520268956/d98837d8k.htm">October&nbsp;
14, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1655759/000119312520316409/d96003d8k.htm">December&nbsp;14, 2020</A> (other than Item 7.01); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1655759/000119312518280053/d589006d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed on September&nbsp;21, 2018, including any amendments or reports filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Arvinas, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 Science Park </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">395 Winchester Ave. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New Haven,
Connecticut 06511 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(203) <FONT STYLE="white-space:nowrap">535-1456</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_5"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated by reference in this prospectus include &#147;forward-looking statements&#148; within the meaning of
Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act. All statements, other than statements of historical facts, contained in this prospectus and the information incorporated by reference herein, including statements
regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148;
&#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;target,&#148; &#147;potential,&#148; &#147;goals,&#148; &#147;will,&#148;
&#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;continue&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this prospectus include, among other things, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our current and future clinical trials of <FONT
STYLE="white-space:nowrap">ARV-110,</FONT> <FONT STYLE="white-space:nowrap">ARV-471</FONT> and <FONT STYLE="white-space:nowrap">ARV-766,</FONT> including statements regarding the period during which the results of the clinical trials will become
available; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and our ability to obtain, marketing approval of <FONT STYLE="white-space:nowrap">ARV-110</FONT>
and <FONT STYLE="white-space:nowrap">ARV-471,</FONT> and the ability of <FONT STYLE="white-space:nowrap">ARV-110</FONT> and <FONT STYLE="white-space:nowrap">ARV-471</FONT> and our other product candidates to meet existing or future regulatory
standards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to pursue research and development of other product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential advantages of our platform technology and our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our scientific approach and platform technology may potentially address a broad range of
diseases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of our arrangements with Yale University and Professor Craig Crews; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential receipt of revenue from future sales of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance and clinical utility of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding the potential market opportunity for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our sales, marketing and distribution capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain arrangements for manufacture of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential achievement of milestones and receipt of payments under our collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into additional collaborations with third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our business and operations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our
forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. See </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the &#147;Risk Factors&#148; section of this prospectus for more information. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions,
joint ventures or investments we may make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents incorporated by reference in this prospectus completely and
with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements except as required by applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_6"></A>ARVINAS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Business </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins. We use our
proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body&#146;s own natural protein disposal system to selectively remove disease-causing proteins. We
believe that our targeted protein degradation approach is a therapeutic modality that may provide distinct advantages over existing modalities, including traditional small molecule therapies and gene-based medicines. Our small-molecule PROTAC
technology has the potential to address a broad range of intracellular disease targets, including the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as &#147;undruggable&#148; targets. We
are using our PROTAC platform to build an extensive pipeline of product candidates to target diseases in oncology, neuroscience, and other therapeutic areas. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were formed under
the laws of the State of Delaware in February 2013 as a limited liability company under the name Arvinas, LLC. In July 2013, Arvinas, LLC converted into a Delaware corporation and changed its name to Arvinas, Inc. In December 2014, we completed a
series of transactions pursuant to which Arvinas, Inc. became a direct, wholly owned subsidiary of Arvinas Holding Company, LLC, a Delaware limited liability company. Immediately prior to our initial public offering, we converted from a Delaware
limited liability company to a Delaware corporation and changed our name to Arvinas, Inc. Our office is located at 5 Science Park, 395 Winchester Ave., New Haven, CT 06511 and our telephone number is (203)
<FONT STYLE="white-space:nowrap">535-1456.</FONT> Our website address is www.arvinas.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this
prospectus solely as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless otherwise indicated in
the applicable prospectus supplement. General corporate purposes may include research and development costs, the acquisition or <FONT STYLE="white-space:nowrap">in-license</FONT> of other products, product candidates, businesses or technologies,
repayment and refinancing of debt, working capital and capital expenditures. We may temporarily invest the net proceeds in a variety of capital preservation instruments, including short-term, investment grade, interest-bearing instruments and U.S.
government securities, until they are used for their stated purpose. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net
proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_8"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer debt securities, which may be senior or subordinated. We refer to the senior debt securities and the subordinated debt securities collectively as
debt securities. The following description summarizes the general terms and provisions of the debt securities. We will describe the specific terms of the debt securities and the extent, if any, to which the general provisions summarized below apply
to any series of debt securities in the prospectus supplement relating to the series and any applicable free writing prospectus that we authorize to be delivered. When we refer to &#147;the Company,&#148; &#147;we,&#148; &#147;our,&#148; and
&#147;us&#148; in this section, we mean Arvinas, Inc. excluding, unless the context otherwise requires or as otherwise expressly stated, our subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue senior debt securities from time to time, in one or more series under a senior indenture to be entered into between us and a senior trustee to be
named in a prospectus supplement, which we refer to as the senior trustee. We may issue subordinated debt securities from time to time, in one or more series under a subordinated indenture to be entered into between us and a subordinated trustee to
be named in a prospectus supplement, which we refer to as the subordinated trustee. The forms of senior indenture and subordinated indenture are filed as exhibits to the registration statement of which this prospectus forms a part. The senior
indenture and the subordinated indenture are referred to individually as an indenture and together as the indentures, and the senior trustee and the subordinated trustee are referred to individually as a trustee and together as the trustees. This
section summarizes some of the provisions of the indentures and is qualified in its entirety by the specific text of the indentures, including definitions of terms used in the indentures. Wherever we refer to particular sections of, or defined terms
in, the indentures, those sections or defined terms are incorporated by reference in this prospectus or the applicable prospectus supplement. You should review the indentures that are filed as exhibits to the registration statement of which this
prospectus forms a part for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither indenture will limit the amount of debt securities that we may issue. The applicable
indenture will provide that debt securities may be issued up to an aggregate principal amount authorized from time to time by us and may be payable in any currency or currency unit designated by us or in amounts determined by reference to an index.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The senior debt securities will constitute
our unsecured and unsubordinated general obligations and will rank equally in right of payment with our other unsecured and unsubordinated obligations. The subordinated debt securities will constitute our unsecured and subordinated general
obligations and will be junior in right of payment to our senior indebtedness (including senior debt securities), as described under the heading &#147;&#151;Certain Terms of the Subordinated Debt Securities&#151;Subordination.&#148; The debt
securities will be structurally subordinated to all existing and future indebtedness and other liabilities of our subsidiaries unless such subsidiaries expressly guarantee such debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt securities will be our unsecured obligations. Any secured debt or other secured obligations will be effectively senior to the debt securities to the
extent of the value of the assets securing such debt or other obligations. Unless otherwise indicated in the applicable prospectus supplement, the debt securities will not be guaranteed by any of our subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement and/or free writing prospectus will include any additional or different terms of the debt securities of any series being
offered, including the following terms: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and type of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be senior or subordinated debt securities, and, with respect to any subordinated
debt securities the terms on which they are subordinated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initial aggregate principal amount of the debt securities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which we will sell the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates of the debt securities and the right, if any, to extend such date or dates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates, if any, at which the debt securities will bear interest, or the method of determining such
rate or rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates from which such interest will accrue, the interest payment dates on which such interest will be
payable or the method of determination of such dates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the right, if any, to extend the interest payment periods and the duration of that extension;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner of paying principal and interest and the place or places where principal and interest will be payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions for a sinking fund, purchase fund or other analogous fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any redemption dates, prices, obligations and restrictions on the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency, currencies or currency units in which the debt securities will be denominated and the currency,
currencies or currency units in which principal and interest, if any, on the debt securities may be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any conversion or exchange features of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be subject to the defeasance provisions in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in definitive or global form or in definitive form only upon
satisfaction of certain conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be guaranteed as to payment or performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any special tax implications of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any events of default or covenants in addition to or in lieu of those set forth in the indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other material terms of the debt securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When we refer to &#147;principal&#148; in this section with reference to the debt securities, we are also referring to &#147;premium, if any.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may from time to time, without notice to or the consent of the holders of any series of debt securities, create and issue further debt securities of any
such series ranking equally with the debt securities of such series in all respects (or in all respects other than (1)&nbsp;the payment of interest accruing prior to the issue date of such further debt securities or (2)&nbsp;the first payment of
interest following the issue date of such further debt securities). Such further debt securities may be consolidated and form a single series with the debt securities of such series and have the same terms as to status, redemption or otherwise as
the debt securities of such series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may present debt securities for exchange and you may present debt securities for transfer in the manner, at the
places and subject to the restrictions set forth in the debt securities and the applicable prospectus supplement. We will provide you those services without charge, although you may have to pay any tax or other governmental charge payable in
connection with any exchange or transfer, as set forth in the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Debt securities may bear interest at a fixed rate or a floating rate. Debt
securities bearing no interest or interest at a rate that at the time of issuance is below the prevailing market rate (original issue discount securities) may be sold at a discount below their stated principal amount. U.S. federal income tax
considerations applicable to any such discounted debt securities or to certain debt securities issued at par which are treated as having been issued at a discount for U.S. federal income tax purposes will be described in the applicable prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities with the principal amount payable on any principal payment date, or the amount of interest payable on any
interest payment date, to be determined by reference to one or more currency exchange </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rates, securities or baskets of securities, commodity prices or indices. You may receive a payment of principal on any principal payment date, or a payment of interest on any interest payment
date, that is greater than or less than the amount of principal or interest otherwise payable on such dates, depending on the value on such dates of the applicable currency, security or basket of securities, commodity or index. Information as to the
methods for determining the amount of principal or interest payable on any date, the currencies, securities or baskets of securities, commodities or indices to which the amount payable on such date is linked and certain related tax considerations
will be set forth in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Terms of the Senior Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Covenants. </I>Unless we indicate otherwise in a prospectus supplement with respect to a particular series of senior debt securities, the senior debt
securities will not contain any financial or restrictive covenants, including covenants restricting either us or any of our subsidiaries from incurring, issuing, assuming or guaranteeing any indebtedness secured by a lien on any of our or our
subsidiaries&#146; property or capital stock, or restricting either us or any of our subsidiaries from entering into sale and leaseback transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Consolidation, Merger and Sale of Assets. </I>Unless we indicate otherwise in a prospectus supplement with respect to a particular series of senior debt
securities, we may not consolidate with or merge into any other person, in a transaction in which we are not the surviving corporation, or convey, transfer or lease our properties and assets substantially as an entirety to any person, in either
case, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successor entity, if any, is a U.S. corporation, limited liability company, partnership or trust;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successor entity assumes our obligations on the senior debt securities and under the senior indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after giving effect to the transaction, no default or event of default shall have occurred and be
continuing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have delivered to the senior trustee an officer&#146;s certificate and an opinion of counsel, each stating
that the consolidation, merger, conveyance, transfer or lease and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture, comply with the senior indenture and all conditions precedent provided for
in the senior indenture relating to such transaction have been complied with. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions described in the bullets above do not
apply (1)&nbsp;to our consolidation with or merging into one of our affiliates, if our board of directors determines in good faith that the purpose of the consolidation or merger is principally to change our state of incorporation or our form of
organization to another form or (2)&nbsp;if we merge with or into a single direct or indirect wholly-owned subsidiary of ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The surviving business
entity will succeed to, and be substituted for, us under the senior indenture and the senior debt securities and, except in the case of a lease, we shall be released from all obligations under the senior indenture and the senior debt securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Protection in the Event of a Change in Control. </I>Unless we indicate otherwise in a prospectus supplement with respect to a particular series of
senior debt securities, the senior debt securities will not contain any provisions that may afford holders of the senior debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether
or not such transaction results in a change in control). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Events of Default. </I>Unless we indicate otherwise in a prospectus supplement with respect
to a particular series of senior debt securities, the following are events of default under the senior indenture with respect to senior debt securities of each series: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to pay interest on any senior debt securities of such series when due and payable, if that default
continues for a period of 30 days (or such other period as may be specified for such series); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to pay principal on the senior debt securities of such series when due and payable whether at maturity,
upon redemption, by declaration or otherwise (and, if specified for such series, the continuance of such failure for a specified period); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance of or breach of any of our covenants or agreements in the senior indenture applicable
to senior debt securities of such series, other than a covenant breach which is specifically dealt with elsewhere in the senior indenture, and that default or breach continues for a period of 90 days after we receive written notice from the trustee
or from the holders of 25% or more in aggregate principal amount of the senior debt securities of such series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain events of bankruptcy or insolvency, whether or not voluntary; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other event of default provided for in such series of senior debt securities as may be specified in the
applicable prospectus supplement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An event of default by us under any other debt, including any other series of debt securities, is not
a default under the senior indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an event of default other than an event of default specified in the fourth bullet point above occurs with
respect to a series of senior debt securities and is continuing under the senior indenture, then, and in each such case, either the trustee or the holders of not less than 25% in aggregate principal amount of such series then outstanding under the
senior indenture (each such series voting as a separate class) by written notice to us and to the trustee, if such notice is given by the holders, may, and the trustee at the request of such holders shall, declare the principal amount of and accrued
interest on such series of senior debt securities to be immediately due and payable, and upon this declaration, the same shall become immediately due and payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an event of default specified in the fourth bullet point above occurs and is continuing, the entire principal amount of and accrued interest on each series
of senior debt securities then outstanding shall automatically become immediately due and payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the prospectus
supplement relating to a series of senior debt securities originally issued at a discount, the amount due upon acceleration shall include only the original issue price of the senior debt securities, the amount of original issue discount accrued to
the date of acceleration and accrued interest, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon certain conditions, declarations of acceleration may be rescinded and annulled and past
defaults may be waived by the holders of a majority in aggregate principal amount of all the senior debt securities of such series affected by the default, each series voting as a separate class. Furthermore, subject to various provisions in the
senior indenture, the holders of a majority in aggregate principal amount of a series of senior debt securities, by notice to the trustee, may waive a continuing default or event of default with respect to such senior debt securities and its
consequences, except a default in the payment of principal of or interest on such senior debt securities (other than any such default in payment resulting solely from an acceleration of the senior debt securities) or in respect of a covenant or
provision of the senior indenture which cannot be modified or amended without the consent of the holders of each such senior debt security. Upon any such waiver, such default shall cease to exist, and any event of default with respect to such senior
debt securities shall be deemed to have been cured, for every purpose of the senior indenture; but no such waiver shall extend to any subsequent or other default or event of default or impair any right consequent thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of a majority in aggregate principal amount of a series of senior debt securities may direct the time, method and place of conducting any
proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to such senior debt securities. However, the trustee may refuse to follow any direction that conflicts with law or the senior
indenture, that may involve the trustee in personal liability or that the trustee determines in good faith may be unduly prejudicial to the rights of holders of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
series of senior debt securities not joining in the giving of such direction and may take any other action it deems proper that is not inconsistent with any such direction received from holders
of such series of senior debt securities. A holder may not pursue any remedy with respect to the senior indenture or any series of senior debt securities unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder gives the trustee written notice of a continuing event of default; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of such series of senior debt securities make a written
request to the trustee to pursue the remedy in respect of such event of default; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requesting holder or holders offer the trustee indemnity satisfactory to the trustee against any costs,
liability or expense; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not comply with the request within 60 days after receipt of the request and the offer of
indemnity; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">during such <FONT STYLE="white-space:nowrap">60-day</FONT> period, the holders of a majority in aggregate
principal amount of such series of senior debt securities do not give the trustee a direction that is inconsistent with the request. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These limitations, however, do not apply to the right of any holder of a senior debt security of any affected series to receive payment of the principal of
and interest on such senior debt security in accordance with the terms of such debt security, or to bring suit for the enforcement of any such payment in accordance with the terms of such debt security, on or after the due date for the senior debt
securities, which right shall not be impaired or affected without the consent of the holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The senior indenture requires certain of our officers to
certify, on or before a fixed date in each year in which any senior debt security is outstanding, as to their knowledge of our compliance with all covenants, agreements and conditions under the senior indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Satisfaction and Discharge</I>. We can satisfy and discharge our obligations to holders of any series of debt securities if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have paid or caused to be paid the principal of and interest on all senior debt securities of such series
(with certain limited exceptions) when due and payable; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we deliver to the senior trustee for cancellation all senior debt securities of such series theretofore
authenticated under the senior indenture (with certain limited exceptions); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all senior debt securities of such series have become due and payable or will become due and payable within one
year (or are to be called for redemption within one year under arrangements satisfactory to the senior trustee) and we deposit in trust an amount of cash or a combination of cash and U.S. government or U.S. government agency obligations (or in the
case of senior debt securities denominated in a foreign currency, foreign government securities or foreign government agency securities) sufficient to make interest, principal and any other payments on the debt securities of that series on their
various due dates; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and if, in any such case, we also pay or cause to be paid all other sums payable under the senior indenture, as and
when the same shall be due and payable and we deliver to the senior trustee an officer&#146;s certificate and an opinion of counsel, each stating that these conditions have been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under current U.S. federal income tax law, the deposit and our legal release from the debt securities would be treated as though we took back your debt
securities and gave you your share of the cash and debt securities or bonds deposited in trust. In that event, you could recognize gain or loss on the debt securities you give back to us. Purchasers of the debt securities should consult their own
advisers with respect to the tax consequences to them of such deposit and discharge, including the applicability and effect of tax laws other than the U.S. federal income tax law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Defeasance. </I>Unless the applicable prospectus supplement provides otherwise, the following discussion
of legal defeasance and covenant defeasance will apply to any series of debt securities issued under the indentures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Legal Defeasance</I>. We can
legally release ourselves from any payment or other obligations on the debt securities of any series (called &#147;legal defeasance&#148;) if certain conditions are met, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We deposit in trust for your benefit and the benefit of all other direct holders of the debt securities of the
same series cash or a combination of cash and U.S. government or U.S. government agency obligations (or, in the case of senior debt securities denominated in a foreign currency, foreign government or foreign government agency obligations) that will
generate enough cash to make interest, principal and any other payments on the debt securities of that series on their various due dates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There is a change in current U.S. federal income tax law or an IRS ruling that lets us make the above deposit
without causing you to be taxed on the debt securities any differently than if we did not make the deposit and instead repaid the debt securities ourselves when due. Under current U.S. federal income tax law, the deposit and our legal release from
the debt securities would be treated as though we took back your debt securities and gave you your share of the cash and debt securities or bonds deposited in trust. In that event, you could recognize gain or loss on the debt securities you give
back to us. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We deliver to the trustee a legal opinion of our counsel confirming the tax law change or ruling described above.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we accomplish legal defeasance, as described above, you would have to rely solely on the trust deposit for repayment of the debt
securities. You could not look to us for repayment in the event of any shortfall. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Covenant Defeasance</I>. Without any change in current U.S. federal
tax law, we can make the same type of deposit described above and be released from some of the covenants in the debt securities (called &#147;covenant defeasance&#148;). In that event, you would lose the protection of those covenants but would gain
the protection of having money and securities set aside in trust to repay the debt securities. In order to achieve covenant defeasance, we must do the following (among other things): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Deposit in trust for your benefit and the benefit of all other direct holders of the debt securities of the same
series cash or a combination of cash and U.S. government or U.S. government agency obligations (or, in the case of senior debt securities denominated in a foreign currency, foreign government or foreign government agency obligations) that will
generate enough cash to make interest, principal and any other payments on the debt securities of that series on their various due dates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Deliver to the trustee a legal opinion of our counsel confirming that under current U.S. federal income tax law
we may make the above deposit without causing you to be taxed on the debt securities any differently than if we did not make the deposit and instead repaid the debt securities ourselves when due. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we accomplish covenant defeasance, you could still look to us for repayment of the debt securities if there were a shortfall in the trust deposit. In fact,
if one of the events of default occurred (such as our bankruptcy) and the debt securities become immediately due and payable, there may be such a shortfall. Depending on the events causing the default, you may not be able to obtain payment of the
shortfall. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Modification and Waiver. </I>We and the trustee may amend or supplement the senior indenture or the senior debt securities of any series
without the consent of any holder: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to convey, transfer, assign, mortgage or pledge any assets as security for the senior debt securities of one or
more series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence the succession of a corporation, limited liability company, partnership or trust to us, and the
assumption by such successor of our covenants, agreements and obligations under the senior </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
indenture or to otherwise comply with the covenant relating to mergers, consolidations and sales of assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with requirements of the SEC in order to effect or maintain the qualification of the senior indenture
under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants such new covenants, restrictions, conditions or provisions for the protection of the
holders, and to make the occurrence, or the occurrence and continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the senior indenture or in any supplemental indenture or to
conform the senior indenture or the senior debt securities to the description of senior debt securities of such series set forth in this prospectus or any applicable prospectus supplement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for or add guarantors with respect to the senior debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to establish the form or forms or terms of the senior debt securities as permitted by the senior indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under the senior indenture by a successor trustee, or
to make such changes as shall be necessary to provide for or facilitate the administration of the trusts in the senior indenture by more than one trustee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, change or eliminate any of the provisions of the senior indenture in respect of one or more series of
senior debt securities, provided that any such addition, change or elimination shall (a)&nbsp;neither (1) apply to any senior debt security of any series created prior to the execution of such supplemental indenture and entitled to the benefit of
such provision nor (2)&nbsp;modify the rights of the holder of any such senior debt security with respect to such provision or (b)&nbsp;become effective only when there is no senior debt security described in clause (a)(1) outstanding;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change to the senior debt securities of any series so long as no senior debt securities of such
series are outstanding; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the rights of any holder in any material respect.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other amendments and modifications of the senior indenture or the senior debt securities issued may be made, and our compliance with
any provision of the senior indenture with respect to any series of senior debt securities may be waived, with the consent of the holders of a majority of the aggregate principal amount of the outstanding senior debt securities of each series
affected by the amendment or modification (voting as separate series); provided, however, that each affected holder must consent to any modification, amendment or waiver that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extends the final maturity of any senior debt securities of such series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduces the principal amount of any senior debt securities of such series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduces the rate, or extends the time for payment of, interest on any senior debt securities of such series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduces the amount payable upon the redemption of any senior debt securities of such series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes the currency of payment of principal of or interest on any senior debt securities of such series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduces the principal amount of original issue discount securities payable upon acceleration of maturity or the
amount provable in bankruptcy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waives a continuing default in the payment of principal of or interest on the senior debt securities (other than
any such default in payment resulting solely from an acceleration of the senior debt securities); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes the provisions relating to the waiver of past defaults or impairs the right of holders to receive payment
or to institute suit for the enforcement of any payment or conversion of any senior debt securities of such series on or after the due date therefor; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modifies any of the provisions of these restrictions on amendments and modifications, except to increase any
required percentage or to provide that certain other provisions cannot be modified or waived without the consent of the holder of each senior debt security of such series affected by the modification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adversely affects the right to convert or exchange senior debt securities into common stock or other property in
accordance with the terms of the senior debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduces the above-stated percentage of outstanding senior debt securities of such series whose holders must
consent to a supplemental indenture or modifies or amends or waives certain provisions of or defaults under the senior indenture. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It
shall not be necessary for the holders to approve the particular form of any proposed amendment, supplement or waiver, but it shall be sufficient if the holders&#146; consent approves the substance thereof. After an amendment, supplement or waiver
of the senior indenture in accordance with the provisions described in this section becomes effective, the trustee must give to the holders affected thereby certain notice briefly describing the amendment, supplement or waiver. Any failure by the
trustee to give such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such amendment, supplemental indenture or waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Personal Liability of Incorporators, Stockholders, Officers, or Directors. </I>The senior indenture provides that no recourse shall be had under any
obligation, covenant or agreement of ours in the senior indenture or any supplemental indenture, or in any of the senior debt securities or because of the creation of any indebtedness represented thereby, against any of our incorporators,
stockholders, officers or directors, past, present or future, or of any predecessor or successor entity thereof under any law, statute or constitutional provision or by the enforcement of any assessment or by any legal or equitable proceeding or
otherwise. Each holder, by accepting the senior debt securities, waives and releases all such liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Concerning the Trustee. </I>The senior
indenture provides that, except during the continuance of an event of default, the trustee will not be liable except for the performance of such duties as are specifically set forth in the senior indenture. If an event of default has occurred and is
continuing, the trustee will exercise such rights and powers vested in it under the senior indenture and will use the same degree of care and skill in its exercise as a prudent person would exercise under the circumstances in the conduct of such
person&#146;s own affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The senior indenture and the provisions of the Trust Indenture Act incorporated by reference therein contain limitations on
the rights of the trustee thereunder, should it become a creditor of ours or any of our subsidiaries, to obtain payment of claims in certain cases or to realize on certain property received by it in respect of any such claims, as security or
otherwise. The trustee is permitted to engage in other transactions, provided that if it acquires any conflicting interest (as defined in the Trust Indenture Act), it must eliminate such conflict or resign. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may have normal banking relationships with the senior trustee in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unclaimed Funds. </I>All funds deposited with the trustee or any paying agent for the payment of principal, premium, interest or additional amounts in
respect of the senior debt securities that remain unclaimed for two years after the date upon which such amounts became due and payable will be repaid to us. Thereafter, any right of any holder of senior debt securities to such funds shall be
enforceable only against us, and the trustee and paying agents will have no liability therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Governing Law. </I>The senior indenture and the senior
debt securities will be governed by, and construed in accordance with, the internal laws of the State of New York. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Terms of the Subordinated
Debt Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than the terms of the subordinated indenture and subordinated debt securities relating to subordination or otherwise as
described in the prospectus supplement relating to a particular series of subordinated debt securities, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the terms of the subordinated indenture and subordinated debt securities are identical in all material respects to the terms of the senior indenture and senior debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional or different subordination terms may be specified in the prospectus supplement applicable to a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Subordination. </I>The indebtedness evidenced by the subordinated debt securities is subordinate to the prior payment in full of all of our senior
indebtedness, as defined in the subordinated indenture. During the continuance beyond any applicable grace period of any default in the payment of principal, premium, interest or any other payment due on any of our senior indebtedness, we may not
make any payment of principal of or interest on the subordinated debt securities (except for certain sinking fund payments). In addition, upon any payment or distribution of our assets upon any dissolution,
<FONT STYLE="white-space:nowrap">winding-up,</FONT> liquidation or reorganization, the payment of the principal of and interest on the subordinated debt securities will be subordinated to the extent provided in the subordinated indenture in right of
payment to the prior payment in full of all our senior indebtedness. Because of this subordination, if we dissolve or otherwise liquidate, holders of our subordinated debt securities may receive less, ratably, than holders of our senior
indebtedness. The subordination provisions do not prevent the occurrence of an event of default under the subordinated indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;senior
indebtedness&#148; of a person means with respect to such person the principal of, premium, if any, interest on, and any other payment due pursuant to any of the following, whether outstanding on the date of the subordinated indenture or incurred by
that person in the future: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of the indebtedness of that person for money borrowed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of the indebtedness of that person evidenced by notes, debentures, bonds or other securities sold by that
person for money; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of the lease obligations that are capitalized on the books of that person in accordance with generally
accepted accounting principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all indebtedness of others of the kinds described in the first two bullet points above and all lease obligations
of others of the kind described in the third bullet point above that the person, in any manner, assumes or guarantees or that the person in effect guarantees through an agreement to purchase, whether that agreement is contingent or otherwise; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all renewals, extensions or refundings of indebtedness of the kinds described in the first, second or fourth
bullet point above and all renewals or extensions of leases of the kinds described in the third or fourth bullet point above; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">unless,
in the case of any particular indebtedness, renewal, extension or refunding, the instrument creating or evidencing it or the assumption or guarantee relating to it expressly provides that such indebtedness, renewal, extension or refunding is not
superior in right of payment to the subordinated debt securities. Our senior debt securities constitute senior indebtedness for purposes of the subordinated indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_9"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This
description is based upon, and is qualified by reference to, our certificate of incorporation, our bylaws and applicable provisions of Delaware corporate law. You should read our certificate of incorporation and bylaws, which are filed as exhibits
to the registration statement of which this prospectus forms a part, for the provisions that are important to you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists
of 200,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share. As of December&nbsp;9, 2020, we had issued and outstanding 41,844,381 shares of our common stock, including
257,890 shares of unvested restricted stock subject to repurchase by us, and no shares of preferred stock were outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Meeting</I>. Annual meetings of our stockholders are held on the date designated in accordance with our bylaws. Written notice must be mailed to each
stockholder entitled to vote not less than ten nor more than 60 days before the date of the meeting. The presence in person, by means of remote communication in a manner, if any, authorized by the board of directors in its sole discretion, or by
proxy of the holders of record of a majority of our issued and outstanding shares entitled to vote at such meeting constitutes a quorum for the transaction of business at meetings of the stockholders. Special meetings of the stockholders may be
called for any purpose only by the board of directors. Except as may be otherwise provided by applicable law, our certificate of incorporation or our bylaws, all elections of directors shall be decided by a plurality of the votes cast by the
stockholders entitled to vote on the election, and all other questions shall be decided by a majority in voting power of the votes cast by the holders of all of the shares of stock present or represented at the meeting and voting affirmatively or
negatively on such matter at a duly held meeting of stockholders at which a quorum is present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. Each holder of common stock is
entitled to one vote for each share held of record on all matters to be voted upon by stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends</I>. Subject to the rights, powers and
preferences of any outstanding preferred stock, and except as provided by law or in our certificate of incorporation, dividends may be declared and paid or set aside for payment on the common stock out of legally available assets or funds when and
as declared by the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation, Dissolution and Winding Up</I>. Subject to the rights, powers and preferences of any outstanding
preferred stock, in the event of our liquidation, dissolution or winding up, our net assets will be distributed pro rata to the holders of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Rights</I>. Holders of the common stock have no right to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convert the stock into any other security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have the stock redeemed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase additional stock; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain their proportionate ownership interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The common stock does not have cumulative voting rights. Holders of shares of the common stock are not required to make additional capital contributions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transfer Agent and Registrar</I>. Computershare Trust Company, N.A. is transfer agent and registrar for the common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are authorized to issue &#147;blank check&#148; preferred stock, which may be issued in one or more series upon authorization of our board of directors. Our
board of directors is authorized to fix the designations, powers, preferences and the relative, participating, optional or other special rights and any qualifications, limitations and restrictions of the shares of each series of preferred stock. The
authorized shares of our preferred stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed. If the
approval of our stockholders is not required for the issuance of shares of our preferred stock, our board may determine not to seek stockholder approval. The specific terms of any series of preferred stock offered pursuant to this prospectus will be
described in the prospectus supplement relating to that series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A series of our preferred stock could, depending on the terms of such
series, impede the completion of a merger, tender offer or other takeover attempt. Our board of directors will make any determination to issue preferred shares based upon its judgment as to the best interests of our stockholders. Our directors, in
so acting, could issue preferred stock having terms that could discourage an acquisition attempt through which an acquirer may be able to change the composition of our board of directors, including a tender offer or other transaction that some, or a
majority, of our stockholders might believe to be in their best interests or in which stockholders might receive a premium for their stock over the then-current market price of the stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preferred stock has the terms described below unless otherwise provided in the prospectus supplement relating to a particular series of preferred stock.
You should read the prospectus supplement relating to the particular series of preferred stock being offered for specific terms, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and stated value per share of the preferred stock and the number of shares offered;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price at which the preferred stock will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate, or method of calculation of dividends, the dates on which dividends will be payable, whether
dividends will be cumulative or noncumulative and, if cumulative, the dates from which dividends will commence to accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any redemption or sinking fund provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the currency of the United States, the currency or currencies including composite currencies in
which the preferred stock is denominated and/or in which payments will or may be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any conversion provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we have elected to offer depositary shares as described under &#147;Description of Depositary
Shares;&#148; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other rights, preferences, privileges, limitations and restrictions on the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preferred stock will, when issued, be fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> Unless otherwise
specified in the prospectus supplement, each series of preferred stock will rank equally as to dividends and liquidation rights in all respects with each other series of preferred stock. The rights of holders of shares of each series of preferred
stock will be subordinate to those of our general creditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described under &#147;Description of Depositary Shares,&#148; we may, at our option, with
respect to any series of preferred stock, elect to offer fractional interests in shares of preferred stock, and provide for the issuance of depositary receipts representing depositary shares, each of which will represent a fractional interest in a
share of the series of preferred stock. The fractional interest will be specified in the prospectus supplement relating to a particular series of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rank.</I> Unless otherwise specified in the prospectus supplement, the preferred stock will, with respect
to dividend rights and rights upon our liquidation, dissolution or winding up of our affairs, rank: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">senior to our common stock and to all equity securities ranking junior to such preferred stock with respect to
dividend rights or rights upon our liquidation, dissolution or winding up of our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a parity with all equity securities issued by us, the terms of which specifically provide that such equity
securities rank on a parity with the preferred stock with respect to dividend rights or rights upon our liquidation, dissolution or winding up of our affairs; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">junior to all equity securities issued by us, the terms of which specifically provide that such equity securities
rank senior to the preferred stock with respect to dividend rights or rights upon our liquidation, dissolution or winding up of our affairs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;equity securities&#148; does not include convertible debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends</I>. Holders of the preferred stock of each series will be entitled to receive, when, as and if declared by our board of directors, cash
dividends at such rates and on such dates described in the prospectus supplement. Different series of preferred stock may be entitled to dividends at different rates or based on different methods of calculation. The dividend rate may be fixed or
variable or both. Dividends will be payable to the holders of record as they appear on our stock books on record dates fixed by our board of directors, as specified in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends on any series of preferred stock may be cumulative or noncumulative, as described in the applicable prospectus supplement. If our board of directors
does not declare a dividend payable on a dividend payment date on any series of noncumulative preferred stock, then the holders of that noncumulative preferred stock will have no right to receive a dividend for that dividend payment date, and we
will have no obligation to pay the dividend accrued for that period, whether or not dividends on that series are declared payable on any future dividend payment dates. Dividends on any series of cumulative preferred stock will accrue from the date
we initially issue shares of such series or such other date specified in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No dividends may be declared or paid or
funds set apart for the payment of any dividends on any parity securities unless full dividends have been paid or set apart for payment on the preferred stock. If full dividends are not paid, the preferred stock will share dividends pro rata with
the parity securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No dividends may be declared or paid or funds set apart for the payment of dividends on any junior securities unless full
dividends for all dividend periods terminating on or prior to the date of the declaration or payment will have been paid or declared and a sum sufficient for the payment set apart for payment on the preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation Preference</I>. Upon any voluntary or involuntary liquidation, dissolution or winding up of our affairs, then, before we make any distribution
or payment to the holders of any common stock or any other class or series of our capital stock ranking junior to the preferred stock in the distribution of assets upon any liquidation, dissolution or winding up of our affairs, the holders of each
series of preferred stock shall be entitled to receive out of assets legally available for distribution to stockholders, liquidating distributions in the amount of the liquidation preference per share set forth in the prospectus supplement, plus any
accrued and unpaid dividends thereon. Such dividends will not include any accumulation in respect of unpaid noncumulative dividends for prior dividend periods. Unless otherwise specified in the prospectus supplement, after payment of the full amount
of their liquidating distributions, the holders of preferred stock will have no right or claim to any of our remaining assets. Upon any such voluntary or involuntary liquidation, dissolution or winding up, if our available assets are insufficient to
pay the amount of the liquidating distributions on all outstanding preferred stock and the corresponding amounts payable on all other classes or series of our capital stock ranking on parity with the preferred stock and all other such classes or
series of shares of capital stock ranking on parity with the preferred stock in the distribution of assets, then the holders of the preferred stock and all other such classes or series of capital stock will share ratably in any such distribution of
assets in proportion to the full liquidating distributions to which they would otherwise be entitled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon any such liquidation, dissolution or winding up and if we have made liquidating distributions in full
to all holders of preferred stock, we will distribute our remaining assets among the holders of any other classes or series of capital stock ranking junior to the preferred stock according to their respective rights and preferences and, in each
case, according to their respective number of shares. For such purposes, our consolidation or merger with or into any other corporation, trust or entity, or the sale, lease or conveyance of all or substantially all of our property or assets will not
be deemed to constitute a liquidation, dissolution or winding up of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption</I>. If so provided in the applicable prospectus
supplement, the preferred stock will be subject to mandatory redemption or redemption at our option, as a whole or in part, in each case upon the terms, at the times and at the redemption prices set forth in such prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to a series of preferred stock that is subject to mandatory redemption will specify the number of shares of preferred stock
that shall be redeemed by us in each year commencing after a date to be specified, at a redemption price per share to be specified, together with an amount equal to all accrued and unpaid dividends thereon to the date of redemption. Unless the
shares have a cumulative dividend, such accrued dividends will not include any accumulation in respect of unpaid dividends for prior dividend periods. We may pay the redemption price in cash or other property, as specified in the applicable
prospectus supplement. If the redemption price for preferred stock of any series is payable only from the net proceeds of the issuance of shares of our capital stock, the terms of such preferred stock may provide that, if no such shares of our
capital stock shall have been issued or to the extent the net proceeds from any issuance are insufficient to pay in full the aggregate redemption price then due, such preferred stock shall automatically and mandatorily be converted into the
applicable shares of our capital stock pursuant to conversion provisions specified in the applicable prospectus supplement. Notwithstanding the foregoing, we will not redeem any preferred stock of a series unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if that series of preferred stock has a cumulative dividend, we have declared and paid or contemporaneously
declare and pay or set aside funds to pay full cumulative dividends on the preferred stock for all past dividend periods and the then current dividend period; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if such series of preferred stock does not have a cumulative dividend, we have declared and paid or
contemporaneously declare and pay or set aside funds to pay full dividends for the then current dividend period. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we will
not acquire any preferred stock of a series unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if that series of preferred stock has a cumulative dividend, we have declared and paid or contemporaneously
declare and pay or set aside funds to pay full cumulative dividends on all outstanding shares of such series of preferred stock for all past dividend periods and the then current dividend period; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if that series of preferred stock does not have a cumulative dividend, we have declared and paid or
contemporaneously declare and pay or set aside funds to pay full dividends on the preferred stock of such series for the then current dividend period. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, at any time we may purchase or acquire preferred stock of that series (1)&nbsp;pursuant to a purchase or exchange offer made on the same terms to
holders of all outstanding preferred stock of such series or (2)&nbsp;by conversion into or exchange for shares of our capital stock ranking junior to the preferred stock of such series as to dividends and upon liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If fewer than all of the outstanding shares of preferred stock of any series are to be redeemed, we will determine the number of shares that may be redeemed
pro rata from the holders of record of such shares in proportion to the number of such shares held or for which redemption is requested by such holder or by any other equitable manner that we determine. Such determination will reflect adjustments to
avoid redemption of fractional shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the prospectus supplement, we will mail notice of redemption at least 30 days
but not more than 60 days before the redemption date to each holder of record of preferred stock to be redeemed at the address shown on our stock transfer books. Each notice shall state: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the redemption date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares and series of preferred stock to be redeemed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the redemption price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where certificates for such preferred stock are to be surrendered for payment of the
redemption price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that dividends on the shares to be redeemed will cease to accrue on such redemption date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the holder&#146;s conversion rights, if any, as to such shares shall terminate; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the specific number of shares to be redeemed from each such holder if fewer than all the shares of any series are
to be redeemed. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If notice of redemption has been given and we have set aside the funds necessary for such redemption in trust for the
benefit of the holders of any shares called for redemption, then from and after the redemption date, dividends will cease to accrue on such shares, and all rights of the holders of such shares will terminate, except the right to receive the
redemption price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. Holders of preferred stock will not have any voting rights, except as required by law or as indicated in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise provided for under the terms of any series of preferred stock, no consent or vote of the holders of
shares of preferred stock or any series thereof shall be required for any amendment to our certificate of incorporation that would increase the number of authorized shares of preferred stock or the number of authorized shares of any series thereof
or decrease the number of authorized shares of preferred stock or the number of authorized shares of any series thereof (but not below the number of authorized shares of preferred stock or such series, as the case may be, then outstanding). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion Rights</I>. The terms and conditions, if any, upon which any series of preferred stock is convertible into our common stock will be set forth in
the applicable prospectus supplement relating thereto. Such terms will include the number of shares of common stock into which the shares of preferred stock are convertible, the conversion price, rate or manner of calculation thereof, the conversion
period, provisions as to whether conversion will be at our option or at the option of the holders of the preferred stock, the events requiring an adjustment of the conversion price and provisions affecting conversion in the event of the redemption.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transfer Agent and Registrar</I>. The transfer agent and registrar for the preferred stock will be set forth in the applicable prospectus supplement.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration Rights
Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are party to a registration rights agreement, or the Registration Rights Agreement, dated as of September&nbsp;26, 2018, with certain of
our stockholders. The Registration Rights Agreement provides these stockholders with certain rights with respect to registration of shares of our common stock under the Securities Act as described in additional detail below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights. </I>Subject to specified limitations set forth in the Registration Rights Agreement, at any time, the holders of 20% of the
then outstanding shares of common stock having rights under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registration Rights Agreement, which we refer to as registrable shares, may at any time demand in writing that we register all or a portion of the registrable shares under the Securities Act. We
are not obligated to file a registration statement pursuant to this provision on more than two occasions, and we are not obligated to file a registration statement pursuant to this provision within 180 days of the effective date of any other
registration statement that we may file. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights. </I>At any time we are eligible to file
a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> subject to specified limitations set forth in the Registration Rights Agreement, the stockholders that are party to the Registration Rights Agreement may demand in writing
that we register on Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrable shares having minimum gross proceeds in each registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> of at least $2,500,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights. </I>If we register any of our securities, either for our own account or for the account of other security holders, we will
be required to register all registrable shares that the holders of such securities request in writing be registered within 20 days of mailing of notice by us to all such holders of the proposed registration, to the extent that inclusion will not
diminish the number of securities included by us. The underwriter of any underwritten offering will have the right to limit, due to marketing factors, the number of shares registered by these holders. The holders of registrable shares waived these
piggyback registration rights in connection with the filing of the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses and
Indemnification. </I>Pursuant to the Registration Rights Agreement, we are required to pay all registration expenses, including registration and filing fees, exchange listing fees, printing expenses, fees and disbursements of our counsel and the
fees and expenses of one counsel to represent the stockholders selling registrable shares, and one counsel to represent the stockholders holding at least a majority of registrable shares, in addition to any state Blue Sky fees and expenses, and the
expense of any special audits or &#147;cold comfort&#148; letters incident to or required by such registration, but excluding all underwriting discounts, selling commissions and stock transfer taxes applicable to the sale of registrable shares, and
fees and disbursements of counsel for any shareholder, other than as provided above. The Registration Rights Agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to indemnify the selling stockholders
under the applicable agreement in the event of material misstatements or omissions in the registration statement attributable to us, and the selling stockholders under the applicable agreement are obligated to indemnify us for material misstatements
or omissions in the registration statement attributable to them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Provisions of Our Certificate of Incorporation and Bylaws and Delaware Law That May
Have Anti-Takeover Effects </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware Law. </I>We are subject to Section&nbsp;203 of the Delaware General Corporation Law, or the DGCL. Subject to
certain exceptions, Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with any &#147;interested stockholder&#148; for three years following the date that the person became an
interested stockholder, unless either the interested stockholder attained such status with the approval of our board of directors, the business combination is approved by our board of directors and stockholders in a prescribed manner or the
interested stockholder acquired at least 85% of our outstanding voting stock in the transaction in which it became an interested stockholder. A &#147;business combination&#148; includes, among other things, a merger or consolidation involving us and
the &#147;interested stockholder&#148; and the sale of more than 10% of our assets. In general, an &#147;interested stockholder&#148; is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person
affiliated with or controlling or controlled by such entity or person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Staggered Board; Removal of Directors. </I>Our certificate of incorporation and
our bylaws divide our board of directors into three classes with staggered three-year terms. In addition, our certificate of incorporation and our bylaws provide that directors may be removed only for cause and only by the affirmative vote of the
holders of at least 75% of our shares of capital stock present in person or by proxy and entitled to vote. Under our certificate of incorporation and bylaws, any vacancy on our board of directors, including a vacancy resulting from an enlargement of
our board of directors, may be filled only by vote of a majority of our directors then in office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Furthermore, our certificate of incorporation provides that the authorized number of directors may be changed only by the resolution of our board of directors. The classification of our board of
directors and the limitations on the ability of our stockholders to remove directors, change the authorized number of directors and fill vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to
acquire, control of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder Action; Special Meeting of Stockholders; Advance Notice Requirements for Stockholder Proposals and
Director Nominations</I>. Our certificate of incorporation and our bylaws provide that any action required or permitted to be taken by our stockholders at an annual meeting or special meeting of stockholders may only be taken if it is properly
brought before such meeting and may not be taken by written action in lieu of a meeting. Our certificate of incorporation and our bylaws also provide that, except as otherwise required by law, special meetings of the stockholders can only be called
by our board of directors. In addition, our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of
directors. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors, or by a stockholder of record on the record
date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#146;s intention to bring such business before the meeting. These provisions could have the
effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. These provisions also could discourage a third party from making a tender offer for our
common stock, because even if it acquired a majority of our outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or approving a merger, only at a duly called stockholders meeting and not by
written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Super-Majority Voting.</I> The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any
matter is required to amend a corporation&#146;s certificate of incorporation or bylaws, unless a corporation&#146;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our bylaws may be amended or repealed by
a majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders
of at least 75% of the votes that all our stockholders would be entitled to cast in any election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of incorporation
described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_10"></A>DESCRIPTION OF DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may, at our option, elect to offer fractional
shares of preferred stock, which we call depositary shares, rather than full shares of preferred stock. If we do, we will issue to the public receipts, called depositary receipts, for depositary shares, each of which will represent a fraction, to be
described in the applicable prospectus supplement, of a share of a particular series of preferred stock. Unless otherwise provided in the prospectus supplement, each owner of a depositary share will be entitled, in proportion to the applicable
fractional interest in a share of preferred stock represented by the depositary share, to all the rights and preferences of the preferred stock represented by the depositary share. Those rights include dividend, voting, redemption, conversion and
liquidation rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of preferred stock underlying the depositary shares will be deposited with a bank or trust company selected by us to act
as depositary under a deposit agreement between us, the depositary and the holders of the depositary receipts. The depositary will be the transfer agent, registrar and dividend disbursing agent for the depositary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary shares will be evidenced by depositary receipts issued pursuant to the deposit agreement. Holders of depositary receipts agree to be bound by
the deposit agreement, which requires holders to take certain actions such as filing proof of residence and paying certain charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The summary of terms
of the depositary shares contained in this prospectus is not a complete description of the terms of the depositary shares. You should refer to the form of the deposit agreement, our certificate of incorporation and the certificate of designation for
the applicable series of preferred stock that are, or will be, filed with the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends and Other Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will distribute all cash dividends or other cash distributions, if any, received in respect of the preferred stock underlying the depositary
shares to the record holders of depositary shares in proportion to the numbers of depositary shares owned by those holders on the relevant record date. The relevant record date for depositary shares will be the same date as the record date for the
underlying preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If there is a distribution other than in cash, the depositary will distribute property (including securities) received by it
to the record holders of depositary shares, unless the depositary determines that it is not feasible to make the distribution. If this occurs, the depositary may, with our approval, adopt another method for the distribution, including selling the
property and distributing the net proceeds from the sale to the holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Preference </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a series of preferred stock underlying the depositary shares has a liquidation preference, in the event of the voluntary or involuntary liquidation,
dissolution or winding up of us, holders of depositary shares will be entitled to receive the fraction of the liquidation preference accorded each share of the applicable series of preferred stock, as set forth in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withdrawal of Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the related
depositary shares have been previously called for redemption, upon surrender of the depositary receipts at the office of the depositary, the holder of the depositary shares will be entitled to delivery, at the office of the depositary to or upon his
or her order, of the number of whole shares of the preferred stock and any money or other property represented by the depositary shares. If the depositary receipts delivered by the holder evidence </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a number of depositary shares in excess of the number of depositary shares representing the number of whole shares of preferred stock to be withdrawn, the depositary will deliver to the holder at
the same time a new depositary receipt evidencing the excess number of depositary shares. In no event will the depositary deliver fractional shares of preferred stock upon surrender of depositary receipts. Holders of preferred stock thus withdrawn
may not thereafter deposit those shares under the deposit agreement or receive depositary receipts evidencing depositary shares therefor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption
of Depositary Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we redeem shares of preferred stock held by the depositary, the depositary will redeem as of the same redemption date
the number of depositary shares representing shares of the preferred stock so redeemed, so long as we have paid in full to the depositary the redemption price of the preferred stock to be redeemed plus an amount equal to any accumulated and unpaid
dividends on the preferred stock to the date fixed for redemption. The redemption price per depositary share will be equal to the redemption price and any other amounts per share payable on the preferred stock multiplied by the fraction of a share
of preferred stock represented by one depositary share. If less than all the depositary shares are to be redeemed, the depositary shares to be redeemed will be selected by lot or pro rata or by any other equitable method as may be determined by the
depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the date fixed for redemption, depositary shares called for redemption will no longer be deemed to be outstanding and all rights of the
holders of depositary shares will cease, except the right to receive the monies payable upon redemption and any money or other property to which the holders of the depositary shares were entitled upon redemption upon surrender to the depositary of
the depositary receipts evidencing the depositary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting the Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon receipt of notice of any meeting at which the holders of the preferred stock are entitled to vote, the depositary will mail the information contained in
the notice of meeting to the record holders of the depositary receipts relating to that preferred stock. The record date for the depositary receipts relating to the preferred stock will be the same date as the record date for the preferred stock.
Each record holder of the depositary shares on the record date will be entitled to instruct the depositary as to the exercise of the voting rights pertaining to the number of shares of preferred stock represented by that holder&#146;s depositary
shares. The depositary will endeavor, insofar as practicable, to vote the number of shares of preferred stock represented by the depositary shares in accordance with those instructions, and we will agree to take all action that may be deemed
necessary by the depositary in order to enable the depositary to do so. The depositary will not vote any shares of preferred stock except to the extent it receives specific instructions from the holders of depositary shares representing that number
of shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Charges of Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay all transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangements. We will pay charges of the
depositary in connection with the initial deposit of the preferred stock and any redemption of the preferred stock. Holders of depositary receipts will pay transfer, income and other taxes and governmental charges and such other charges (including
those in connection with the receipt and distribution of dividends, the sale or exercise of rights, the withdrawal of the preferred stock and the transferring, splitting or grouping of depositary receipts) as are expressly provided in the deposit
agreement to be for their accounts. If these charges have not been paid by the holders of depositary receipts, the depositary may refuse to transfer depositary shares, withhold dividends and distributions and sell the depositary shares evidenced by
the depositary receipt. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and Termination of the Deposit Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The form of depositary receipt evidencing the depositary shares and any provision of the deposit agreement may be amended by agreement between us and the
depositary. However, any amendment that materially and adversely alters the rights of the holders of depositary shares, other than fee changes, will not be effective unless the amendment has been approved by the holders of a majority of the
outstanding depositary shares. The deposit agreement may be terminated by the depositary or us only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all outstanding depositary shares have been redeemed; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there has been a final distribution of the preferred stock in connection with our dissolution and such
distribution has been made to all the holders of depositary shares. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resignation and Removal of Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary may resign at any time by delivering to us notice of its election to do so, and we may remove the depositary at any time. Any resignation or
removal of the depositary will take effect upon our appointment of a successor depositary and its acceptance of such appointment. The successor depositary must be appointed within 60 days after delivery of the notice of resignation or removal and
must be a bank or trust company having its principal office in the United States and having the requisite combined capital and surplus as set forth in the applicable agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notices </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will forward to holders of
depositary receipts all notices, reports and other communications, including proxy solicitation materials received from us, that are delivered to the depositary and that we are required to furnish to the holders of the preferred stock. In addition,
the depositary will make available for inspection by holders of depositary receipts at the principal office of the depositary, and at such other places as it may from time to time deem advisable, any reports and communications we deliver to the
depositary as the holder of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the depositary will be liable if either we or it is prevented or delayed by law or any circumstance beyond its control in performing its
obligations. Our obligations and those of the depositary will be limited to performance in good faith of our and their duties thereunder. We and the depositary will not be obligated to prosecute or defend any legal proceeding in respect of any
depositary shares or preferred stock unless satisfactory indemnity is furnished. We and the depositary may rely upon written advice of counsel or accountants, on information provided by persons presenting preferred stock for deposit, holders of
depositary receipts or other persons believed to be competent to give such information and on documents believed to be genuine and to have been signed or presented by the proper party or parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_11"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue units comprised of one or more of the other securities that may be offered under this prospectus, in any combination. The following, together
with the additional information we may include in the applicable prospectus supplement, summarizes the material terms and provisions of the units that we may offer under this prospectus. While the terms summarized below will apply generally to any
units we may offer, we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each unit will
be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued
may provide that the securities included in the unit may not be held or transferred separately at any time, or at any time before a specified date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
applicable prospectus supplement will describe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the material terms of the units and of the securities comprising the units, including whether and under what
circumstances those securities may be held or transferred separately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any material provisions relating to the issuance, payment, settlement, transfer or exchange of the units or of
the securities comprising the units; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any material provisions of the governing unit agreement that differ from those described above.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_12"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue warrants to purchase common stock, preferred stock, depositary shares or debt securities. We may offer warrants separately or together with one
or more additional warrants, common stock, preferred stock, depositary shares or debt securities, or any combination of those securities in the form of units, as described in the applicable prospectus supplement. If we issue warrants as part of a
unit, the accompanying prospectus supplement will specify whether those warrants may be separated from the other securities in the unit prior to the expiration date of the warrants. The applicable prospectus supplement will also describe the
following terms of any warrants: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the specific designation and aggregate number of, and the offering price at which we will issue, the warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currency units in which the offering price, if any, and the exercise price are payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will begin and the date on which that right will expire or,
if you may not continuously exercise the warrants throughout that period, the specific date or dates on which you may exercise the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the warrants are to be sold separately or with other securities as parts of units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the warrants will be issued in definitive or global form or in any combination of these forms, although,
in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any applicable material U.S. federal income tax consequences; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents,
transfer agents, registrars or other agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any
securities exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of any equity securities purchasable upon exercise of the warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, aggregate principal amount, currency and terms of any debt securities that may be purchased upon
exercise of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the preferred stock, depositary shares or debt securities with which
the warrants are issued and the number of warrants issued with each security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date from and after which any warrants issued as part of a unit and the related debt
securities, preferred stock, depositary shares or common stock will be separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock, preferred stock or depositary shares purchasable upon exercise of a warrant
and the price at which those shares may be purchased; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information with respect to book-entry procedures, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anti-dilution provisions of, and other provisions for changes to or adjustment in the exercise price of, the
warrants, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any redemption or call provisions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange or
exercise of the warrants. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_13"></A>FORMS OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each debt security, depositary share, unit and warrant will be represented either by a certificate issued in definitive form to a particular investor or by
one or more global securities representing the entire issuance of securities. Unless the applicable prospectus supplement provides otherwise, certificated securities will be issued in definitive form and global securities will be issued in
registered form. Definitive securities name you or your nominee as the owner of the security, and in order to transfer or exchange these securities or to receive payments other than interest or other interim payments, you or your nominee must
physically deliver the securities to the trustee, registrar, paying agent or other agent, as applicable. Global securities name a depositary or its nominee as the owner of the debt securities, depositary shares, units or warrants represented by
these global securities. The depositary maintains a computerized system that will reflect each investor&#146;s beneficial ownership of the securities through an account maintained by the investor with its broker/dealer, bank, trust company or other
representative, as we explain more fully below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue the debt securities, depositary shares, units and warrants in the form of one or more fully registered global securities that will be deposited
with a depositary or its nominee identified in the applicable prospectus supplement and registered in the name of that depositary or nominee. In those cases, one or more global securities will be issued in a denomination or aggregate denominations
equal to the portion of the aggregate principal or face amount of the securities to be represented by global securities. Unless and until it is exchanged in whole for securities in definitive registered form, a global security may not be transferred
except as a whole by and among the depositary for the global security, the nominees of the depositary or any successors of the depositary or those nominees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If not described below, any specific terms of the depositary arrangement with respect to any securities to be represented by a global security will be
described in the prospectus supplement relating to those securities. We anticipate that the following provisions will apply to all depositary arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ownership of beneficial interests in a global security will be limited to persons, called participants, that have accounts with the depositary or persons that
may hold interests through participants. Upon the issuance of a global security, the depositary will credit, on its book-entry registration and transfer system, the participants&#146; accounts with the respective principal or face amounts of the
securities beneficially owned by the participants. Any dealers, underwriters or agents participating in the distribution of the securities will designate the accounts to be credited. Ownership of beneficial interests in a global security will be
shown on, and the transfer of ownership interests will be effected only through, records maintained by the depositary, with respect to interests of participants, and on the records of participants, with respect to interests of persons holding
through participants. The laws of some states may require that some purchasers of securities take physical delivery of these securities in definitive form. These laws may impair your ability to own, transfer or pledge beneficial interests in global
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as the depositary, or its nominee, is the registered owner of a global security, that depositary or its nominee, as the case may be,
will be considered the sole owner or holder of the securities represented by the global security for all purposes under the applicable indenture, deposit agreement, unit agreement or warrant agreement. Except as described below, owners of beneficial
interests in a global security will not be entitled to have the securities represented by the global security registered in their names, will not receive or be entitled to receive physical delivery of the securities in definitive form and will not
be considered the owners or holders of the securities under the applicable indenture, deposit agreement, unit agreement or warrant agreement. Accordingly, each person owning a beneficial interest in a global security must rely on the procedures of
the depositary for that global security and, if that person is not a participant, on the procedures of the participant through which the person owns its interest, to exercise any rights of a holder under the applicable indenture, deposit agreement,
unit agreement or warrant agreement. We understand that under existing industry practices, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we request any action of holders or if an owner of a beneficial interest in a global security desires to give or take any action that a holder is entitled to give or take under the applicable
indenture, deposit agreement, unit agreement or warrant agreement, the depositary for the global security would authorize the participants holding the relevant beneficial interests to give or take that action, and the participants would authorize
beneficial owners owning through them to give or take that action or would otherwise act upon the instructions of beneficial owners holding through them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Principal, premium, if any, and interest payments on debt securities, and any payments to holders with respect to depositary shares, units or warrants,
represented by a global security registered in the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may be, as the registered owner of the global security. None of us, or any trustee, unit agent, warrant
agent or other agent of ours, or any agent of any trustee, unit agent or warrant agent will have any responsibility or liability for any aspect of the records relating to payments made on account of beneficial ownership interests in the global
security or for maintaining, supervising or reviewing any records relating to those beneficial ownership interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that the depositary for any
of the securities represented by a global security, upon receipt of any payment to holders of principal, premium, interest or other distribution of underlying securities or other property on that registered global security, will immediately credit
participants&#146; accounts in amounts proportionate to their respective beneficial interests in that global security as shown on the records of the depositary. We also expect that payments by participants to owners of beneficial interests in a
global security held through participants will be governed by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of customers or registered in &#147;street name,&#148; and will be the
responsibility of those participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the depositary for any of the securities represented by a global security is at any time unwilling or unable to
continue as depositary or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by us within 90 days, we will issue securities in
definitive form in exchange for the global security that had been held by the depositary. Any securities issued in definitive form in exchange for a global security will be registered in the name or names that the depositary gives to the relevant
trustee, unit agent, warrant agent or other relevant agent of ours or theirs. It is expected that the depositary&#146;s instructions will be based upon directions received by the depositary from participants with respect to ownership of beneficial
interests in the global security that had been held by the depositary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_14"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through underwriters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through dealers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to purchasers; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of these methods of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may issue the securities as a dividend or distribution or in a subscription rights offering to our existing security holders. This prospectus
may be used in connection with any offering of our securities through any of these methods or other methods described in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may directly solicit offers to purchase securities, or agents may be designated to solicit such offers. We will, in the prospectus supplement relating to
such offering, name any agent that could be viewed as an underwriter under the Securities Act, and describe any commissions that we must pay. Any such agent will be acting on a best efforts basis for the period of its appointment or, if indicated in
the applicable prospectus supplement, on a firm commitment basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of the securities may be effected from time to time in one or more
transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price, or prices, which may be changed from time to time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each prospectus supplement will describe the method of distribution of the securities and any applicable restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to the securities of a particular series will describe the terms of the offering of the securities, including the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name of the agent or any underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the public offering or purchase price and the proceeds we will receive from the sale of the securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts and commissions to be allowed or <FONT STYLE="white-space:nowrap">re-allowed</FONT> or paid to the
agent or underwriters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all other items constituting underwriting compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts and commissions to be allowed or <FONT STYLE="white-space:nowrap">re-allowed</FONT> or paid to
dealers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any exchanges on which the securities will be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any underwriters or agents are utilized in the sale of the securities in respect of which this prospectus is delivered, we will enter into an underwriting
agreement or other agreement with them at the time of sale to them, and we will set forth in the prospectus supplement relating to such offering the names of the underwriters or agents and the terms of the related agreement with them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a dealer is utilized in the sale of the securities in respect of which this prospectus is delivered, we will sell such securities to the dealer, as
principal. The dealer may then resell such securities to the public at varying prices to be determined by such dealer at the time of resale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we offer securities in a subscription rights offering to our existing security holders, we may enter into
a standby underwriting agreement with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a standby underwriting
arrangement, we may retain a dealer-manager to manage a subscription rights offering for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Remarketing firms, agents, underwriters, dealers and other
persons may be entitled under agreements which they may enter into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, and may be customers of, engage in transactions with or perform
services for us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If so indicated in the applicable prospectus supplement, we will authorize underwriters or other
persons acting as our agents to solicit offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus supplement. Each contract will be
for an amount not less than, and the aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom the contracts, when authorized,
may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts
will not be subject to any conditions except that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase by an institution of the securities covered under that contract shall not at the time of delivery be
prohibited under the laws of the jurisdiction to which that institution is subject; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are also being sold to underwriters acting as principals for their own account, the
underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons acting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain agents, underwriters and dealers, and their associates and affiliates may be customers of, have borrowing relationships with,
engage in other transactions with, and/or perform services, including investment banking services, for us or one or more of our respective affiliates in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the securities, any underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of
the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may overallot in connection with the offering, creating a short position for their own accounts. In
addition, to cover overallotments or to stabilize the price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other securities in the open market. Finally, in any offering of
the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases previously distributed
securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels. Any such underwriters
are not required to engage in these activities and may end any of these activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT>
of the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise or the securities are sold by us to an underwriter in a firm commitment
underwritten offering. The applicable prospectus supplement may provide that the original issue date for your securities may be more than two scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish
to trade securities on any date prior to the second business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than two scheduled
business days after the trade date for your securities, to make alternative settlement arrangements to prevent a failed settlement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities may be new issues of securities and may have no established trading market. The securities
may or may not be listed on a national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In compliance with the guidelines of the Financial Industry Regulatory Authority, or FINRA, the aggregate maximum discount, commission or agency fees or other
items constituting underwriting compensation to be received by any FINRA member or independent broker-dealer will not exceed 8% of the proceeds from any offering pursuant to this prospectus and any applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_15"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement indicates otherwise, the validity of the securities in respect of which this prospectus is being delivered will be
passed upon by Wilmer Cutler Pickering Hale and Dorr LLP. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc211246_16"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements, incorporated in this prospectus by reference from the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019, have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report, which is incorporated herein by
reference. Such consolidated financial statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">$250,000,000 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g20220g01m85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:57pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS SUPPLEMENT
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:57pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Goldman Sachs&nbsp;&amp; Co. LLC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Piper
Sandler </B></P> <P STYLE="margin-top:57pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">December &nbsp;&nbsp;&nbsp;&nbsp;, 2020 </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g20220g01m85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g20220g01m85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1C24&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5\            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-
M!"8       X             /X   #A"24T$#0      !    %HX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              !5    _@         !
M      $              /X   !5                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     #BH    !    H
M #8   '@  !E0   #@X &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( #8 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MLLHU=:=TB222*'__T/54DEA]
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@ 5@$! P$1  (1 0,1 ?_$ !\   (" @,! 0$
M           )" H&!P$"!0L$ __$ $X0   & 0," P,%"@H'"0    $" P0%
M!@< "!$)$A,A,105%@H7(D%1&#(S.6%Q@9&Q\!DC0G)V=Z&RL[4D)3B6M\'1
M-C=$5EAGE=/Q_\0 '0$  @(# 0$!              <&" ,$!0D" ?_$ %$1
M  (! P,"! ,#!0H*!PD   $" P0%$0 &$A,A!Q0Q02)180@5,B,V<8&A%C-"
M4G-T=9&QP30W56)RE+*SM-$7)#535I/P0V-EHZ2UT]3A_]H # ,!  (1 Q$
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MVDEE8NY9F/(]SC!)P.VO7>@H*6V45+;Z&%*>DHH(Z:GAC552.*)0B*JJ H[
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M@PQAC0 !\9 9B0.Q'<9TQM!%)NBDW03*DB@F1%),@ 4B::90(0A0#R I2@
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M4 YSCU(QCZYQJ:U<LU<MT2UG*K.Q%CA7A"G:2L'(M)2/<%$I3?Q3MDJLB80
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M&"4X()+GMZG5RG;IF>!W$8(Q)G&M"F6'RC0JW<$FQ%2K#&NY:-16E8990HB
MNX25]MB'I1X,F[9+IG IR"4*V7FV36:[7&U3YZE!5STQ8@CFL;D1R@'OQECX
MR+\U8'3DMU9'<*&DKHB.%5!',!Z\2Z@NAQ_"C?DC?)E(U3SZ]^5I[<[O_P 6
M;2Z&L:1+C=M5Z$Q8HF,NV5R;E9]&/I9<01[P_P!%C7=6C'I>TQVJL2\ _:8I
MRA8[PDM\5CVA<=Q58X><:>K=CA6%#;TD1%RWNSK42)_&$J8SD93^_:J2Z;@I
M+13Y;RRQ4Z*#D-55;(TAP/3C&8E;(R.)]/>X;MVP_ X"P=BS#=:;E;Q&.Z3
M5AN $*0ZRD;'H(.72_;Y'<.G!55UU!$3**G,<PB(CJN%XN,UWNE?<IV+25M5
M-.Q)S@2.651\E (    ';&G!;J..WT-+10C$=-!'$N?4\% )/U)&2?<]];GU
MS=;NJ)?5P_'2U;^EVVW_ #>#U:OP]_Q9S_S:]_[N72,W9^>D?\K;/]M=7L4_
MP:?\PO\ =#55-//7?1HU4WZH+%G)];O8-&R#9)XP?S.'6;UJX3*J@Y:N+^=)
M=!9,X"4Z:J9S$,4P"!BB(:L#L1FC\+MWR*Q1DBN3*P.&5EHP0R^X(^8.1V.,
M@:5&Z0K;VV\K %6>D# @$$>8(P<^QR0?I\]+TZB&V?*'20WO5/<+M]</X;&U
MGLRUTQI(MTUC1D0^(Z!U9L838D[4E8U5%55)LS5.'MU?<G;D$QV2YRS'9M[H
M/$/:U19KPJR5U/ *:M0D!Y4X\8*Z+)R) P!9AW28<C^,*8[N*V56TKY%<K>6
M2GEF,U*1G@C=S+2R=P"C9/%2<M&2OJI.KDNRS=G0MZ>WRD9SHBR* 3C,&-LK
MOM":SVGW-@1-.>KD@4H^(0[9P<KA@JJ1,7T4Y8OTR^&Y+JMNY]O5>V+Q56JK
M!/2;G3SXPE33.28ID/H>0[.!^&164]QIR66[07JW05T!'Y10)8\Y,,R@=2-O
M]$G(/NI#>AU5<^4B?[=6V3^HJK_\8;]I^>"WYHWW^EJC_P"VT6E5XD?]NV_^
MC8_^,J=74"^@?F#]FJQZ=6N=&C21^O;N7#!.Q^=H\3( TN&>I1*B1::2P)/"
MUUF=M(VQZW$![^$D31K%7@H@9&15(/KIH>$MC^]MU0U4B<J:T1FLD)!*]8\D
MIU;])#N.X[Q@^VH1OZY^0L<D"-QFKVZ"8.#TP5:8C] *@_1CZ=M1\Z0VQ2%E
MNE9?X"XQ"9IC=S%V2><>UI !B1GLOL= 4[U2]WLI%(^.EP3 .T%C*&*/)A$>
MQXC;KECW]234TA,>W9(8EXG&9.7*K';.6(=XLX)*X'?&N=L^Q(VU:B.=/CNZ
MR2$,/X''C 1\@0JOCYDG4(/D]F89;".Z+/VS"Z.%6?OU66D89B\$S?P[=0GJ
ML7*]B2PAVGD(D$#H(D #*=IE  WKJ4^,-N2ZV&T;GIE5NETTE92#BFJU$D8)
M [\).08D]AC7%\/:QZ&Z7"S3''4:1D4]L2T[%'[>W).) 'KZ]\Y%QK5;M.+6
M*7RK-[O2;;3G1_#;VFN3, JIY_Q996/<,O$\N1X3%8#B >8@7@-;%+.:6IIZ
ME1DP313 ?,QN&Q^O&L4\0GAEA;L)8WC)^0=2N>WRSKY]V$\LYTZ)N^6X,[/2
M5YA@V+)4NT0K\BK%O?,;O)5M(QDY7),R?@>.<6$?*,UB>(B5XW4CW)DP\82V
M^NEOM7BCM6F:"J6)R4JJ>1"&-+7+&T<D4Z YP.3QL" 2I5USVU7ZBK*[9%\F
M66 R*I>"56!45%,SJR21N>W+"AE/<9'$G&3J\=M2WHX WCT&*O.&;S#R[ARP
M9.)ZG*R#(ENJ,@X;E5<1$_#D7,Y;.6:OC(^,4AFKHJ(N&JJK<Y%#58O^V;OM
MNLDI;G221!780U(1O+U,8; EAE( 97&#C.5)"L PQIXVJ]6^\TZ3T4Z.2JM)
M"6'6A8@$I(@.05.03W!QD$COJ5VN!KJZ-&C6F]PN8H/;]@[*^:;$9+W9C.AV
M.WJ-U3@F#]W%1RRL7%$./  O,2HLHIL'/TG#Q,H>NNC:+=)=[I;[7%GG75<%
M-D#/!97"R28^4<?*1OHIUIW"LCM]#5ULOX*6"68C^,44E5'U=L(/JVJ"G3;W
MTX>VU[P\B;M]R\'>[]9[!%VUQ735%A#OGB=QOLT1[8[)('F9>**BJ6-%]'H"
M@JL=0DR]!0"%*43VZWMM2Y7O;=%MZQRTE)!#)3B?S$DJH::DC*0P1]*.0LID
MX.0P7'30#)& @MMWVCMMXJ;O<XYZB619C&851B)JB0-+*W-TP<$J,$G#L"#@
M:<'O'Z[.R+=5MES#@5[BS.;9Q?ZB\80;^0A*<+.,M#)1*4K4@X42MRSA%LWF
MV3+VU5NFHX!B9R4B:@F%,ZVVWX4[IL%\MMW2NM3"CJ5>5$EJ>3P,"DZ &G +
M&)VX!B%+\3D=CJ87C?ECNMLK*!J2X#S$)5&:.#BLJD/$Q(GR L@7D0">.1@Y
MP=<_)H-R7NB[YDVMS+\P,[-'H9.I35901YDHH$(FS)(@<W"9#LCQ+@J27X18
MSA02<@8P[OC?9.K2VR_QJ"T#M0U1 Q^3D)D@)('<ANHI)]%QWQC.OX9W()-6
M6IV.)1YJ 'TY)\$H&?3(XGM[Y[>YN):KAIPZ7QU6_P 73N[_ *GI[_&9ZE^P
M?SSVY_2<']C:X&Z?S=O'\RE_NU2)V ].C<GO@K>3[#@3(M;IB&.G<>SFXV:L
M5G@W<T\?Q[E\R(P) Q[MNN<4T#(%,]50[55"@!@)R8+1;OWG9-K34,%WHIJI
MJU"T4D4%/*L2(41^9F=2OKGX0>V3ZC21V_MRYWR*KEM]3' *?IJZO++&TC,G
M)0HC4@]A@%L8)]1VUJ7;?ML#/&\& VP[@LHR>))E];7]"D;!8&KJS.V=I9/5
M&"5=32=OVY0<RC](63!=1V1F*RJ2JAP1-WCTKU>_NG;<]]L] EQB6FCJTAB*
MTZ- Z!S/\*$A8T8.XX%L XR=:=MMOG[REKN-6U)(TK4S22*92)5)41 %E^)G
M'!"3C)!]-?0\VD[3,2;,<-PF&,/Q:S6%CU%)&9FI 4EIVUV!TFF1].S;E--,
MJCA8$DTF[=(I4&35))!(#&!59:G&X=P7'<MREN=RD#2N D429$-/"I)2&)22
M0HR2222S$D]L 6&M-II+-1QT5&G%%[NYQSED(^*1R/4GT '91@#W)DWKAZZ>
MDT]=C;&&XC8/?+!$L =7;;Z[2S37CII 9R>#@&KAGD./!0 %0&IJ6]E)U1$G
MX=]7(P!\TRB#*\*;[]S;NHXI&*TMX4VN89(42S$-1OCTY"J2.($]@D\GSP8;
MOJV?>-@J'109Z BMB[=^$8(J%SZ@=!GDP/Q/$F>VH _)]][<#"[0,^XDR/+"
MDVVJM[1F",454 IR8HG&,A9)EDS*H8!5/$6J+LCQ42B4I!L\<W @=Q!-+O&#
M:TTFX[3<:&/+;@,%N=5'8W")D@B=N/8"2GD@4#+'\@[$ZC_A]>HTM%?1U+X%
MJ$M8I[?X&ZM*X'^A(DKG^549U!?HQ8TL&]SJ6Y2W=Y ;>\8W'LY9,K2RJP&7
M:A?LBR,VWJ4>0JH=HM6#(D^Z:$+V^QGC8T4TR 5,"RKQ,KH=K;(H-MTAX/61
M04$0& ?*4*0M4N<=^;.85+'/,.^23Z\/9E-+?-RU5WJ1S6F>2J<G.!45!D6%
M1]%7J8],!5^$8&KOFJNZ=VC1HU1+ZN'XZ6K?TNVV_P";P>K5^'O^+.?^;7O_
M '<ND9NS\](_Y6V?[:ZO8I_@T_YA?[H:JIIYZ[Z-&JH74Q_'E=/G\MBPL'Z\
MB"/Z_+3_ -D?XJ]X_P C<S_]&!_?[=]*G<_Y\;<_E*/_ (K5A;>3M.QUO/P+
M<<(9%:)@WFV2SJLSY$2*R%0MK9!7W'9(TQA*8%H]V<IET"J)$?,S.&*Y_ <*
M *>VWN"MVS=J:Z43'E$P6>$DA*BG8CJP28]G7.#@\6XL!D#3"O-JI[S03T-2
MHQ(I,;X!:*8#,<BY]U;&?3*Y7.#JF9L"W.Y1Z/\ OBNFWS/Q'K#&$U:&U+RU
M%\KK1T<(G+\)Y;KB9BE,JT(Q>MY!15!,%).KOUTSH*/F[(C>R^[K%;_$;:M+
M>+05:OBIS56^0X#N/2HMTQ!P&YJ4 8D1SHI4A&?DF;!<JO9]\FM]P#)2O((:
MQ224'8=&KB[=P RL<8+0N1@L% WW\HPE(V;WK[5)F(>MI**EMOM,DHR19+)N
M6;^/?9:O;EF\:KI&,FNW<MU4UD%4S&(HF<IRB)1 =<CP9C>+:M_BD5D>.\U4
M<B,I#HZ6ZC5D(/HP8%2"!@C![]M;WB.P>]VUD(97ML+*RD%2C5E00P/<$$'L
M?3!SZ=]77B^@?F#]FJPZ=FN=&C5$;Y0'N2CLQ;XHO$HR+M7'^W^)B:G+!&"F
MN<;!,.$9B[O&2*JA$AE62;A*#$BATDSK0Z)3' O)PM=X065[;M:2XA5%9>)9
M*B,R94=&)3%2JQ /Y-B#-GU D. 3VTB]_P!Q6KOJ4G(FGMZ)&_'U$CD/.RAL
M#FH*IZ@?"/7.=-.QG\HCV,8PQ[2<<U_$&>F<+2JS#UJ-;MX.E$03;Q#%%H I
M$^,0[2G,F90 X_E^?UZ@5=X-[KKJRJK9[E:6EJIY)Y&::J+<I6+?%_U8G/<#
MW_OU)Z;Q%L5+3P4T=%7JD$21*!'   B@8QU\CT^6.^D&Y)WNXO)U/8;>MM\B
M;54*>]R'6KC.0]K;1\?(D7? DPO!#M8>0DF!V"[55PY:I X-XAR%,HBF8 X;
ME#M:X'8DNU[S)3U%4M'44\,L#O(A5/CI3RD1'YA@%8X/;/?OJ!U-[I1N>.]6
MZ.6"%JB.9TF"*V6PDPQ&[H5*L67!R<>@]=?0ZI]HBKO4ZU<H)<KF%M<#$V**
M7*(&!6/F6*$@T,(E$0[O!<$ P (\& 0^K5.*B"2EJ)Z:4<9:>62&0?)XW*-^
MK(./F-6%AE6:*.9#E)8TD4^OPNH8>GT.LCUAUDU$[=?LFVZ[T*8-/SK0V4\=
MJFN$!;&'9&W*K.%R=IG,%/I)'<(EY BBC!T5W&.3IIF<LE13()9!M_=%YVQ4
M^9M56T(8@S4[Y>EG SVFA)"MV) <<74$\6&3KDW:R6Z]0]&O@$F >G*N%FB)
M]XY,''U!!4^X.J96\'I?;R>E];WVXG!EOGI3%59F3O8?*=!DW+*R4Z*7D"EC
M&.08A,J)A;&!1!E(.3-GU9D3F(BY$OM0- LMMW?FVM]TRV:[4T$=PJ(^$E!6
M1J\%3($/-J*4Y^+X2R#DDZ#NOX"VDU>-L7K:\KW&@F=Z2)^2U4#%9(4+X1:A
M!@%>ZJQ(:)NP('+CJR=T<NI8^WYXAGH+)R4?'YUQ.XAXNV+1Z8-(^ZQ$NT?J
MP]LCV7(@U?*C#R+>?8H"=LV=I(.T!10D4FC9)^).R%VC<H9*(N]JN*R24P<\
MGI9(V02T[M_"0=1#"[?$REE.3&69E;/W(U^HWCJ0%KZ0HLY4829'#&.51GLQ
MX,)%'PA@",!@H<QI:ZF.JX'RD3<V7'.V>A;;X5^*-ASY9E9JQ(HJ )R8^QRX
MC7RS=VF4>](DQ;9&OJL53\)K_#TFD4J@IJ=CI\%;%YV^U=ZE3,%H@Z<)(]:R
ML#HI7/8F.G296 [CKQGMD:7/B/<_+6N"W(V)+A+SD /I34I1V!'^?,T7'. 2
MC#OC77I@='3:1:-EN'\@;F<%QE^RIDV)6R$]D9BP7B(7C:[9W!W]/B$V,!98
M9HEX-8/%.70+-!=!(.WA%%1(5,I#?7B1N*#<]RH['=9*2@H9!1JD<-+(LDT"
MA*F3G-!*Q!G#JOQ8X*IQDG7YM?9UHDLM'4W*A6HJZN/S+M(\Z%8I?BA0+'*@
M&(N#$D<N3-D^FF!?P,/3(#TVHU;_ 'SRI]G'_GS[-1#_ *3-\_\ B"?_ %6W
M^_KC_JF1_7_=J0?N-VS_ ))A[?\ O:KY@_\ ?_,#57C<7C]ETE^KU1+90(Y2
MKX;6M5>MU;8@[?+1[;&MP$(>TPI74BX=/G[.M"Y?$ SYTX64<QB1SKG$.\'M
M9JQ_$+PYK*>K<5%S%/-33/P0.U=3_E*>7$:JJ//Q4810H5\8'II7W&G7:>\*
M:6!3%1M-%-&,L56FF_)RH&9BS+%D_B).4'?W-[:)E&<W%1LS'+%7CY9@SDF*
MY1 2K-'S=-RW4 0$0X.BJ0WD(^OKJJ4B-%(\3C#QNR./DR,58?J((T]59757
M4Y5U#*?FK $']8(.H$=5O\73N[_J>GO\9GJ6;!_//;G])P?V-KA;I_-V\?S*
M7^[26ODO_P#V W3?TPHWZ?\ 4K_]GY/TZ9OCK_AEA_FM3_O(]0OPP[4UT^LU
M.?\ Y;#6AOE".R.0Q;DRL[YL3,G$9%VN4C(O)BT.0Z!H"^,!2&MVX3MP 4 F
MB()Q[IR8Z90D&T>FF43N%##U_![="5]#/M2XLLCTZ/+0B3#=:E?(GI@&/?I9
M+JH#'@TA..(US_$&R/2U45]I RI*Z+5%.QCG7 BF[$8Y@!">YY!0!WT_'I1;
MX(_?!M5K%LE7Z!\LT%-I2,M1P*$%T:?8M0*PLXHAVG!I;&"02(+>$DB,HG+-
M4"^&T*(J3Q VJ^U;_/31HPM]66JK<Y[KT6.7@S_&IW/#!)/3,;$Y8ZGVU;VM
M[M44KL/-T_&"K7MGJ*OPRX'H)E'+T Y!P!@#3- Y^L.!_7^X?9Z#]H /EJ#Z
MDNO.F(B,L$3*0,TQ;R<--QKZ(EHYVF59K(1DDV59OV+E(P=JC=VU65063-R4
MZ:ABB' Z^XY'BD26-BDD3K)&ZG#(Z,&1E/L58 @^Q&OET61&1U#(ZLC*PR&5
M@592/D02#]"=?,VW*4K)6PC<UNKVZUR<DH1BZ&PXJ?N!$Q7%HP[9)JOWBJG7
M,($+S/UUA5GCL2 < (Y?,P.)5%!&\%DJZ+=UCL%ZGB25EZ-P0 ]J>Y4\4U)4
M@=C^\SO.JY[?"A]?6M%SAJ=OW.ZVZ)V16$M&Q/9I:.5XYHLX[?E(5B8]B!R8
M9[][EW08VRA@'8E4K?+QWL=SW!2+C+,RHJGVN4Z[)(HL*&S!00*I[*I5FC&<
M31,'"+R<?\??\C6KQ9OAN^[*BGCDYTMG06Z( DIUD)>K8#)&1.S19&,K"GRT
MY-AVS[NL44KJ%FN#FLDR,$1L L"Y(!X])5D /8&1L$^NG6:6.IKHT:-42^KA
M^.EJW]+MMO\ F\'JU?A[_BSG_FU[_P!W+I&;L_/2/^5MG^VNKV*?X-/^87^Z
M&JJ:>>N^C1JJ%U,?QY73Y_I'A7_B&;3_ -D?XJ]X_P A=/\ @UTJ=S_GQMS^
M4H_^)U:]T@--;5?WKK=-S[J+$)MQ6)H(7&>,+PCI:3CHYOXC_(N-F@K/Y*#!
M-,HK/9VM"=U-5PA/$7=)'EH9%%=Q(L0;MWPIWK]PW+[FN,N+3<Y5"/(V$H:U
ML(DV20$BG 6*8G 4].4D"-LP#?6VQ=:,W"DC!KZ)&+*H^*IIA\31_62/XGB]
MSET )9<4R;#FV\Y8#;S5;Q).I@<'PS'&-0>OE3KO&](+>)&T0T&NHJ JF2@'
M=AE(Z, YQ(TA4XR-1(FWCTBA9>*UTEO%ZJ*5!&;K*]?4*@ 1JLTD=/+(H'PD
MS+3QR28 +RF1SDN=)>6NGK%H8IG+^1B6EA8]\0"H>6-"3ZB-I75#V"QA% XK
MKZFY?0/S!^S5"]6GUK#-F4H+".(LE9=LJJ:<+CFEV&W/"JJ D#H8:-7=M8],
MX_\ B)-X1O'M2^8G<NDB% 1, :WK70372XT5N@!,M;50TRD#/'JN%:0@?P8U
M+.W^:I.M6MJHZ*DJ:N7\%-#),PR!G@I8*"?=B H^I&J2_2*VGP'4CWC9TS1N
M/K@Y QQ$*3-MN,<_>R\6A8+QD"5?.H9%1]#OXY^8&*+1^Y>-V[XBA?'9'5'P
MSE ]H/$3<$VR=MVJV66?R=;(L5-3.B1.T-)2(JRGA*LBCF6149DP>+@8([I/
M:%IBW'>:^MN,9GIDYS3(Y=1)/42,5!9&4GCQ9F&0>ZY&",V>/X&'ID?5M2JP
M?FN>5./U?'?'Z?7\ND9_TF;Y_P#$$_\ JMO_ /U--#]QNV?\E0_^;4__ )])
MUZUO2CVWX5VLL\W[7<1,L=2>/;4T&^(P\U;9D):JS)/8RNW*=EGIM-LE"O2D
M6.JV]G.8')2G\0H< R/##Q O=SO[6J_7)JQ*V!A1F6*GCZ=3&>7%3!#$6,J_
M" V0,$]M0W>VU+=1VM:ZUTBTSTTHZX1I7#Q..(+"61P C=\C'XL=_33)^A%N
M4'/FQ>JUJ6D/;;?@^2<8YF@45\5T,2GWOJR\<F$>X3N6)UTB\A]%-J0@"( &
MH3XKV3[IW743QIPIKJ@K8L#"]0_!.JX[85P#D>I8GZF2[$N7G[%#&[\IJ%C3
M/[GB/BC))/<D$_+  [8P2VW)%_K>*Z#<<CV]^A&5FD5V5LLV^<J%21;L(IHJ
M[6,=0WD3O!/L*(^7<8-+NCI)JZKIZ*F1I)ZJ:.")%&2SR,%  'KZY/T&I94U
M$=+3S5,S!8H(WE=B< *@)/?]6-++V:]9C9SNX:!%+76.PSDD';AL% R;*L81
M:41!RJFQ<UJ==G;0\^+QL5)92/:KDE6BIE4EF'A)D<+3C<OAIN7;K=3RKW*B
M*JWFZ!'F$9P"ZSQ)RDAXME0Y!C8 'GDE1&K-O*S7=0O72BJ22/+U3K&6&2%,
M4A(23D,'BIYJ<@KZ$[;ZB^Z';IA[:3F\,HWFFN@N6++C6JY2#S$8^FKW)V.O
MO8R-AH6&3<'=2 /EWB0+N4TA:L6?C/WBR#-NLN3G[+L-YNFX;5]WTM2OEJ^F
MGFJA&ZQ4D<,R2/-+(5 3@%.!GDS8107(&MS<5SMU':JT5<\)Z]+/%'!S4O4-
M)$RK&B9);D2,G!"J2QPH)U7G^3.8HMTCDS..82(.6]+KD;7JDLZ4*=-I)3,T
MSL;D$&IS !'2\6BW14>%2$YFA))F94"@Z2$SB\<*^GCHK5;2RM53/-4<1W9(
MHFA')L?A$A8A2W=RC8SQ[+[PSI)C47&KQB!$AAS_ !I'ZC8'8<BBC+'VYKGU
M&KD^JV:<.D7=0#HP/M_VYR#SQ<]T"]0IE>KE/IL9BIEB \TLVJT!(/)B?9I7
M0<J0J:<C9I68G7)94M2[XM)XQ;';R98M-1PU-H^)B[1L<MII;$*BIFGJ:I[@
MURZ0:HE18H7-+Y"7*01Q1+T_,?E"KMRCZA"P;<&S#?[I'7SW,PPQ1PPK2+2%
M\11LSR*)A51X>5G<]3I<D!4 -P!T[^&B&$!$1<'%-D6<9#Q[.,CVC=,J*#9F
MQ;IMFR"*1.")II(ID(0A0[2E  #R#2NDD>:2261B\DKM([,22S,26))]22<G
M4W1%C140!510JJ.P"J,  >P ]![:]+7QKZTICJ?=*NM]2!MC%V.5?F:MN-U)
MAL6SDH);^,W RO@JEA7$>-RI1FA&3XB[U!R20<=QW:Q#M^.#:8.Q=_3[*:N7
MR'WG35HB)IS6>3$4L>090_E:KD70A""@P%!!SJ)[GVK%N04I-5Y.6F+CJBG\
MQU(WQ^3*]:#B V3D,<Y[CL-3XVW8JLF#L&XSQ%;+\7)\SCRJQ=56O?PX>J+6
M)&);D:MGSJ#//V?V-T=$A06 DPY3,8 $@$#RU$KU7P72Z5UQIZ/R$59425"T
MG6%0(#(Q8HLHAI^2@GL>DI^>N];:26AH::CFJ/-R4\2Q&H,?2,O 8#&/J2\2
M1Z_&=>5NNP1]T[MTR[@'XI^"/G4IS^I_%GN3XD]Q>W'1/[?[B][P/O/PO"X]
ME]\1_?W<^TDX\\E@NOW'>;;=_+^:^[ZI*GR_5Z'6X9^#J].;IYS^+I/C^*=?
M-UH?O.W5E )>@:N!X>KPZG3Y?PNGSCYXQZ<US\]0MZ7W3)_@W:_E.#'-GSR_
M.7,0<M[5\W'S>>Y?<K)PS]G\#X\O'O'VGQ_$\7QF/@]O9X:O/<$FWUOC]VLU
M!-]U_=GD8I8N/G?.=7J,K<N7E*3AQXXQQ;/KD>FN+MC;/[G(JJ/SOG/,M&W+
MRWE^'34KC'7GY9SG.5Q\M3YSSA2C[BL17W"^16!7]2R!79&OR0 0AG++VYLH
MBA)QYS>;>2C5CD=L7*9DU4'"1#I*)G #A$K3=*JS7&DN=$_"HHYDFC.3Q;@P
M)C<>Z. 5<'(()R#KOU]%!<:2HHJA0T51&T;=@2O($!USZ.A^)3ZA@".XTH_I
MR='6\=._,LMD>N;O?G#IEJ@7=>N>-'>#C5A&?;=WM,*]2L!,P6%*-EH61(@X
M2?EKSHR[47L>!&Z#]8Q6)O3Q(I=Y6R.BGVYY.IIYEFI:Y;J*@PMW61#";9"9
M(Y8R5*=9</QD)9E U$=N;/GV[6O4QW?S,$T9CFIFH>EU!ZHW4%9(%=&[\NFQ
M(Y+V#$Z>;I5:G.C]_P!O_7]FC1I&74EZ+<#OZS_0LZ1V66V+'<=686G9(C!J
M"T^O<8>!FG;UC(1[Y"?B"1TZ$/)O(,SEVU>H@W8PH@7L:J)G:FR?$V7:-GK+
M2]N-P62>6IHI/,B$4TLL:JZ.AAD+P]6-9N*LI+-+_&SJ$;CV7#N"O@KO.&D9
M(DAJ$$'5ZZ1R%E8-UH^#\&,?)ED&%C/'X2&=E6Z]%5.NP=6@V:$?"UV(CH.*
M8MB DW9QT6T29,VR"8"()I(MT4TR$ 1[2E  'RTL)II*B:6>5B\LTCRR,QR6
M=V+,Q/N2223J:1QI%&D4:A4C1411Z*J@*H'T   ^FO;UBU]Z-&C2)-W'12'=
M-O3BMWP;E0HH1LOC:5''OS.?$WC_ #>NV+KP/BSYTZ_X7O?V+P_%^&E/8/$[
MO#>]G:9K;>\3A8=L2;<-C-67BK8Q6_>?0X^<5UY>6^[YL]/EG'7'/'JFH+=M
MEFZ7I;Q]YB#B],WEO)=7/EF#8ZWFX\<\8STCQSZ-CN]HH=I2EYY[2@'/ISP'
M'.E3J=:YT:-*@W,=,(=Q6^7;YO/^>[X/#!$C2I#YM_FV^(/BGX/L0SW@_%_Q
M[">Y/>//LGB?"\O[)^'['/X'3 LF^ON;:MXVS]U^9^]DJD\[Y[H^7\S"(L^6
M\G+U>& V/,1\OP_#ZZBETVQ]Y7RW7GSW1^[VA;RWENIUNE+U,=;S$?3Y?A_>
MGQZ]_337]+_4KUP8I3E,0P 8I@$IBF !*8I@X$! ?(0$!$! ?(0\M'IZ:-5J
MMS?R=2F9AW(6O.&),],\+5:X61I<WF,%,5'M;"'LJSHCZR&@)9O?ZR1E"34D
M5:3:0XQ)D819ZY9,5/=:+%FV=MC\9:FVV2GM5PM+7.HIH'I8Z\7#RSO %X0=
M6,T<_.6),1M)U 9556<=0NS+:Z>'<%;<9JZDKUH8IG$II?*=94E+<I#&PJ8@
MJ.V6$?#"%B!E,*+*P!P !]@<:26F3J&V_/:Q9-YVW"T[>J_EH,-(762A#V2T
M_!)KXH]KT0\&36@$H<MOI8H&?2;>*<GD!EE0228*-A8K [%1"2[2O\.V;W3W
MF6W_ 'FU*DO0IS5>4"S2+TQ-U3356>,9D7@(QDORYCCAN/?;7)>;;+;XZOR8
MG:/JR]#S'*-&YF/AUH,<G"'ES....)SD:WZ;/3XK?3LPM-XMB[T.3YZTW!];
M[->E*F6F&DEE6S6.C&",%\26T[-M%Q;)JW#_ %XN1RY!P]!%L9R9(N[O;>$V
M\KI%<)*0T,4%,E-!2>9\T(P&9Y',O0I@S22.S?O(*@A<D '6KMO;\6W:)Z1)
MS5/+,TTDYBZ/(E555"=28J%50/WP@ME@!DC3$=0W4BUJK.6(Z[GG$&1L.6L"
MA Y%J<O5WRPMP="S]XMC$:R!6PJMP<'CW@-WQ$!70!8[<$Q62 W>7?M5QFM-
MQHKE3_OU%41U"#/'EP;+)RPW'FO)">)P&S@XQK5KJ2.OHZFCE_>ZF)XF.,XY
M#LV,C/%L,!D9QC(TL/ID=**P].&WY'EVFY@<NU+(T0R8O*<OB,:,,?*1KOQF
M4XE,$R=;B.')&PF8K(FB$2*HG,8BB(^6IUOGQ AWI3T,;6/[MJ**1V6I%Q%7
MSC=</$8C04Q52WQ@B4X/;!&HQMG:C[;EJ76Y>;BJ44&$TA@"NIR'#"JF!./A
M(*>GH1IKN1<=TK+-(LN.,BUV/M=*M\4ZA+%7Y,ASLY*->)BDN@H*1TUDS"4W
M*:R"J2Z)P*HDH0Y0,"_HZRJM]5!6T4ST]532++!,F.4;J<@@$$'ZA@5([$$=
MM2NHIX:N"6FJ(UE@F1HY8V[JZ,,$'T/ZP01[:K39K^3&8HL]L?SF"MR=FQ36
MGRRJZ=)N>/T<G)QAE3"8K6*L[>ZTJ3+'( (D03EV4U(]G:*TJN<HF,[[7XYW
M"GITBNUD@N,Z#!JZ:L-"TGMRD@:EJH^9]S$T4>?2(#L%I6^&-)+,TE!<I:.)
MCGH2TXJ@GT243P/Q'L'#GYMV&M<5/Y+FU2FH]Q>MY3B0KR+I(\I&57"2<5,R
M#,A@\5LRG)?)TRRB7"A X3>+5^831-P(LE@#@=VH\>"8G%)MD),5(22HNIDB
M1B" 6BCH(FD4'N5$T1;^.IP1KQ>%RB13->B\0(Y+%0".1E _"'>KE523[F-_
MT9 Q99VU;:<0[2L1UW"N$ZY\.TRO@JX,9RX%_-3TR[!/WE8[)*G(FK*SDH=)
M,SIR9-%NBBDWCXYJQBV;)BV2%[O=QW#<9KI=)^O538'90D442D]."",=HXH\
MGBN2Q)9W9Y'=V95MME'::2.BH8NE!'D]SR>1SCG+(Q[M(^!R.   %55154;[
&UR=;^O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g20220g75k20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g20220g75k20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5KA:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/D5L:6YS/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!355!46#(N86DF(WA!.U5S97)N86UE.B @
M(" @(" @(" @(" @<G(Q.3(Q,#0F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @
M(" @(#$T+41E8RTR,#(P(#$P.C$T.C4T)B-X03M%4U0@5&EM93H@(" @(" @
M(" @(" @(#$T+41E8RTR,#(P(#$S.C$T.C4T)B-X03M38W)I<'0@5F5R<VEO
M;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V
M+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF
M(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S
M92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C
M97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S
M96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!#86QI8G)I+4)O
M;&0F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @
M(" @(" @1W)A9&EE;G0F(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @
M(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX;7 Z365T861A=&%$871E
M/C(P,C M,3(M,314,3 Z,34M,#<Z,# \+WAM<#I-971A9&%T841A=&4^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(P+3$R+3$T5#$P.C$U+3 W.C P
M/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P
M,C M,3(M,314,3 Z,30Z-3DM,#<Z,# \+WAM<#I#<F5A=&5$871E/@H@(" @
M(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-3-B H
M5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I4:'5M
M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @
M(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I9VAT/C$Q,CPO>&UP1TEM9SIH
M96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'
M/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$+S=107-51VAV9$<Y
M>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C>$$[05%"
M24%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"055%
M0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=1
M1$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$
M03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!0451
M9T%C045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%04%!
M04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!
M028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-
M0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(
M:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)
M2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q
M>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM
M2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U
M<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53355%1E52
M3FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y
M5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG
M<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B
M1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L
M2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#
M15%-4D%$.$%F:VM/>%9K1VEA9C52;# T>F%T<28C>$$[37-.-7I93&)22V9S
M:T%)>&(P,T@R<3$Y<U92:VUM+VPT<&I+-G!D3W%Y,&U(14%T155:=5-F=2]H
M64U!:$)R-"]*5EIB95AV2T9X1B8C>$$[3$].9CE&66Q$1TM724Q*43A+:&%S
M3UI(2G9S*T=+;TQ53DLX<W<R8SAT;G)*=6)M35)M1S--1$M*3UA$:T]:3WA8
M:S,S67%K94MU>"8C>$$[5DUT27,Y1G5)8F\V:F9.6E-O1DYT4D1)2$I$5D)!
M.2M09D95.&919DE*;%5*-6AD63!H5G!364A9=DHX6$E*<W9(641R6'(Q>%9"
M-B8C>$$[;G!(;$=+,VQL<TYA86%65G)&8DY!,5=957%#+W=G8W1Y3G1S5EDW
M:7)C65%U;V,P46MC:C1$=FER2S=V479)-DQC6$9T<FI01D<V<"8C>$$[1F%-
M:$UR0G%J;'HT<40Y;75Y8F)$1E9G,$AY5'AK<C5I67-O2$5I,F-#<$Q$,W)1
M2T0Y3TMP9G%U;6%$8C):;7-.54XU34IF5#E)>"8C>$$[96Y6844X>%9Q,#)!
M-F1C5E4Y0W1D075$8TIQ.3-*6B]"+V]S:4QY2% O3%5+>$DY:%1&53-0;'IY
M44I'565A07EJ-THK<7E#=G=S9B8C>$$[2'A!1TMP6G%T:#5C9S V3UA4=%-E
M-G9$24)*0S!44B]U,E1L6&9A<4U/2C,S<FEQ=F]';BM4-VEY3#9X<4TQ<&0K
M<$EQ>%)R5E-I>"8C>$$[<55*4$)Q8VXU1"M(9D966CE+.&MT8EA*5%9P634P
M;4EG0E%Y2S!8;W$Q3FMJ2E!R37DX.71H6&IV:7%*=4Y$+T%#*VE4:DAR,&MR
M,"8C>$$[03E265A!0C5'<#1L9"]H4%-V8G)V:7%2*UED3# O5')U2T=X=C Q
M1THT56QA95!I04AE=%5O<DY1:C,S>%9'-F)P+VLK-# V25AM;R8C>$$[>E=E
M;W536E<T1U-&4C9L04]+<GER=T9F=%EQ<GDV1C5.:75)46YM1#9Z0UHT,&U!
M9V5*:$5X26MC35$T<7101$9737-!1TE"1$%';B8C>$$[261$.2M+<'(U9F<X
M=5-Y>6I7-35O27=&14IG;U-73%59=%97,D%X5DUP4$PO:W=20FLX>6AP0UA(
M03)S;TAW:"M"<B]!2E)69G9X5B8C>$$[2G189S!U1U,S1VYZ1UI89U(W9VQU
M45=9,35+0U5I,D<S8C94:7$W431D1&MN;B]413!S34-W:W=E:%1K,'AD5D%.
M5F(T94I::CAS5B8C>$$[5'8X07<Y-4=F:7DK6G941&LO03%R25-O<65.4TMD
M<5EQ:V5R5RMK47!:2%1R:#4S:V=6<C!/4'-45E!*5BM&9'%5.&9N:7)Q1$UE
M>28C>$$[.'@T."]W0V-F;3E&+TMN4TY*=C1.4TXY6E%86FIA25)M94I*3TY1
M,6%C9V%6<&LT1C(S6G-Z24=Z8E!F.$ME5G8K<E!9+SA!4TY$+R8C>$$[04TP
M-4XR5$=,<E=F>7IT<GEA,&)38EHU64AE3U%X,F-,04Y'47 W5C-:<41B8V<T
M5E@S97%F;')A=7E3-E9A.'A)675)=$E+;&=)>28C>$$[84%G9'!G9F]0:&ER
M2E X04-N;&(O<7HR4"]33D0O>E1G5C,K1E!+,R]6;G-F*VMA2"]M;D989C15
M.')F.5=E>"]W0VMA2"]M;D96:R8C>$$[=FQN>6Y&13AS;6M72WAX<5=C+U9O
M:E%+2VYO=4MS675.9CA!>71I5T8T.4UT8FE+96Y"-#=/3'5Z3'5R<6ID67HR
M=W%N1VDR6&MN5B8C>$$[,&MA,3!7,5@P9VAD6DQ70E=(<4E(031G16I9.3A6
M5$PO0VYL8B]Q>C)0.$$P:E$O.# T1E$Q>C5:,$)(<$9O;&EY,#8O5EEJ=B]W
M3R8C>$$[46M4,&)94FE2=6AM.'4V4T]M9S)0+U-*1B]Z5&M/3U193650=E4R
M.'8V84]M9U=0+U-*2"]W03 T3T]F8WI'4$8S<6)A1EDY=DPY:B8C>$$[+W="
M26-F.$%Z5&<X4V9C>4=,1C-Q8F%*83EV3#%J+S!H>"\P>5!I6D\U:TU/2'8K
M,5DR:E$Y=DQL:B\P:%(O,'=E2FLW;5%W65 U,R8C>$$[,G%B85%",#AT,E O
M045H4B]W0DU(:35E-6M.4' O-3,R<50V6$E/;FQQ>"\V454O<&Q:>EIU-S='
M63 R;2]N9F%O3G Q,$]N;&EY4"8C>$$[+U)G;CE-<4]O,4@X,S='=V%84R]Z
M=G15;G-D4D@R9DLQ:V8K:D)0-EI59%9Q=C5V,DUX<$Y(+U K,$M,,FUR:G U
M5G-J+S(W,"]P;"8C>$$[571:<D]K4#EI5UDP96DO;B]W0WE#:3EV<F\V954W
M3"]!3&AY+W="37!L<G1D,&@O<U,R1%)A2"MF+W-G<SE(>D(O,4M6;"\S1&PO
M<"8C>$$[:U!Z+T%':"]-+S)*5"M2,$@X+R]!1U%D-E!M1"]Q57),+W5(3"]4
M2#@O,F@O32\R2E@X:F]0-2\K>41V4CAW9CE3;%IF.7<U9C99+R8C>$$[;BLP
M4#5N*WA++VMD0B]0+T%.:T=995<O3"MN,V5M3$YQ+VPV=W1R;W-2=T9T14-6
M2%)I<%@T9FQM.#!/6$Q02&558TUV>#AN4V$S2"8C>$$[:6AK<D5E2TMA+S15
M.')F.5=E>"\V4F]F*V%C>DA%9"]H5'ET+W="5V5X+S92;V8K86-69"]H5'ET
M+S%:-T@O<$=H+S5P>%8S*T902R8C>$$[,R]6;G-F.$%P1V@O-7!X5C1X-6$P
M:E1T4TXV;#5C3&)M0T%Y=W,P:7AG<T13;%="<C%Y:T(U=E0T;WIU>E=Z3E!Y
M8T9B8E92-'9$-R8C>$$[9&YY54A99&PX<$TK+U(Q=B]03B]Y4&TO-7)Y>#)J
M1CE2.#)E54Q(53-S2C-U;75);4MY<VIZ37%C04=::65F4F52-F5"=W%O-F@U
M>"8C>$$[.&]757A7-FIV1F-64$QL26%S1E9M6"LY<GE7<6<Q+U9V:6AL:3)&
M<WEH9S@Q1T92*R]M-R]W0WIW2EAF;S8S+T%*-78K4C@S+TYE2R8C>$$[<%)R
M,G)A1F]8;VTO:W5L5V-/5EI*6C-O22M02W1(<BLR3VXV9U1I<49I.# K535B
M67I#-G515FE-<GA&<G)K1D%F<E%L9CA!9%15,R8C>$$[,RMK65953%AZ5C5/
M=5E'=4$Y>6QU:BMM6EAA96=.1E!26%IQ9DA4<#@X5E4T9E!F:V533V%68G$W
M0E(R56ET,E,T444X=FA*04)64R8C>$$[4GE)3D(P>%9',EAM<GEF95A%3G1"
M9GIM-6YC4DI%6'5W9E50-TIA=D=V,#!X5DYB;4));C1Q2FU&2S$Y968X035R
M>755:4<R1TU%8R8C>$$[,$DX:DPP:FU0+U!E-"\U<GES-50S3G<P.&4Y464X
M;%AP0DUF*V4Y>"]W03$U134U9'I93DI$*V-O=G%D>793,FU0.$%Z,W5F*V$X
M9R8C>$$[9%),=6)";V]F>FM02G)D-'93>FU0+U!E-2\U<7EU5W)M4#17>5!:
M*TTO>&9C:$I0375O<C!S2FHO=T$Y<G(O;7)-85AA3U%F=R]E,R8C>$$[4C=,
M>$@K4#=L9E-T8W9B,E9K;6EA>D%:5E8U6G)Q:#5"=CA!:7AE-F=F5&IH-U)Y
M5$Y%0U!V=')Z.6Y9-$-W5$PS56E).55U5W504R8C>$$[25E*-DM3*W V,#)Z
M33-%;V$S03,W:F8U:&-K3F9K37%O8V=F,F96*T]T341O64-.,F5D9G0K;CAD
M3%=A:'$Q.6%E:5E96'9U8VE2="8C>$$[2$103TA)671U=$I:4#524V\W-S!W
M6G4P37-+;T-E-#5F2'I0-$MC3V=X>G5Y66)(;CA0269G36]85#1#;TI--FMI
M<%5Z>E9(=',U>B8C>$$[8T%U;TEB+U(Q=CA!>GIF.&HU=BMA.%9D*VIR9BME
M8B]!2DAZ9C@Q-'$W.4A7+SA!4$XO>5!M+S5R>%8S-D]T+S4U=BM2.#,O0418
M:28C>$$[<G8P9&(O>GIF.&HU=BMA.%9D*VIR9CA!;FTO-4AZ9C@Q-'$W.4A7
M+S@X,R]!0U!M+W=#83A69"MJ<F8K96(O:V9.+WI8:7)V,&1B+R8C>$$[04TX
M,R])*V(O;79&6$14-V-'=D]B8B]I*V(O;79&6&I(;$M65C W6&LY24U467E(
M,7%S0W5X1DYJ>#-R-%8W9$LU4TAN.4MF5% X028C>$$[<7-P+TIW5G1T5DAI
M.%!T,F9*46-Z<W9L2FXS-D]T+S4U=CA!:V9.+WI8;&IT16<X>E@X96ME:4ED
M3'9T5&553GDY0U-C<6=Q0CA4028C>$$[=#ER:V-+<G)A-DXS<DIS1S!Q-VIG
M54U8=DIP-7=T3TE)-&=M:')64CER-S9(1E4Y+U(Q=B]03B]Y4&TO-7)W2S<Y
M2%<O=T103B]Y4"8C>$$[;2\U<GA683)L,FI5-4=6<61+>GI(<4MF>C1Q<VPP
M,GEI:658:D\S0E-3<5141FE&0DY!3V8S67%X5S0X>E)Q:TQ7,F<V<$EK=$]3
M>28C>$$[3F-2=7178T5L45A88FA8-UAC655*>&]Q=S9I<W8Q:7=U3$8T94@W
M=5=A971844U10U-O*T=T3G-5<&].27-G86HQ46$Q<4IP=78X028C>$$[=V5"
M54IQ0T,R+W4Q;6LR<B]F>B]!34AY<DI-:FLS-&-1;'I,2$Y3.'AA:&%G;4MX
M;6MP+WAD9&9W8DYB<74P36U-8E)T,FU$<WI&4"8C>$$[;D]V:VXS;#$R,5!3
M-#=U-G0W:3!L8VM'3G U.7=0,FQQ.6%(,WI-,%=O;&QX:55O.$ID9')-16-7
M47AJ3&E#6B]O-C,O;FTO-4AZ9B8C>$$[.#$U;'5+-SE(5R\X.#,O22MB+VUV
M1EAF;S8S+T%*-78K4C@S+TYE2W4O4C%V+U!.+W=!:C5V.$%M=D989F\V,R]N
M;2\U2'IF.#$T<28C>$$[-SE(5R]W1%!.+WE0;2\U<GA6,S9/="\U-78X06MF
M3B]Z6&ER=C!D8B]W03@S+TDK8B]M=D989F\V,R]N;2\U2'IF.$%.94MU+U(Q
M=B8C>$$[+U!.+WE0;2\U<GA6,S9/="]W0V5B+VMF3B]Z6&ER=C!D8B]Z>F8X
M04DK8B]!2G)X5C,V3W0O-35V*U(X,R].94MU+U(Q=CA!>GIF."8C>$$[:C5V
M*V$X5F0K:G)F*V5B+T%*2'IF.#$T<3<Y2%<O.$%03B]Y4&TO-7)X5G<P*S-"
M<GIM,B]W0TPU=CA!;79&6&@O;'-Z:3 Q;C!O,B8C>$$[:R\P2BM81U5X9T1K
M2VQG1UAK07145'5A1'9L265C,#DQ2W8U<DUV>6-&8F)64C1V1#=D;GE52% W
M3#536CDK:G)F.$%N;2\U2'IF."8C>$$[,359-U)I,3,U:VMH=EIR95!23E5M
M4THS45-I4S154'A92W),53!O>')49G180W%R2G)K<5A,>"]O:E5046IK0TY-
M,#%Y1%%M2F596"8C>$$[96]R3#0Y:FER2E P9&(O>GIF.$%)*V(O04IR=TML
M4&U/-D=J,E5D>D)A6&5O3SAN<"MJ1%!C8V=/1$YY,DPO>54V9%1I<590-6QM
M0R8C>$$[4DUU:#9M6%I3,'-2;6U$2T]!6E-+36%G<U=(*WA09F)#:#)K*UI*
M8C8Y:'1P=$<Q1S%786XW,7!R:V=";#56,S1I:6Y9-S1Q,T@U<28C>$$[9T)K
M5S0P8E=%6D=L04U:;FM2:$988TU85#=82&)B-F-5<7-N;4M&3&8V=TY+,55X
M0U)K6E,P-&LT<D=S;DI51&UT95<Q4T]H,S=9<28C>$$[=DAM2WI-:U59,'97
M954Q3TDO96EH67-">4IM1DLX2S<K27A63V)M,4UB,&E%>DQ4<C8Q=V8Q4&QC
M<$5C;3)%26MB;$-T2&1$<$9-9B8C>$$[*V5T>B]W0E9-:'AY-VTP67-F97!T
M.69(4T-9+S@Y3&XO<7!K5&MN,TUX:'AF>G9T0VMZ-FU/;'1-9CA!6C-8+T%&
M57=E3%!U6D14-"8C>$$[=C4S,FA386970C!T2FHO<W)V.$$V<5I(>'-N9#EJ
M36%B1"]/*S!+5#-E=6IP6E1(+UI89B]65$EN3FPO;2]95UDP=40K9CA!849"
M.28C>$$[43AY1#=/;GI(-F)Z+W%P;%5T5&U(2U R1G-':C S."\O6D)19E9F
M3EDK>G!K>"MI.2\V<3543%=A:V-O9C=%=&<P3VPO;B\W2TMG*R8C>$$[=&5C
M:#EN4UIJ+W-B-R]Q<FQ%=&9Q>'EX+W=#>&LR1',O4B\V<"]S;R]Q54<Q+WIY
M3VUJ5$@O65@O=T0Q5GEM6&%E="\Q3"]9>2]7>B8C>$$[2%IU:2]W0E4O=T)L
M2#E3,R]%4&YR+W%Z5&8X04%8+R]!1E9Y4#AP-C<O578Y:$PY868U3C!8*W$O
M=T-Y:BMP,RM)9E!8+U9M;2\T0R8C>$$[+W=$*W%U4#AP-C<O049,+T%'178Q
M<B]*=6DO,5@O6E(O57DO>3)T.69A67,K<5<P,6YC;&E05#EE-%=Q:F\S0FY,
M3#AJ;3<P3V),:R8C>$$[>#A74U!$3#AD3VIP9&)H>#0X;%DU8U5F>#$V<'(K
M:G)F*V5B+VMF3B]W03$U;4])-SE(5R]W1%!.+WE0;2\U<GA6,S9/="\U-78X
M028C>$$[:V9.+WI8:7)V,&1B+W=!.#,O22MB+VUV1EAF;S8S+VYM+S5(>F8X
M04YE2W4O4C%V+U!.+WE0;2\U<GA6=S K,T)R>FTR+S1V;2\U<B8C>$$[>%8T
M=#5485E71W9C27A)=C%"=S1*-D$W8V=/3&10;4UP1'HR;'9H;B]66E@K5&=R
M8F%Q1#!,46IB8G,O:&MO3V(R6'EK>C<Y2%<O."8C>$$[.#,O22MB+VUV3$AA
M2E)R,31.3&$R5TMZ=DPS-G=*4WI25#-"0V5K;DUC=4IB-UA40W%L;U=P<'%T
M-V,R-7-R-C!3,U5(,7!P8FQ69"8C>$$[:7I,4F582'-T9C19<6YN-D]T+S4U
M=CA!:V9.+WI89U8S-D]T+W=#96(O:V9.+WI8:7%7-C5+;6U7,$TP5G1D,W!L
M;FIH355-.#5:428C>$$[-4Y8,EDW1$95061B4C57:F<P>E5Z=W(V:&QK;FI(
M,C)4-&%-.69S13ET<5E64S$O3W%2;T=M,$Q727=(2')&;75!<5)"2W4O3&PQ
M5B8C>$$[='%'9S<Q>%%J3%1Z6' Q,$E':3!V5W5&>'9(25),>#0O1#A64DUF
M:"M+=GEX4VED13%U,3%38U%F;R]68DYY5V\Q=S!Y2GA(27%3,R8C>$$[<61W
M=C-M;4MP;F0R+W!.4TU43TMD9E=N4#9N>755:4]49&IH13AY9UI:8G!F<W=4
M2"]N<F,O.$%.959(3$QU8VE/;GAN*TI">3,K<"8C>$$[3#EM,&U0.$%Z,'5V
M*V$X<FQQ2FIO,U(P94DO>&9A151%8BM305-L+U1B-&%X<SDQ56-L0C,O9D19
M9"LO=&<X8DE293-Y4#8R<5=$128C>$$[1%<U*TDO56]78RMR6$5%57-L64=K
M54TP5$YC5E=P<#-U;"ME.414-DLP63E6;6M!5%$K2"](=G@X<G1Y86)$16M#
M>CAF*T\O:C4P<B8C>$$[<%4K;WHV>DQ:6$YT36)626QK1C)K<S9"5TER=U W
M-E94+W-7>5=N,5=75U5W;$@P,3E83#1C>CEH66%J5%EO-&A/37969DQN*V=F
M828C>$$[12LO4C%V.$%Z>F8X:C5V*V$X,E1R;F9O-C,O;FTO-4AZ9CA!3F5+
M=2]2,78O4$XO>5!M+S5R>%8S-D]T+W=#96(O:V9.+WI8:7)V,"8C>$$[9&(O
M>GIF.$%)*V(O04IR>%8S-D]T+S4U=BM2.#,O3F5+=2]2,78X07IZ9CAJ-78K
M83A69"MJ<F8K96(O04I(>F8X,31Q-SE(5R\X028C>$$[4$XO>5!M+S5R>%8S
M-D]T+S4U=BM2.#,O0418:7)V,&1B+WIZ9CAJ-78K83A69"MJ<F8X06YM+S5(
M>F8X,31Q-SE(5R\X.#,O04-0;28C>$$[+W=#83A69"MJ<F8K96(O:V9.+WI8
M:7)X4'DR25)P,G)L<F57-6UM=#)I9U=&63-:1TE*3'-#=VM#:G5652]H;$EE
M9# O=T)-=')S328C>$$[=2]*=T$R,G%G-V=V1%5F42M39S4S6F9+5%!V,%AP
M;B]!0WE1+W=$2710-EI9-U)*4$UL-V$V4#9(;V%#9%)--&M0.$%O.$E006]6
M0R8C>$$[:'%),4]F4&(U659784IQ9&QQ;6]35VIA0DI:>'!','$S33EV=U)Q
M3T953'E29G1+95AJ:7%F9F]V5% K5U-(+T%*1G O5$%R=C!8<"8C>$$[;B],
M2D0O>4Q4*VU+<U-(;4Y$9$Y"+VA35F5,1F9684E"3FU503%%6C)94'1H46EO
M=&%S2G)*-3 P12MS<WEX:3)A17$O<'953$LQ628C>$$[.6QA;3%!93%A8C!5
M<59V<CEV3EDS13,K1VY3.6E%6FES1VEP2DE(9%5C<51'1F]H:T9F-%EQ=4AM
M5%-#-%%E5V(X:W-50D9L2%1K1R8C>$$[-#!Q5R]W07AI<3!E6F1+865*1CAT
M6&9P=49,4TYA24MC;%9G2V)J8FU+-S=B-'%N=#-:5S!B56@P*T9X5'(V25 V
M:&QC<$5C;3=(0R8C>$$[2C5L07ER2W8R9$IH4"]2=51L4GE4-VY):F=X9GIV
M=$-%;&TQ0F9S84Q#9BMJ5FIL8W,R5'4K=W0P9$QG4$]8,FA&43)M;U,R+W$O
M528C>$$[-TM*-DQ72C=.<2]%0B]L<G-#9"LK,U1T:4HU:4PR*U(O5S%3>#1"
M2W1Z+VY$.5-'<S1D875)27!8,"MZ9UHQ1$Y%.6E35G%A9#4Q*R8C>$$[93E$
M*T9C9DAM,4UG1%%(*V%F.$%I+W@X<G-Y671.16M!:R\U=R\T:CAF3VQD3%,O
M9E=P<D\Y,&TR87A33EA3.5,S34DU34%E4$8R:R8C>$$[-4AT<V1S;G X*V,U
M5$-C9E)8,552.35,1%!G=T1%2G=L-C<K;7=F=4%4-SE&-EHO>7E1+SAI,"]P
M;7AD93<Y1C9:+WEY42\X:3 O<"8C>$$[:7)V,%AP;B]!0WE1+W=$2710-EEQ
M-SE&-EHO>7E1+SAI,"]P:7)V,%AP;B]!0WE1+W=$2710-EEQ-SE&-EHO>7E1
M+SAI,"]P:7)V,"8C>$$[6'!N+T%#>5$O=T1)=% V67$W.48V6B]Y>5$O.&DP
M+W!I<G8P6'!N+T%#>5$O=T1)=% V67$W.48V6B]Y>5$O.&DP+W!I<G8P6'!N
M+R8C>$$[04-Y42]W1$ET4#99<3<Y1C9:+WEY42\X:3 O<&ER=C!8<&XO04-Y
M42]W1$ET4#99<3<Y1C9:+WEY42\X:3 O<&ER>%AY:$IO<4QQ6B8C>$$[,5%O
M149S5VA$0D-X9%150TU0.$%T2'149DM1.#EP5$%C6$8S37,O2G=!,C)Q9S=G
M=D159E$K4V<U=EIF2U1.<BLP,"LQ<W W;$Y/:B8C>$$[;F%&0S1H4TI3>E5&
M8419-S59-U)J:VYM:7=225<O=W9D:W15>2\V2U!H5E%#94]X-4AE9T(T-%5,
M-"]-,FQ.4%!'+VQQ.552:VU.>"8C>$$[6G%1-G%O2E!A:#5%:6TO5#9-57!P
M;U4K;39V2%!+3DA.;DA%-%--6%5#>'4T-&AI,T=M=W%A9&-#<' K:3E-+S5:
M268K4F%F,'A6028C>$$[-C!T:G Q9S$Q1G!3,VIQ>4PV14U3;'IZ8TQ5554Y
M2S%X5FIQ*V$W5U-75EEV2V0Q>%97949P3%E*>D-1=$EA+T%W1&-L-$M!5%AR
M-R8C>$$[6596:C5M,#5,85,U;CAU5%<X34-'85EY44EP15E,055Q2T9J=TIO
M4T\R*RM+<B\X56%*>$)(;'4K645+,59S;S-&1W)19W%X0C9D:B8C>$$[,WA6
M1S92<4]L-FIE3F%(435B5U)!-T=383-267%+5C)$.7EE63=E3TMO*S=S8F1'
M<$1947-+9C<V52]W>755:4]49&IJ13@P1$Q$8R8C>$$[1#=';5%N+VYG37%-
M-3EZ:U)X675P46-V-E5(,DY*:% O4G5-<FQL>3EZ9$A"<"MS=G128TUA=&)L
M<')%2D]!=%5&;E5B9V-Q55$O6B8C>$$[3F1U+VHS=T1,3W0W=C-.57-/4&DR
M<78V=U$Y;#8W,CA46%=N3$A/>6=Y271Q,4%A;6]R-DQ5,C,W*T9D.7%-96]Y
M:T1I0D(Y>"\T;B8C>$$[.&9(87I,<#A12C130U!E4"M++TAW,U4P=$QY9E=:
M64HY2FA85%)%<D,T84QG4DE2=7$X:VHU:78K4TUN<#@K95=5>&Q(.3-84'HK
M428C>$$[=C5-3E)G=WAX06E8<G9L-69-,3@P*R]296UF.'-K4"]!0TQ4*VUB
M1C$W=C!8<&XO04-Y42]W1$ET4#99<3<Y1C9:+WEY42\X:3 O<"8C>$$[:7)V
M,%AP;B]!0WE1+W=$2710-EEQ-SE&-EHO>7E1+SAI,"]P:7)V,%AP;B]!0WE1
M+W=$2710-EEQ-SE&-EHO>7E1+SAI,"]P:7)V,"8C>$$[6'!N+T%#>5$O=T1)
M=% V67$W.48V6B]Y>5$O.&DP+W!I<G8P6'!N+T%#>5$O=T1)=% V67$W.48V
M6B]Y>5$O.&DP+W!I<G8P6'!N+R8C>$$[04-Y42]W1$ET4#99<3<Y1C9:+WEY
M42\X:3 O<&ER=C!8<&XO04-Y42]W1$ET4#99<3AA.&]V9&I3=DU!4U)L="]Q
M5#@P<CA*67%13B8C>$$[:G18:E@O4&-5:#4O4VLX12LW:%I0*U1G0G1T5D(S
M0F5';RMH.&Q">D]Y*U5M9F9O=E10*U=32"]!2D9P+U1,2&%*5#5I9W4W4S)I
M9B8C>$$[4G1&='(K6FY+>5)U23 T<GA.1W%E4#=62RLR2W(Y1U0V-EIX939&
M2%E#26A9,EE2=4I30WEU5DA&4T9"6#1396].85EQ;68V3#!Z+R8C>$$[04I:
M268K4F%F,'A6,S9,,'HO;&MH+S5&<"]41E5$<E9M8F5W85A43DQT-W4W1$E&
M:%I%5493-$1M<#0Y1G%E=4MS9%<W.#)34WEJ+R8C>$$[04%L8E%X;%=A1&TP
M3&M&65=)5FE#=%,P;T%";TM$-SA+<7AU.69J='!*-2]+.$%-2T=5=W@X2D=F
M9'5-83A!>#5556(P4#)U;3)+<B8C>$$[+W(K=&-14C5.:F):5'100TLQ<C U
M>'%D:%1Q0FEQ3C!J-C5C,VI186@U9&AT259$:UA184HQ2D)8:6]13'DS1$AF
M,CDX5E)L+V%W=R8C>$$[;B]2.4]H:S(O=T(X:'8Q1$MS:W!$:S,T8V-*9E5A
M63=Q5B]R:T%0,6)125IF1"]22D<O-&EC,75P,65O9U!20R]G6%HT3D9P<&96
M3R8C>$$[=C@V2V4K6&]$93982&-A;G!-3FYD35-':3E*4E5$;S-&9U=7=F=C
M>DY&;7E:35EL:VIW>3=V>'ED9G)-5U!(:TUC8W5+4#0K85HO;R8C>$$[=E10
M*U=32"]!2D9P+U1-<'A89F]V5% K5U-(+T%*1G O5$989F]V5% K5U-(+VM7
M;CE-5F0K:3E-+S5:268X06M7;CE-5F0K:3E-+R8C>$$[-5I)9BM2868P>%8S
M-DPP>B]L:V@O=T-2868P>%8S-DPP>B]L:V@O-49P+U1&6&9O=E10*U=32"]!
M2D9P+U1&6&9O=E10*U=32"]K5R8C>$$[;CE-5F0K:3E-+S5:268X06M7;CE-
M5F0K:3E-+S5:268K4F%F,'A6,S9,,'HO;&MH+W=#4F%F,'A6,S9,,'HO;&MH
M+S5&<"]41EAF;R8C>$$[=E10*U=32"]!2D9P+U1&6&9O=E10*U=32"]K5VXY
M359D*VDY32\U6DEF.$%K5VXY359D*VDY32\U6DEF*U)A9C!X5C1(87DV,6%W
M5"8C>$$[45%2>4I(8T1J2U!3<6%&4W T:W%3=%99<5-T2V<P>7)H3'I-9D5I
M0T%$=C50479Y9V=L:G1T545S8DIY84=G8T56,F9X>55"5',K>B8C>$$[66M#
M5G,V+U)E;68X<VM0+T%#3%0K;51D;6LS;4=$56)9=T129$=T8GIM<VAM85)5
M54EW2V5M2U97=DMR9F1H5EIO565P,T8U3D1Q*R8C>$$[:#(Q<$5I:WAZ4G)'
M>7-W64%#=%-D>'8P>%904#!8<&XO3$I$+W=!:3 O<&=6,S9,,'HO;&MH+S5&
M<"]41E5$<E9M8F5W85A43DQT-R8C>$$[=3=$249H6D551E,T1&UP-#E&<65U
M2W-D5S<X,E-3>6HO0U9T1$=66F]/8E%U459H66A724LQ3%-G04=G;U!V=W%R
M1S<Q*T\R:VYN."8C>$$[<G=!=V]:5$1(=VM:.3(T>')W1$AL4E)V42]A-F)9
M<78K=C8Q>$)(:S).=&Q/,#A)<E=V5&Y'<#)&3V]'2V\S4U!R;'IE3D)Q2&PR
M1R8C>$$[,&A53U)D0F]N56M&94MH079,8TUD+V(S>%9'86A926XK.'1J0S(S
M*RMK3R\S6E1K36AY8CA-64@V;4]A:W9M6D%F<6UL47-E,RMJ>"8C>$$[;DYB
M<7,R<$$Y02MX,FU$0G!$.5(K,5!V3'1L3E!P8V-M<C9D8G<S:$IQ:7AP=799
M<TMF0V9B37I25'EY>&<U4E5N6&%Y1TM/46I%8B8C>$$[:6UF-DPP>B]!2EI)
M9BM2868P>DQC5C,V3#!Z+T%*6DEF*U)A9C!X5C,V3#!Z+VQK:"\U1G O5$98
M9F]V5% X06QK:"\U1G O5$989B8C>$$[;W944"M74T@O:U=N.4U69"MI.4TO
M=T-74T@O:U=N.4U69"MI.4TO-5I)9BM2868P>%8S-DPP>B]!2EI)9BM2868P
M>%8S-DPP>B]L:R8C>$$[:"\U1G O5$989F]V5% X06QK:"\U1G O5$989F]V
M5% K5U-(+VM7;CE-5F0K:3E-+W=#5U-(+VM7;CE-5F0K:3E-+S5:268K4F%F
M,"8C>$$[>%8S-DPP>B]!2EI)9BM2868P>%8S-DPP>B]L:V@O-49P+U1&6&9O
M=E10.$%L:V@O-49P+U1&6&9O=E10*U=32"]K5VXY359E2#96828C>$$[-F9.
M86%J2F1%*W1$0GET4GI#5F-T5&]D,BM1+W1'-6U30TMD8D5#:F).+WEJ04YV
M<6=)<4,P3E(Y1#5I83-M2$DP,TES-2]296UF."8C>$$[<VM0+T%#3%0K;5E,
M;$E(5C=";W):2#!Z5')7868Q541X>5)R5#!Y84U187)U3W5+<65J>&TX5GIF
M-D9&<#5667EO8C!P95)D87-">"8C>$$[56993S)+<&PK:3E-+W=#5U-(+VM7
M;CE-5F0K:3E-+S5:268K4F%F,'A60C9N<"]#1TPY2&%F87E44$MI>65R1W9&
M66EF:F9B:51X1R8C>$$[2W!$8GEE6G!(16-N;'4Q:F(P951Y1EEW9VQ)0F]0
M:DI)56UH2&9X=V]68D=45WIE4E(S+T%*8V=J=&I*>&QN:5=*+V<T.%$T54U3
M2R8C>$$[>54R<'-U*TM62WIK.'IM.5)B-WDU6G@R5E%:2DEG<G9W66M50V=N
M-&@X3F4S.$9#3#!R.4Q81W)Y45@S;#8S=$Y/0W-9-VEK5$UF:28C>$$[4$-V
M16XY;6Q25')81DMA6&1L8E)T4TA4-%A&3W9O9R]Q1U9Y:U)Y8G-C26YM541+
M<W$O6C!M12\Y1S5/5DA*4'5C:4]$1B]/*S!)4R8C>$$[5V)51BMX;W-*+S9.
M5T]6>7I:3S<W0S-2,'5!.#5F84548C)U;U17<U4W5U9N13=I471!,6UX9&5"
M3D)V26<K2VTQ4TU24$U11'-/9B8C>$$[42]R1%902&=J26IC.'0K268X4U5.
M8E)A,4Y$>F94-T]*=6)P=TYI9'=R541$;$]M>D0K640W='AJ=WIA;5%U9TXO
M-7 O=T-,2#90;"8C>$$[=3)Z=S9A2F]%;F(K8U X06E$*VXU-TER5&]B,716
M*W$S;6PR>E=H:3E4-C!L=4EE3#AI071'96)L54-U>$)(9DQC1V)/8VY$265M
M<B8C>$$[=7$O5$IP>EES27@X550V<C589C9!;E@V3#!Z+T%*6DEF*U)A9C!Z
M4&-&,S9,,'HO04I:268K4F%F,'A6,S9,,'HO;&MH+S5&<"]41B8C>$$[6&9O
M=E10.$%L:V@O-49P+U1&6&9O=E10*U=32"]K5VXY359D*VDY32]W0U=32"]K
M5VXY359D*VDY32\U6DEF*U)A9C!X5C,V3#!Z+R8C>$$[04I:268K4F%F,'A6
M,S9,,'HO;&MH+S5&<"]41EAF;W944#A!;&MH+S5&<"]41EAF;W944"M74T@O
M:U=N.4U69"MI.4TO=T-74T@O:R8C>$$[5VXY359D*VDY32\U6DEF*U)A9C!X
M5G<P>E1186DP:$)(42MM;CE-5F5195=N:EA29&9&0S!J5W<R2V=Q0GEP>7)Y
M1RLY3VUB8DPY528C>$$[9F4T1U V4WEB.&]W1&(V;T-+9W1$5691*UDK=#5H
M=# S27 S<G)8.6QD<4Y0.'9W,W1M<V9/4U5,2'E-;%133E9(>$1:9G1C5%%K
M8B8C>$$[6FA/56A%=5!-:E=5;DQY<&)2,W%+:DI6-&UJ8W1+1EI.='AX:DYA
M,7A68TPW5U=61U1Y9$AX;$%:5TUS24MQ=W%#-G-I<T=&9#%X5B8C>$$[5C!E
M6%8W:3EI9S%(>7A$85<W06E7-D11<T9:5EDX9V=Q4T=)04$W5C<T<7E,.48V
M6B]Y>5$O.$%)=% V6491,G!714U6:&-35T]N5R8C>$$[.#DT:4U925=204=C
M1%E%-UEQ>#(S=79-475)5&0K5F]%=$=O,"]P96LX:4M89&%!5BM*9T]",DAJ
M:%9D3DXU;6IE5TI02W1P35,W;28C>$$[0V-34DMG:E9I1D1O4EAM=T<Q1W!U
M3VTK2W(T-W980F%).'9K*TDS0C)E3EIO04]Q:78R5S8Q8C=V9EI63F1*='!,
M9WE$54Y(=#=3:28C>$$[;S!D0D<K-V-U4V)6<G<T:C1T<3$V1$%R96]A8U99
M+U9,2T5J="LV:B]I37%Y1UA2>4U)>"]W051(3E-T4$YQ,2MP-F9#9D0Y>F)N
M.28C>$$[67I787%E<D@Y,E!U9'!G>#9)+U5F=EI*;U=N=DIP8T1A=%E7,&0X
M4BLX5D54-D-A0V=*2%5$32]34WEN1T1L1E1D6'$T-'AK4&AM-"8C>$$[22\X
M05)E;68X<VM0+TET4#9::W5/-SE&-EHO>7E1+SAI,"]P:7)V,%AP;B]!0WE1
M+W=$2710-EEQ-SE&-EHO>7E1+SAI,"]P:7)V,"8C>$$[6'!N+T%#>5$O=T1)
M=% V67$W.48V6B]Y>5$O.&DP+W!I<G8P6'!N+T%#>5$O=T1)=% V67$W.48V
M6B]Y>5$O.&DP+W!I<G8P6'!N+R8C>$$[04-Y42]W1$ET4#99<3<Y1C9:+WEY
M42\X:3 O<&ER=C!8<&XO04-Y42]W1$ET4#99<3<Y1C9:+WEY42\X:3 O<&ER
M=C!8<&XO04-Y428C>$$[+W=$2710-EEQ-SE&-EHO>7E1+SAI,"]P:7)V,%AP
M;B]!0WE1+W=$2710-EEQ-SE&-EHO>7E1+SAI,"]P:7)H<&UM9S%&<$-#3V@Y
M3B8C>$$[4#99<3AD.'1X>G9P3W5M2G=O5S)$4U98;%915%5F85=H*R\U6G0X
M<$A&2#-U=G@X:7EN.'!/4#%B5D]63U!+2W1E;$M0;4YR95EB="8C>$$[3GE,
M3"]W1&Y79CA!;'DO-4I:9W55;$=T-FQB,G-Q4C9:<%9L9DLX8DTP-6UT-#%2
M=T1X56]D,G(W2$-Q:F\Q,TY09%(O<$\P,'4R="8C>$$[;5=2;C1E;5=59U)L
M1G)Z64AK6&9T*WHW-'%N=B]/<R\X=5@O04-3=TLW+VY79CA!;'DO-4I9<3<O
M;E=F*UA,+T%*2EEQ:U=Q87(Y5B8C>$$[,4(P=$Y(<V(V=T-64U):<F5.>2]W
M-U5A=3(U-V8R;%5V;CAZ,VQS<W-S=FQM,&MJ5VY&66)I0C(W9&M6,F)D=7DY
M<U5+.%=U,V-I9B8C>$$[1C5E<V]M4D]B36)I,UE/=VHU*VUQ,$)8:S-W0G%M
M:#,S>%9K<6YY,%%#4EI!,#-(-W)B06Q"86<R;&<O-DHY5#9D:$%D+SA!6EI6
M:R8C>$$[-'5J:UE2:B]!26U.86Y.<E%"*W!I,'(R;VQM9BM*1$YB<7!A=78S
M9C9(85E)-DPK4"]F2B]W0U<R=%<P<4TV,$Q!6#%46&HV05!(="8C>$$[>D,O
M1'DK5UIM:$]9-'@T,S$O:FTV-U=J0TUH.$PV13 O=T-D6B\U8W8K4U=:8FE/
M+W=#9%HO-6-V*U-72W4O-3%N+VQY+S5*67$W+R8C>$$[04HQ;B]L>2\U2EEQ
M-R]N5V8K6$PO:VQI<G8X06Y79BM83"]K;&ER=BMD6B\U8W8K4U=+=2]W0V1:
M+S5C=BM35TMU+S4Q;B]L>2\U2B8C>$$[67$W+T%*,6XO;'DO-4I9<3<O;E=F
M*UA,+VML:7)V.$%N5V8K6$PO:VQI<G8K9%HO-6-V*U-72W4O=T-D6B\U8W8K
M4U=+=2\U,6XO;"8C>$$[>2\U2EEQ-R]!2C%N+VQY+S5*67$W+VY79BM83"]K
M;&ER>#-4=%,K<#9:9C):=$AK;'960T-C3G@T04=T0W9!.'%N,WIC>6I:0G9K
M-B8C>$$[-DUQ0D9C,F$O;$MJ2F(V;5A"56-O:E5I;EHO2$U05SAW-4=M-49M
M+S95,'HO;')H+W=#4FEF,7I#8VQI33$O-38K<&E+3%5D23EC;"8C>$$[954U
M:RM)8V9T53(T565N.'4Q9G!W;U8Q,5AZ;CE93'1D84XV4E-N<"MQ.4$S06M.
M5W1F=&UH,S9D0C-X4VHY23%45C)V6E@Q93@P-28C>$$[3%AH>&=J=%I+;FQZ
M4'A-6#,K>%1V:7%C9G!45% K5W5(+VM9;CEC0W!D<C)O,TPV95)O=6]7:U8X
M1T)6<#-5;U9&86IV,7A62T8Q:B8C>$$[>G9W3EIT1$1#;D4K<DME5S1&4'1#
M;3%46#A-2W%(-F(X*WA"5C4V4&-.2DM4-F=M25=/33AJ4G9J43=B055"4&II
M<4LO4R]N2&I*+R8C>$$[<$=I5D)1>%5K;#-5:SAW,W@W14-L1&EQ+U1.53@Q
M2S!+-FAD-E,V0C$Y9#!K8FU53$YZ-#=H87%V1VTR2W!N<4=P9VXO4DQY2' R
M;"8C>$$[:4<O*WE/535"3&\U1T4T+S1M3F%N9F5B4T0Y5'9)-CEQ5#)O+W=#
M2DYM<S%59%A8-W8X05$W5$),4F9X+W=#*UI"-6(Q2S584V]X<B8C>$$[5C=B
M1RMQ83A:27EE4&)M5E!(;#AS>F1#37=X:GAV<B]!0GID9')4:$]1*T8Y0V%F
M<%144"M7=4@O:UEN.6-Y,T5D*VQ.32\U831F*R8C>$$[4FEF,7A6,S95,'HO
M04IA-&8K4FEF,7A6,S95,'HO;')H+S5'2B]81EAF<%144#A!;')H+S5'2B]8
M1EAF<%144"M7=4@O:UEN.6-69"8C>$$[*VQ.32]W0U=U2"]K66XY8U9D*VQ.
M32\U831F*U)I9C%X5C,V53!Z+T%*831F*U)I9C%X5C,V53!Z+VQR:"\U1THO
M6$989G!45% X028C>$$[;')H+S5'2B]81EAF<%144"M7=4@O:UEN.6-69"ML
M3DTO=T-7=4@O:UEN.6-69"ML3DTO-6$T9BM2:68Q>%8S-E4P>B]!2F$T9BM2
M:28C>$$[9C%X5C,V53!Z+VQR:"\U1THO6$989G!45% X06QR:"\U1THO6$98
M+S)1/3T\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB
M;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-
M33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @
M(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C)&141$
M-$1#,D8S145",3%!-#!%1$$Y-#(U-T1"1CA!/"]X;7!-33I);G-T86YC94E$
M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C)&141$-$1#
M,D8S145",3%!-#!%1$$Y-#(U-T1"1CA!/"]X;7!-33I$;V-U;65N=$E$/@H@
M(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y
M,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U
M;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R
M:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C)%141$-$1#,D8S145",3%!
M-#!%1$$Y-#(U-T1"1CA!/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @
M(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C)%141$-$1#,D8S145",3%!
M-#!%1$$Y-#(U-T1"1CA!/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @
M(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&
M1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\
M+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV
M961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z,D1%1$0T1$,R1C-%14(Q,4$T,$5$03DT
M,C4W1$)&.$$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C M,3(M,314,3 Z,30Z-#4M,#<Z,# \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C)&141$-$1#,D8S145",3%!-#!%1$$Y-#(U-T1"1CA!/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(P+3$R+3$T5#$P.C$U+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O
M<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*(" @(" @(" @/&EL;'5S=')A=&]R
M.E-T87)T=7!0<F]F:6QE/E!R:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O
M9FEL93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%10
M9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @
M(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @
M(" @(" @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O9R\B/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^
M1F%L<V4\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \
M>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(
M87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G.DY086=E
M<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53
M:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T
M1&EM.G<^-C,P+C P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM
M.F@^.#$P+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N
M:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%109SI-87A0
M86=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @
M/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA
M;64^0V%L:6)R:2U";VQD/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&86UI;'D^0V%L:6)R:3PO<W1&;G0Z9F]N=$9A
M;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\
M+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B V+C(R/"]S=$9N
M=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M
M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1FEL94YA;64^8V%L:6)R:6(N='1F/"]S=$9N=#IF
M;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @
M(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G
M.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@
M1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP
M1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^
M"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3 N
M,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 0D"70,!$0 "$0$#$0'_
MQ  >  $  04  P$             !00&!P@) @,* ?_$ '<0   % P$!"0L&
M!0@2# H+  (#! 4&  $'"!$2$Q05%U>7UM<6&"$Q4556E9;4U0D90528V"(R
M-3=A(U)Q=7:QM+4D)28G,T)#1F-D969W@861D[8T-E-R<W2"AI*4H<%%8H>R
MQ,7&T_#Q.$1'9X.$B*2FL]'_Q  = 0$  04! 0$              0($!08'
M P@)_\0 :A$  0(#!08!!0<(% L&!00# 0 " P01!2%1D=$&$C%!8:$'$R)B
M<8$(%#)2DK'2%1@S-73!U/ 6%R,D-$)35%9C9')SDY25LK33X25#1%57@H26
MU=;Q)D5E@X6S-D;"P\2BHZ3B)X;%_]H # ,!  (1 Q$ /P"8JX5NE$2B)1$H
MBE&5C>Y(YI62.L[H_O*ZYH430RMZMU<U@B"#5)UDJ!"2>J47)3$G*#;%%#N6
M04::/866,5B*4;H/-'AC<9,TQ"4.D;9S#RG>0MT?=EK&UFIB25*DIQ=DR0U
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MV,RO(,HD3.\OJ,AO='-*\.JE?PU0A3I4):0)YIY@TR>Z)&<4DN0!0E3J+&E
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M^,#VU3<.([Z)\S/JG],,&>U<W[-Z;XP/;5-PXCOHGS,^J?TPP9[5S?LWIOC
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M'1QQ1DE*\2UU;T*M\;,@D(@F62H0&6N8US U,44G(W1IEBF-TN$(U)E[-B@
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MKN,QH9VR>:9(?BA_DT<5!CZ-Q620E_:)'%3&IY7JH^LA3T4]I4*"0HP"'.\
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MB9^_S_ECQ?I\56C_ !I\,H==_:N4;2\UD;4^]9Y7LWP/\4W?!V1G#ZI^RO\
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ME9S-^ VK DIW1S&,X 1@9KCXS[;[DWPXV]L"/:.U=L3%H;/;.VA ?*0]FIR
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M13U]$WB> %PJ:FE#APY4/+^_/N%YT^9.Q5!<A2*+EPQTF;"FD0HV6Z'O(6]
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M;W$8$*T2=4,!5U" #2X\%(()(!O"]<VR_C/'#HRLTZF;-%W&0DJ%320['&$
M/2)%S8V*EIRFQ0DJ%"G<7II1&K5YZ5(!2XI"1'6&<"UP!-:#@A('$\5D?;;R
MV^BWCMX[WV6M_COX+>6_@J%*;;>'PV\'AOX;>"WCVW\G@\/AHBBTS\R+53TA
M1O#6J6QM00DD21.O2G*6%4J;4CRF3O!!9HC6P]0T+T3H04L"2,UN6)EH B3G
ME&"(K3@65<=Y03N*O'\L:I4E:CDY2Q4U&&F)K!6;_P "5)3S2BBG!N7\%4\7
MNK>-4VK^#*."*SMY-W,D$<12J@$'@:T60-MO+;R^/Z/+4*4VVOLV7M?;;;;P
MV\-O+;RV\-O#XO#1%^__ !_F\=$6+WV;NC6Y+49"9 ,I,9N "-+47,%;<AO^
M%<"H ;W\-_$&UOT5@YNTX\"-%A,9"(810N#R2-T&^CP.>"VVSK E)R5@1XD6
M8:^*S><&.A!H.^6W!T)QI0<R?6K>,R:^ M:]D;3?;X/"2L\'_P"^\/\ V59.
MMR:'"'+\^+8AY$_JHP65;LE9Q-#'G;_VR!^#J.,RQ( 7V60LW^,A;^CR+[>6
MO,V_-@$^2EKK_@Q>O[;ZOQX>S=CK-=6LQ/7?MD#K^YE0&YDD9>W8WLE_V2%_
MZ/[H?IKR.T4Z 3Y*5N!/P(O]LKENP]F.K^>9^[TY?K^YE'FYNE /$VL-_#>W
MA3N'T7M;SG7E^26>_493Y$;^W]7X\/9NPEDNK69M&ZG^-ENO[E5&/.TK#MV-
MD>\&SQIG+Z=G]U;>6O-VU$^*_F$I=7])&Y?^>KAOA]8Y('OJTOXV5_!%2&9]
MEP+[+-<<O^RE<_T?W6_35N[:ZT 2!+R=WH1^G[>KEGAQ8KJ5F[4%:_XV4Y5_
M<:CC=1,R+O>UFF,WV6M?PI77Z?\ +%>1VQM*A/O>1N-/L<QC]T]5<L\,;#=3
M\^VJ*U_QLIRK^XNBCC-2LV!?99GBW^-([>2WD>;>6J#MG:8!(EY&Z_[',?A*
MN6^%E@GC.VOPK=&DAS(_6)P5";J>G1>W8S1.^SRHWCZ-O]V_T5Y';:U+OSM(
M7FGV.8P)_7717,/PFV??3\_6R.'^/DN?^P<E'F:JIZ"U[V9(AX+WMX4;S]&W
MR/MO)7F[;FU17\[6?=7_ !4SR_VI73/![9UU*VA;7&ET:1Z7_:_MW5"9JRR"
M"U[V8X;?9;;X4+W\?KR_)[:W*5L[^+F?PH*Y;X,[-$$FT+=NO_1%G_\ #>BC
MSM7N12[;;,,*OXO&@??IV^20VKPB>(5L,K24LT\>,*:Y?[7S[=5[P_!39AYH
M;1M[V3%GX'_PPX*&4ZS\ED_BQZ#7OL^E _\ DV^*TCM^_6.B^)MN,)W9.R;L
M8,X>=.4Z%?P_ G95_&T]H.)%TQ9O*_G994.?K?RB5:]PQN WV>5ND7Z?))K>
M2L5&\7-H89(;(6,:5XP9X\/5/A7K? '9$FGU4VCX5_15F?\ "5"GZ\<KEVO<
M,8QYX/#^$VR2_D\DIMY:Q4?QJVFA&C;.L(U)XR]H<JX6D%?0O<[['/XVMM,+
M^4U9?,D<[(*AC_E LO%7%8,6QO?<V^ELD_\ W2RU8N-X\;60Z4LS9XUQEK2N
MRM6_LKMGN;]BW&AM?:BE1PF[)YU_\&^\H8_Y1/,A0;W#$\9WV7M;\)KE-_'^
MQ+[5C(WNA-L(9(;96S1I7C*VIR'2UPLA#]S+L.X@&V=J[Z\)RR.0'_@AQ4,?
M\I)FHJU[AB&+K[+_ $M,LO\ 1M^B96\FS_M_16+C>Z2VUADAMD;+75XREK'@
M.ELA7;/<O;".(K;6UM#4W3EC@BAQ-AFM?4%$G?*9YO+V[F'8J\%[V\+1+K_I
M^B:VK#1_=1[=PJ[MB[)&E3?)VSR-.5N!7T/W*>P+J5MS:^^O"<L44 KC81KP
MXW>I11WRH.=2KWM:&8EOLOX-K/,/T?W[_IK#Q_=9^(4(G=L/8WG\*1ML\Z<K
M?:KR'[DSP]?QMS;(7'A/6)R-/\P*'.^52SV7ML&$XAOLOX[LTS\MOHM.K>7R
MUB(WNP_$>'6E@;$FE>,A;O7#:(8*];[D/P[+6N-O;:7C@)ZP\ >/Y'SC@J;Y
MU?/OH3A_U+-.OE6'UYOB7^Q[8;^06_\ \QKU^L_\.O\ /^VO\NL+_E]/G5\^
M^A.'_4LTZ^4^O-\2_P!CVPW\@M__ )C3ZS_PZ_S_ +:_RZPO^7T^=7S[Z$X?
M]2S3KY3Z\WQ+_8]L-_(+?_YC3ZS_ ,.O\_[:_P NL+_E]/G5\^^A.'_4LTZ^
M4^O-\2_V/;#?R"W_ /F-/K/_  Z_S_MK_+K"_P"7T^=7S[Z$X?\ 4LTZ^4^O
M-\2_V/;#?R"W_P#F-/K/_#K_ #_MK_+K"_Y?3YU?/OH3A_U+-.OE/KS?$O\
M8]L-_(+?_P"8T^L_\.O\_P"VO\NL+_E]=,M(^KJ.:EH\<B6DHX[D]@2!42:+
M)QF\#5H]]+3VD4<NI-.4',QIYQ)*E,<<>L9EAQ218<H)4(%Z_P"MO!'QOLKQ
M:LN)+S$.!9>U]F01$M>QX3G^0C0-]D(6I91BOB18D@^)$APXT&)$B1Y"/$9
MCOBPXLM-3/RIXS>#%J>%=ILCP'Q[3V3M&,8=DVO$:SRT&-N.B&S+4$)C(4.>
M9#8]\*+#APX$]!AOC0&0WPYB7E]QJ[NN(I1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$7Q#NWY5<_VP6_PDVM8=Q/K/SK\_(_V>-_"Q/Z;ETFTE,MG/#BQ
M9W$."YC:IE+#)TGMB7'4Q1YD9CHY';H(.CG\T>6EX@RR-B*7&FG, 30-]I*G
M?"C;NI1:<=Y+BL,^82 YQ?\ F;'B(VC:,#WD%A;?\'AO5XT!ZKL5 \M83W_4
MZ+$EX,_.FT6_46RYZ';T!TK*F%9[+2M"/!C6<^4+8A<Z5#A"$VR9:?+@-/,F
MK)<E7?;Y'/\ -]FG]V4:_B1966LWX$7]\WYBOI/P+^U=O?=\I_5WKLE627=4
MHB41:F:E--[WJ'5LR,<].AL;C\0G"5O):VQM<'-1.)40W-C:^*1O+:XIT22/
MLZ=R*1*V>Z&1$JGE48B<D=@6N94UV[RK6GL PICET/*ES=ZE]**PF+21)#,F
M'Y-G4F9)*ID\F?%L[BN_/YD16LLLT^1+$\A6,#(J%Q:SS,,ACSIP:0IV].M<
M(!(W*-N2V]N#$)9WKJ#V7"M=ZHOPIC6_UFL;O"OMO/#=H?;7LKPPQIJF&/X4
MJ:Y'EV0CFRMW:1+)=#26I$)UC4,AC%CZ",CN1(V5[$H+1,,>3O+N%'P"ZJ4/
M#\L*4[TKVW@FIX78'$FIX4]7J4AM!QONO& X#\>ZL2-:.I7%H-E?&*?)I;M#
MLL3'&=GD]:TI6U]#C.,1"'Q.>,YA[(A1E*91/6>,&QQ8Z*!&DB;5ACXK,.D*
MQS.63O7@D7@'J*U-.)X#\;E&[0$ \2*^KGRX]J+/#3C6:MVHE[R?8<*3P-?C
M&/XX0M"'C8J2$$QYW>9"F<#2N!%LP=]7ORIONF)47"2V(D1A8[GC,)+BHW:7
MUK4GEJIH=ZMP%*4[_.M@ZI5241*(L)ZB<8.V8\1R+'S&Y(VEU='6$.J1<O5N
MZ!* 41GL8F)I W!@,)>VXQ:0P&HB'%J.)7H%"@I8F-+-)",,@T(/KX>I014$
M?/ZUKPNTG2]YR"P9,7RI"E=H^# )94;O*<@2:/.9.*I1D9=(+2-5)UBMQE#J
M)HFK<[0.3R,#H_QF;,8'(I400H5#5SO 5 X'>Y#F!3AU'JZ81NDTJ;Q3AT)K
MQKR-U>:G.]K?6$UFA[?(95,H7,\[DY3R6OD\B&N(:(U$5*^<1N.$M[HZ'K')
MQD<^1Q)'(G%$1<MW:$*\;N0G+ F)/DN!ON! H!Z^/;@"HW:4XD5J37#@#C?Q
M*LB2:(E[PMDCVCF%R'R23;4W(5'#)#.5L;(:,Y0#(<08$J*&GNYT3;7AB63%
M"L>W=K9$2]R2HUA-ER@1]@&-[YFX<N7J_&B;I[NYF^H-#T(5%*]&$WG4,@\?
M=YDB9%\#QME>&(!HIIE"6(7MQFA^+EC&"4*)<YJ'1\@ZDV"NS=,(&X'J8Z<R
M.J5$U( 63%<%;P!N%U1R' 5KPI??<A:2!C0\R;SPX\L?;<LRL^%,IN65<@SZ
M;RYC;+2*/(X="'W'2A6@E>/H4U/+<]IXNSI)''G6/#!(7(A8X3)Z6$KE[F;9
MJ1-Q+8WM:(I/%10 #A>0>9QK7("G530U)/J%.(%>HIZ^/2BM[4WI@E6<I%%G
M6/RIL9"FK'DN@BQ6[+I40K2*Y%)H!(VZ46:8RM:VB:!9U,)WXV%S*YL/>%IZ
M-0YH#^ I[%&D"O'E3AUQ]?*]0YI)Y<*'CCQNX^VY8YGNAQPDJ!:- \1<UU?<
MMYBGDN*6)^ ERAIR*Y2 ^)#5/!T=DQR"2XX0O:DN/JT3-8;<I=7T^/.K N5A
M=+U;_3@UH'.E*5NJ./K]=4+3C6\G/V&_V<[EZI!HPGC]*,M/CA(H.Y(9ZR+F
M= A(1)XTI<#$^3(3.H>Z31:VPA?W3.4;01M8U+3IL3D4F1GJ% 5R8B/OSC'4
M4!PH!?=QR(NO_P"BC=-_#IG6^Z^[C6MZRUC#2\JAP<THWL^"WMF6"0Z..\GA
M,531%_(=VW%K1CZ5"3MB%*4U-[ M=FU;,6-N1*+%(7!]6IA)"MXLI5075IT)
M-Y)K?49</4J@WCPO%.'2A^\5C+(VES.V2L*Q3#[S)\+)D\+CPHDT.J*)*CU9
MB='"E,68Y@G421GDQD3?VY6%O<PH(@6U.:812@#9/$(! *O(<T$FAOOX\.G*
MH]>2@M<0!477>L8\Z'^^]>,DT22!T63-Z:)7&FN1S:V:"Y"[B0NPCY0U3Z98
MWED5BLH/3F)U;A&F\J'R-F>D7"!%D)I@ZJ6D@P]:X64 \"E033=YX5J1UPS0
MM-]#2M>]*#M>OU9HSE#C-U,KNM@,>0JH0K8&9@AQ2IC:L<*3H),X=>.10D$9
M-<7""+CY3QTXM 'N*M1CF:X+S(NK4@:;H =0<S?QXUO!KQXT%.?0A"TUY 4X
M8&AX7<*FIX5YA;K8J@#5B['4/@+.B;4*:-,:)"I"TI^#(UCN(OA#Z[[@5K&F
MJGQZ.7O"]6IN-8M7+E"Q88:J/.,%234DXJH"@I^)ZKP>(*-U7JUMG,!%E(]W
M8NZ2YEP?@A#LW7" ;KQ;?Q;>.L/,V69B-$B^7#/*&N[Y/>IYH;QWQ7A7@%M$
MAM"V2EX, RCHAA-W=X1@T.\XNK3R3J<:<2H,S%IH[6MQT7;9?Z@*_P#Z75H;
M!<1^B@/_ "2>((_5!BL@-L& @^\'7?ND?V"H3,0G#OML_%6_9;A?H_MW]%>?
MY'G$$&::*BGV$G_[H7LW;1C:ULY]]/\ *1U_:%0F85/,_KB*M_DP=_)_;UO)
M7F=FW&H]^-O%/L!_M5<#;N&VO^#'FO[K:/\ \<JB,P4H'_7*3;PWO^2AW\=[
M7^OV\E>9V7=RG6^V7(_^\5Z-V_AMK_@MYK^ZV_@RI1X"4"V_S4$VV[/_  0.
M_BV?W1MY*\SLH\U_/S;Z_P"3GG_YR]QXBPP0?J2^[]VM_!53&:>E [[>ZLFW
MZ.)Q_H^GC+]'DKP.QSR2?J@V_P#<Q_MU[L\2X;:?X'>:5_RYO.O[D5"9IN4F
M7O?NN(MMM:WY%,OXO\J6JC\A;Z$?5%MYK^A3T_='17+/%*$VG^!8AI7_ "]H
MXU_<AQ5 9IA5#OMM,D]OV6(S]']UOT50=B7D$?5%HK=^A2?_ ,@+W'BQ"'_<
M<3A3[8-Q)_6?549NE=69M_FV3AV[?_ !E_'M_NO;RUYG86)4?X29<:_H1V!'
MZXZKW9XOPF4_P!$-*?\ >31P_P!A*H1Z2U8]MN[E-;;>]_\ :\;].W^['Z:\
MSL%$-?\ ";+Z_P"2.Y_[0KIGC/!;3_L]%-]?MFS\!Z*D,T@K!VO;N\36VVV?
M[7#;_P#KJU>?Y7\3_.K/Y&[\)7N/&V  1^1R+>*?;1G7]P=51&Z-EAEMG* F
MMXOZVC;^+_+EJ\7^',1]?\+,%:_Y$X\?]JY=^B]6>.4!AK^1N*?_ %5@Q_\
M#^JB3]$:T[_[1DH?!Z+G7^C9Y^M5C$\+HKR?\-0Q7]P.QK^NU>L\?8#.&R\8
MWG_O=@XBG^;BHL[0DN-M>W*8D#M_O4.OY?[X;>6L;%\'8L0D_5^&*U_[M<>/
M^W!7;?=#2[37\BD8W4^W+/\ ABB3?D_W VU[<J2,.WP?[4#K^3^^.WDK&QO
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M_H^FO]Y87_!$^:2>.?1MZ/577&GUDL[_ *1I7_=>+_QY/KS)+_1]-?[RPO\
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M.7[];- LRS32MG2)O'&4E\3^UJT%<KE-MWLDK_;9MV;'AQML\7BV*:L8\_/
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M9XSGV?4H>F8U2HZY'1.7^'^B></L\9S[/J4/3,:I4=<CHH619<QI+69;'I)
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M44Q-RYM1F%SO\+N'#*E_XA-SKQZ=:W7W8<U$OFA0U[2'HS\DM_%H)?,7UKB
MHQ/R8&W,,\CIS%)X]9O9\VLTV$-R.4JW00DF0F^+)3%[HVMT+0M#BH17!X!K
M0\.-1O5!J#6A&'(F[C@W>MV%#3YZ][EDS&VE6V.LO\I1$Q:U[4C5945M#"7"
M.!2,(\LN,6=GA-()X=*7)7(T+"LC!2>+$',B(YO:58D"M4X&$%K!075'##U7
M5Y>WU8 *0VAK6X5H/7U6WM4JI*(E$2B)1%J!F32H+,<[<Y2MFR&)-[G Y?!%
M(XA#U#5/W1JE\&?(::T2B< EUVR4Q)H6OALO9HZY0FRM!(4:,29_*1V/3GU
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M^*[Y0^@E^(R.J<0:F>=?!7V?)_\ >:I5GQ7?*'T$OQ&1U3B#4SSKX*^SY/\
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ML^*[Y0^@E^(R.J<0:F>=?!7V?)_]YJE6?%=\H?02_$9'5.(-3/.O@K[/D_\
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MFOJZKWJ=:H$CJ[-:C%CB4(^02*+0)69+V@"*6/4;U"-&G-;=W.$@VPUJ[KI
MT.?&*P#F99GNY" B-4I$9+FW;@:W<[N'F[PYWW IO]/5UOI[%'2#6(]0V6RJ
M+*L=2";28MY3@:H=#RU+[=O;V?"V.<BRM U/,7CS\HDC@-QFI:-A4.+6QLZT
M\TT;H^1UI2<+"W+@:@"AXW?IB+Z\/GZ)OFM*5X<.5P/M_&_#8S&68^4.99,A
MJR,+(@Y8^<4129 ]G.!3Z^L+@N?VYOEMFQ4Q(&\F/O"B/K+LJUE?9,2=N%2!
MV-9'YL<65-212G.OJZ7<>5>=%4#6O+.M,;P/OK-M0I6L>27-R3/#F!,X+DX
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MR8HN4XI52<W= )'P2YH2UW!3+[BJ)SQ6$E)3EHQ-D;>=)6?!LZ8G(\./93Q
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M*EB,"2ZA,G<#&YP B/.+ 4J&A6!($9=,?8"KL3F4HW 9!58\58K+ (PS'4#
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$1%__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
